| 1 |
Lin L, Zhang K, Xiong Q, Zhang J, Cai B, Huang Z, Yang B, Wei B, Chen J, Niu Q. Gut microbiota in pre-clinical rheumatoid arthritis: From pathogenesis to preventing progression. J Autoimmun 2023;:103001. [PMID: 36931952 DOI: 10.1016/j.jaut.2023.103001] [Reference Citation Analysis]
|
| 2 |
Bolton D, Marcos P. The Environment, Farm Animals and Foods as Sources of Clostridioides difficile Infection in Humans. Foods 2023;12. [PMID: 36900611 DOI: 10.3390/foods12051094] [Reference Citation Analysis]
|
| 3 |
De-la-Rosa-Martinez D, Zinser-Peniche P, Martin-Onraet A, Rivera-Buendía F, Vilar-Compte D. Performance of Clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer. Support Care Cancer 2023;31:187. [PMID: 36843052 DOI: 10.1007/s00520-023-07651-4] [Reference Citation Analysis]
|
| 4 |
Zhao Y, Gong C, Xu J, Chen D, Yang B, Chen Z, Wei L. Research Progress of Fecal Microbiota Transplantation in Liver Diseases. J Clin Med 2023;12. [PMID: 36836218 DOI: 10.3390/jcm12041683] [Reference Citation Analysis]
|
| 5 |
Nguyen NM, Cho J, Lee C. Gut Microbiota and Alzheimer's Disease: How to Study and Apply Their Relationship. Int J Mol Sci 2023;24. [PMID: 36835459 DOI: 10.3390/ijms24044047] [Reference Citation Analysis]
|
| 6 |
Saatchi A, Kim S, Marra F. Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018. Can J Infect Dis Med Microbiol 2023;2023:9465158. [PMID: 36816780 DOI: 10.1155/2023/9465158] [Reference Citation Analysis]
|
| 7 |
Gonzales-Luna AJ, Carlson TJ, Garey KW. Emerging Options for the Prevention and Management of Clostridioides difficile Infection. Drugs 2023;83:105-16. [PMID: 36645620 DOI: 10.1007/s40265-022-01832-x] [Reference Citation Analysis]
|
| 8 |
Mahmoudi H, Hossainpour H. Application and development of fecal microbiota transplantation in the treatment of gastrointestinal and metabolic diseases: A review. Saudi J Gastroenterol 2023;29:3-11. [PMID: 36412458 DOI: 10.4103/sjg.sjg_131_22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Dionne JC, Johnstone J, Heels-Ansdell D, Duan E, Lauzier F, Arabi YM, Adhikari NKJ, Sligl W, Dodek P, Rochwerg B, Marshall JC, Niven DJ, Williamson DR, Reynolds S, Zytaruk N, Cook D. Clostridioides difficile infection in mechanically ventilated critically ill patients: A nested cohort study. J Crit Care 2023;:154254. [PMID: 36682909 DOI: 10.1016/j.jcrc.2023.154254] [Reference Citation Analysis]
|
| 10 |
Wang W, Lu G, Wu X, Wen Q, Zhang F. Colonic Transendoscopic Enteral Tubing Is a New Pathway to Microbial Therapy, Colonic Drainage, and Host-Microbiota Interaction Research. J Clin Med 2023;12. [PMID: 36769429 DOI: 10.3390/jcm12030780] [Reference Citation Analysis]
|
| 11 |
Ueda H, Hase R, Sato A, Hosokawa N. Pseudomembranes on colostomy in a patient with recurrent Clostridioides difficile infection. IDCases 2023;31:e01681. [PMID: 36699967 DOI: 10.1016/j.idcr.2023.e01681] [Reference Citation Analysis]
|
| 12 |
Jiang L, Yuan C, Ye W, Huang Q, Chen Z, Wu W, Qian L. Akkermansia and its metabolites play key roles in the treatment of campylobacteriosis in mice. Front Immunol 2022;13:1061627. [PMID: 36713373 DOI: 10.3389/fimmu.2022.1061627] [Reference Citation Analysis]
|
| 13 |
Wang W, Yan Y, Yu F, Zhang W, Su S. Role of oral and gut microbiota in childhood obesity. Folia Microbiol (Praha) 2023. [PMID: 36626083 DOI: 10.1007/s12223-023-01033-3] [Reference Citation Analysis]
|
| 14 |
Hao S, Yang S, Zhang N, Cheng H. Fecal Microbiota Transplantation Research over the Past Decade: Current Status and Trends. Can J Infect Dis Med Microbiol 2023;2023:6981721. [PMID: 36654766 DOI: 10.1155/2023/6981721] [Reference Citation Analysis]
|
| 15 |
Asaoka M, Horita Y, Wachino C, Kondo S, Hotta Y, Kataoka T, Sanagawa A, Hayakawa T, Nakamura A, Kimura K. Clinical Usefulness of the "MN Criteria" - the Clostridioides difficile Infection Severity Scoring System - in the Japanese Setting. Intern Med 2023;62:59-67. [PMID: 35650131 DOI: 10.2169/internalmedicine.9540-22] [Reference Citation Analysis]
|
| 16 |
Vindenes T, Melinscak H, Linder K, Alsoubani M. Antimicrobial Stewardship in Immunocompromised Hosts. Antimicrobial Stewardship in Non-Traditional Settings 2023. [DOI: 10.1007/978-3-031-21710-4_7] [Reference Citation Analysis]
|
| 17 |
Ardura MI, Kim SC. Infectious Complications of Pediatric Inflammatory Bowel Disease. Pediatric Inflammatory Bowel Disease 2023. [DOI: 10.1007/978-3-031-14744-9_49] [Reference Citation Analysis]
|
| 18 |
Li SL, Zheng SQ, Tang YZ, Liu HM, Mao Q. Progress in understanding of relationship between duodenal mucosal microecology and hepatitis B virus related acute-on-chronic liver failure. Shijie Huaren Xiaohua Zazhi 2022; 30(24): 1074-1078 [DOI: 10.11569/wcjd.v30.i24.1074] [Reference Citation Analysis]
|
| 19 |
Timerbulatov SV, Timerbulatov MV, Akhmerov DR, Timerbulatov VM, Gafarova AR. Pseudomembranous colitis in patients with COVID-19 (review). Koloproktologiâ 2022;21:111-119. [DOI: 10.33878/2073-7556-2022-21-4-111-119] [Reference Citation Analysis]
|
| 20 |
Boicean A, Neamtu B, Birsan S, Batar F, Tanasescu C, Dura H, Roman MD, Hașegan A, Bratu D, Mihetiu A, Mohor CI, Mohor C, Bacila C, Negrea MO, Fleaca SR. Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 and Clostridioides difficile. Biomedicines 2022;11. [PMID: 36672518 DOI: 10.3390/biomedicines11010007] [Reference Citation Analysis]
|
| 21 |
Justice S, Sewell DK, Li H, Miller AC, Polgreen PM. Evidence of within-facility patient-patient Clostridiodes difficile infection spread across diverse settings. Epidemiol Infect 2022;151:e4. [PMID: 36502810 DOI: 10.1017/S0950268822001893] [Reference Citation Analysis]
|
| 22 |
Xie S, Chen P, Wang D, Jiang X, Wu Z, Liao K, Liu M, Zhang S, Chen Y. Application of Procalcitonin for the Rapid Diagnosis of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease. Diagnostics (Basel) 2022;12. [PMID: 36553115 DOI: 10.3390/diagnostics12123108] [Reference Citation Analysis]
|
| 23 |
Baunwall SMD, Andreasen SE, Hansen MM, Kelsen J, Høyer KL, Rågård N, Eriksen LL, Støy S, Rubak T, Damsgaard EMS, Mikkelsen S, Erikstrup C, Dahlerup JF, Hvas CL. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2022;7:1083-91. [PMID: 36152636 DOI: 10.1016/S2468-1253(22)00276-X] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 24 |
Gospodaryk A, Ulakhanova L, Esiev S, Polyakova E, Shansky Y, Bespyatykh J. The role of mef and ermB drug resistance genetic markers in the selection of fecal microbiota donors. BRSMU 2022. [DOI: 10.24075/brsmu.2022.059] [Reference Citation Analysis]
|
| 25 |
Raeisi H, Azimirad M, Asadzadeh Aghdaei H, Yadegar A, Zali MR. Rapid-format recombinant antibody-based methods for the diagnosis of Clostridioides difficile infection: Recent advances and perspectives. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1043214] [Reference Citation Analysis]
|
| 26 |
Bhat MA, Mishra AK, Tantray JA, Alatawi HA, Saeed M, Rahman S, Jan AT. Gut Microbiota and Cardiovascular System: An Intricate Balance of Health and the Diseased State. Life (Basel) 2022;12. [PMID: 36556351 DOI: 10.3390/life12121986] [Reference Citation Analysis]
|
| 27 |
Wei W, Wang S, Xu C, Zhou X, Lian X, He L, Li K. Gut microbiota, pathogenic proteins and neurodegenerative diseases. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.959856] [Reference Citation Analysis]
|
| 28 |
Wen G, Li S, Qin Z, Yang Y, Bai L, Ge W, Liu X, Li J. Isolation, molecular typing and antimicrobial resistance of Clostridium difficile in dogs and cats in Lanzhou city of Northwest China. Front Vet Sci 2022;9. [DOI: 10.3389/fvets.2022.1032945] [Reference Citation Analysis]
|
| 29 |
Zhang F, Yang P, Chen Y, Wang R, Liu B, Wang J, Yuan M, Zhang L. Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.1057492] [Reference Citation Analysis]
|
| 30 |
Wang JG, Liang Q, Dou HH, Ou Y. The global incidence of adverse events associated with fecal microbiota transplantation in children over the past 20 years: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:2031-8. [PMID: 36066910 DOI: 10.1111/jgh.15996] [Reference Citation Analysis]
|
| 31 |
Ma J, Chen T, Ma X, Zhang B, Zhang J, Xu L, Wang Y, Huang J, Liu Z, Wang F, Tang X. Comprehensive bibliometric and visualized analysis of research on fecal microbial transplantation published from 2000 to 2021. BioMed Eng OnLine 2022;21:78. [DOI: 10.1186/s12938-022-01046-y] [Reference Citation Analysis]
|
| 32 |
Bresalier RS, Coronel ES, Zhang HC. Gastrointestinal and Hepatic Complications in Cancer Patients. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm135.pub2] [Reference Citation Analysis]
|
| 33 |
Matsumoto A, Yamagishi Y, Miyamoto K, Higashi S, Oka K, Takahashi M, Mikamo H. Comparison of clinical severity, genotype and toxin gene expression of binary toxin-producing Clostridioides difficile clinical isolates in Japan. Access Microbiology 2022;4. [DOI: 10.1099/acmi.0.000362] [Reference Citation Analysis]
|
| 34 |
Suchman K, Luo Y, Grinspan A. Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort. Dig Dis Sci 2022;67:4866-73. [PMID: 35000023 DOI: 10.1007/s10620-021-07347-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Gonzalez CA, Van Rysselberghe NL, Maschhoff C, Gardner MJ. Clostridium difficile colitis portends poor outcomes in lower extremity orthopaedic trauma surgery. Injury 2022;53:3458-63. [PMID: 36002345 DOI: 10.1016/j.injury.2022.08.026] [Reference Citation Analysis]
|
| 36 |
Krakovski MA, Arora N, Jain S, Glover J, Dombrowski K, Hernandez B, Yadav H, Sarma AK. Diet-microbiome-gut-brain nexus in acute and chronic brain injury. Front Neurosci 2022;16:1002266. [DOI: 10.3389/fnins.2022.1002266] [Reference Citation Analysis]
|
| 37 |
Jones J, Pradhan A, Pizzuti ME, Bland CM, Bookstaver PB. Is Three Company or a Crowd? Comparing and Contrasting U.S. and European Clostridioidesdifficile Clinical Practice Guidelines. Antibiotics 2022;11:1247. [DOI: 10.3390/antibiotics11091247] [Reference Citation Analysis]
|
| 38 |
Wang Y, Zhang S, Borody TJ, Zhang F. Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases. Chinese Medical Journal 2022;Publish Ahead of Print. [DOI: 10.1097/cm9.0000000000002339] [Reference Citation Analysis]
|
| 39 |
Hyte ML, Arphai LJ, Vaughn CJ, Durham SH. The Role of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infections: A Review of the Current Literature and Paradigm Shift after 2021. Antibiotics 2022;11:1211. [DOI: 10.3390/antibiotics11091211] [Reference Citation Analysis]
|
| 40 |
Omer E, Chhabra G. Impact of Clostridioides Difficle Infection and its Therapy on Nutritional Status. Curr Gastroenterol Rep 2022. [PMID: 36056219 DOI: 10.1007/s11894-022-00846-5] [Reference Citation Analysis]
|
| 41 |
Banawas SS. Systematic Review and Meta-Analysis on the Frequency of Antibiotic-Resistant Clostridium Species in Saudi Arabia. Antibiotics 2022;11:1165. [DOI: 10.3390/antibiotics11091165] [Reference Citation Analysis]
|
| 42 |
Xie YC, Jing XB, Chen X, Chen LZ, Zhang SH, Cai XB. Fecal microbiota transplantation treatment for type 1 diabetes mellitus with malnutrition: a case report. Ther Adv Chronic Dis 2022;13:20406223221117449. [PMID: 36003287 DOI: 10.1177/20406223221117449] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 43 |
Wang M, Xie X, Zhao S, Han W, Zhang Y. Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study. Front Microbiol 2022;13:990800. [DOI: 10.3389/fmicb.2022.990800] [Reference Citation Analysis]
|
| 44 |
Ruzicka D, Kondo T, Fujimoto G, Craig AP, Kim SW, Mikamo H. Development of a clinical prediction model for recurrence and mortality outcomes after Clostridioides difficile infection using a machine learning approach. Anaerobe 2022;:102628. [PMID: 35985607 DOI: 10.1016/j.anaerobe.2022.102628] [Reference Citation Analysis]
|
| 45 |
Dibu JR, Haque R, Shoshan S, Abulhasan YB. Treatment of Fever in Neurologically Critically Ill Patients. Curr Treat Options Neurol. [DOI: 10.1007/s11940-022-00732-5] [Reference Citation Analysis]
|
| 46 |
Gang J, Wang H, Xue X, Zhang S. Microbiota and COVID-19: Long-term and complex influencing factors. Front Microbiol 2022;13:963488. [DOI: 10.3389/fmicb.2022.963488] [Reference Citation Analysis]
|
| 47 |
Li Y, Cai H, Sussman DA, Donet J, Dholaria K, Yang J, Panara A, Croteau R, Barkin JS. Association Between Immunosuppressive Therapy and Outcome of Clostridioides difficile Infection: Systematic Review and Meta-Analysis. Dig Dis Sci 2022;67:3890-3903. [DOI: 10.1007/s10620-021-07229-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Mironova M, Ehrlich AC, Grinspan A, Protano MA. Fecal microbiota transplantation may reduce the mortality of patients with severe and fulminant Clostridioides difficile infection compared to standard-of-care antibiotics in a community hospital. J Dig Dis 2022;23:500-5. [PMID: 36183340 DOI: 10.1111/1751-2980.13134] [Reference Citation Analysis]
|
| 49 |
do Rego Furtado LC. Clostridioides difficile infection: an update on its identification, management and prevention. Primary Health Care 2022;32:23-29. [DOI: 10.7748/phc.2021.e1755] [Reference Citation Analysis]
|
| 50 |
Kunishima H, Ohge H, Suzuki H, Nakamura A, Matsumoto K, Mikamo H, Mori N, Morinaga Y, Yanagihara K, Yamagishi Y, Yoshizawa S. Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection. J Infect Chemother 2022;28:1045-83. [PMID: 35618618 DOI: 10.1016/j.jiac.2021.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 51 |
Zyoud SH. Global research on Clostridium difficile-associated diarrhoea: A visualized study. World J Gastroenterol 2022; 28(28): 3720-3731 [DOI: 10.3748/wjg.v28.i28.3720] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 52 |
Spanu D, Pretta A, Lai E, Persano M, Donisi C, Mariani S, Dubois M, Migliari M, Saba G, Ziranu P, Pusceddu V, Puzzoni M, Astara G, Scartozzi M. Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment. World J Hepatol 2022;14:1319-32. [PMID: 36158925 DOI: 10.4254/wjh.v14.i7.1319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Boeriu A, Roman A, Fofiu C, Dobru D. The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases. Pathogens 2022;11:819. [DOI: 10.3390/pathogens11070819] [Reference Citation Analysis]
|
| 54 |
Tan XY, Xie YJ, Liu XL, Li XY, Jia B. A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Evid Based Complement Alternat Med 2022;2022:8266793. [PMID: 35795291 DOI: 10.1155/2022/8266793] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 55 |
Xue L, Deng Z, Luo W, He X, Chen Y. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Cell Infect Microbiol 2022;12:759306. [DOI: 10.3389/fcimb.2022.759306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 56 |
Rakotonirina A, Galperine T, Allémann E. Fecal microbiota transplantation: a review on current formulations in Clostridioides difficile infection and future outlooks. Expert Opin Biol Ther 2022. [PMID: 35763604 DOI: 10.1080/14712598.2022.2095901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Ning Q, Chen T, Wang G, Xu D, Yu Y, Mao Q, Li T, Li L, Li J, Lu X, Li J, Li Z, Zhang W, Xiao Y, Meng Q, Mi Y, Shang J, Yu Y, Zhao Y, Zhao C, Zhao H, Huang J, Peng J, Tang H, Tang X, Hu J, Hu B, Guo W, Zheng B, Chen B, Zhang Y, Wei J, Sheng J, Chen Z, Wang M, Xie Q, Wang Y, Wang F, Hou J, Duan Z, Wei L, Jia J, Chinese Society of Infectious Disease of Chinese Medical Association. Expert Consensus on Diagnosis and Treatment of End-Stage Liver Disease Complicated with Infections. Infectious Diseases & Immunity 2022;2:168-178. [DOI: 10.1097/id9.0000000000000055] [Reference Citation Analysis]
|
| 58 |
Li Y, Zhang T, Sun J, Liu N. Fecal Microbiota Transplantation and Health Outcomes: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. Front Cell Infect Microbiol 2022;12:899845. [DOI: 10.3389/fcimb.2022.899845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 59 |
Sweeney JR, Crawford CV, Yantiss RK. Histological features of Clostridioides difficile colitis in patients with inflammatory bowel disease. Histopathology 2022. [PMID: 35758181 DOI: 10.1111/his.14702] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 60 |
Li Z, Ke H, Lin Q, Shen Z, Chen Y. Global trends in gut microbiota and clostridioides difficile infection research: A visualized study. J Infect Public Health 2022;15:806-15. [PMID: 35759806 DOI: 10.1016/j.jiph.2022.06.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 61 |
Ghezzi L, Cantoni C, Rotondo E, Galimberti D. The Gut Microbiome-Brain Crosstalk in Neurodegenerative Diseases. Biomedicines 2022;10:1486. [PMID: 35884791 DOI: 10.3390/biomedicines10071486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Venhorst J, van der Vossen JMBM, Agamennone V. Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens. Front Microbiol 2022;13:891790. [DOI: 10.3389/fmicb.2022.891790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 63 |
Liu Y, Chen M. Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review. Can J Gastroenterol Hepatol 2022;2022:4209442. [PMID: 35711246 DOI: 10.1155/2022/4209442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 64 |
Lu G, Zhang F. The levels and core delivery ways of gut microbial reconstruction. Sci Sin -Vitae 2022. [DOI: 10.1360/ssv-2021-0381] [Reference Citation Analysis]
|
| 65 |
Choi MH, Kim D, Jeong SH, Lee HM, Kim H. Risk Factors of Severe Clostridioides difficile Infection; Sequential Organ Failure Assessment Score, Antibiotics, and Ribotypes. Front Microbiol 2022;13:900681. [DOI: 10.3389/fmicb.2022.900681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Shang L, Tu J, Dai Z, Zeng X, Qiao S. Microbiota Transplantation in an Antibiotic-Induced Bacterial Depletion Mouse Model: Reproducible Establishment, Analysis, and Application. Microorganisms 2022;10:902. [PMID: 35630347 DOI: 10.3390/microorganisms10050902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 67 |
Zhang WH, Jin ZY, Yang ZH, Zhang JY, Ma XH, Guan J, Sun BL, Chen X. Fecal Microbiota Transplantation Ameliorates Active Ulcerative Colitis by Downregulating Pro-inflammatory Cytokines in Mucosa and Serum. Front Microbiol 2022;13:818111. [PMID: 35444617 DOI: 10.3389/fmicb.2022.818111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 68 |
Cai JR, Chen XW, He YJ, Wu B, Zhang M, Wu LH. Washed microbiota transplantation reduces serum uric acid levels in patients with hyperuricaemia. World J Clin Cases 2022; 10(11): 3401-3413 [DOI: 10.12998/wjcc.v10.i11.3401] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 69 |
Furtado LCDR. Clostridioides difficile: a review of relevant topics for nursing practice and infection prevention and control. Gastrointestinal Nursing 2022;20:28-38. [DOI: 10.12968/gasn.2022.20.3.28] [Reference Citation Analysis]
|
| 70 |
Masaki M, Matsuo T, Kobayashi D, Mori N. SEASON GAP score: A predictor of Clostridioides difficile infection among patients with tube feeding. Journal of Infection and Chemotherapy 2022. [DOI: 10.1016/j.jiac.2022.04.011] [Reference Citation Analysis]
|
| 71 |
Ramos-garcía J, Robles-rivera F, Chávez-soto M, Valdés M, Calzada F, Ortiz-olvera N. Fecal concentration of intravenous vancomycin preparation after oral administration in an experimental model: preclinical assay. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2022.03.005] [Reference Citation Analysis]
|
| 72 |
Sims S, Harris R, Hussein S, Rafferty AM, Desai A, Palmer S, Brearley S, Adams R, Rees L, Fitzpatrick JM. Social Distancing and Isolation Strategies to Prevent and Control the Transmission of COVID-19 and Other Infectious Diseases in Care Homes for Older People: An International Review. Int J Environ Res Public Health 2022;19:3450. [PMID: 35329137 DOI: 10.3390/ijerph19063450] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 73 |
Zhou Y, Liu Z, Chen T. Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. Front Oncol 2022;12:847350. [PMID: 35252014 DOI: 10.3389/fonc.2022.847350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Aira A, Arajol C, Casals-pascual C, González-suárez B, Martí S, Domínguez MÁ, Guardiola J, Soriano Á. Recommendations for stool donor selection for fecal microbiota transplant. Consensus document endorsed by the Catalan Society of Digestology, Catalan Society of Infectious diseases and Clinical Microbiology and the GEMBIOTA group from Spanish Society of Infectious Diseases and Clinical Microbiology. Enfermedades infecciosas y microbiologia clinica (English ed ) 2022;40:142-146. [DOI: 10.1016/j.eimce.2021.12.001] [Reference Citation Analysis]
|
| 75 |
Ramos-garcía J, Robles-rivera F, Chávez-soto M, Valdés M, Calzada F, Ortiz-olvera N. Concentración fecal de la preparación de vancomicina intravenosa posterior a administración oral en un modelo experimental: ensayo preclínico. Revista de Gastroenterología de México 2022. [DOI: 10.1016/j.rgmx.2021.05.007] [Reference Citation Analysis]
|
| 76 |
Atamna A, Babich T, Margalit I, Avni T, Ben Zvi H, Raz NE, Yahav D, Bishara J. Does accepted definition of Clostridioides difficile infection (CDI) severity predict poor outcomes in older adults? Aging Clin Exp Res 2022;34:583-9. [PMID: 34426944 DOI: 10.1007/s40520-021-01953-5] [Reference Citation Analysis]
|
| 77 |
Fan L, Ren J, Chen Y, Wang Y, Guo Z, Bu P, Yang J, Ma W, Zhu B, Zhao Y, Cai J. Effect of fecal microbiota transplantation on primary hypertension and the underlying mechanism of gut microbiome restoration: protocol of a randomized, blinded, placebo-controlled study. Trials 2022;23:178. [PMID: 35209934 DOI: 10.1186/s13063-022-06086-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 78 |
Zhang X, Ishikawa D, Nomura K, Fukuda N, Haraikawa M, Haga K, Shibuya T, Mita T, Nagahara A. Donor Screening Revisions of Fecal Microbiota Transplantation in Patients with Ulcerative Colitis. J Clin Med 2022;11:1055. [PMID: 35207328 DOI: 10.3390/jcm11041055] [Reference Citation Analysis]
|
| 79 |
Carlson TJ, Gonzales-Luna AJ, Garey KW. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med 2022;43:28-38. [PMID: 35172356 DOI: 10.1055/s-0041-1740973] [Reference Citation Analysis]
|
| 80 |
De-la-Rosa-Martinez D, Rivera-Buendía F, Cornejo-Juárez P, García-Pineda B, Nevárez-Luján C, Vilar-Compte D. Risk factors and clinical outcomes for Clostridioides difficile infections in a case control study at a large cancer referral center in Mexico. Am J Infect Control 2022:S0196-6553(22)00073-6. [PMID: 35172185 DOI: 10.1016/j.ajic.2022.02.011] [Reference Citation Analysis]
|
| 81 |
Piekarska A, Gil L, Mikulska M, Mensah-Glanowska P, Sbianchi G, Wendel L, Knelange N, Averbuch D, de la Camara R, Styczynski J. Discrepancies in the management of Clostridioides difficile infections in patients after allogeneic haematopoietic cell transplantation: the results of the Infectious Diseases Working Party EBMT survey. Bone Marrow Transplant 2022. [PMID: 35145219 DOI: 10.1038/s41409-022-01608-7] [Reference Citation Analysis]
|
| 82 |
Shu G, Li B, Dai C, Chen L, Yang X, Lei Z, Zhang M, Guo Y. Preparation of Saccharomyces boulardii powder by spray drying: thermoprotectants optimization and stability evaluation. Prep Biochem Biotechnol 2022;:1-9. [PMID: 35108154 DOI: 10.1080/10826068.2022.2028638] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 83 |
Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O'donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, Mccarthy PL, Munshi NC. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet Haematology 2022;9:e143-61. [DOI: 10.1016/s2352-3026(21)00283-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 84 |
Savigamin C, Mahakit N, Stithit S, Samuthpongtorn C. How to Initiate Fecal Microbiota Transplantation in Developing Countries Using the Behavior Economics Concept of "Choice Architecture". Front Med (Lausanne) 2021;8:746230. [PMID: 35096856 DOI: 10.3389/fmed.2021.746230] [Reference Citation Analysis]
|
| 85 |
Hou H, Chen D, Zhang K, Zhang W, Liu T, Wang S, Dai X, Wang B, Zhong W, Cao H. Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation? Cancer Lett 2022;526:225-35. [PMID: 34843863 DOI: 10.1016/j.canlet.2021.11.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 86 |
Gweon TG, Lee YJ, Kim KO, Yim SK, Soh JS, Kim SY, Park JJ, Shin SY, Lee TH, Choi CH, Cho YS, Yong D, Chung JW, Lee KJ, Lee OY, Choi MG, Choi M; Gut Microbiota and Therapy Research Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea. J Neurogastroenterol Motil 2022;28:28-42. [PMID: 34980687 DOI: 10.5056/jnm21221] [Reference Citation Analysis]
|
| 87 |
Malick A, Wang Y, Axelrad J, Salmasian H, Freedberg D. Obesity is not associated with adverse outcomes among hospitalized patients with Clostridioides difficile infection. Gut Pathog 2022;14. [DOI: 10.1186/s13099-022-00479-z] [Reference Citation Analysis]
|
| 88 |
Azimirad M, Jo Y, Kim MS, Jeong M, Shahrokh S, Asadzadeh Aghdaei H, Zali MR, Lee S, Yadegar A, Shin JH. Alterations and Prediction of Functional Profiles of Gut Microbiota After Fecal Microbiota Transplantation for Iranian Recurrent Clostridioides difficile Infection with Underlying Inflammatory Bowel Disease: A Pilot Study. J Inflamm Res 2022;15:105-16. [PMID: 35023946 DOI: 10.2147/JIR.S338212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 89 |
Augustyn W, Chruściel A, Hreczuch W, Kalka J, Tarka P, Kierat W. Inactivation of Spores and Vegetative Forms of Clostridioides difficile by Chemical Biocides: Mechanisms of Biocidal Activity, Methods of Evaluation, and Environmental Aspects. Int J Environ Res Public Health 2022;19:750. [PMID: 35055571 DOI: 10.3390/ijerph19020750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 90 |
Tsigalou C, Konstantinidis T, Aloizou A, Bezirtzoglou E, Tsakris A. Future Therapeutic Prospects in Dealing with Autoimmune Diseases: Treatment Based on the Microbiome Model. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases 2022. [DOI: 10.1007/978-981-19-4800-8_25] [Reference Citation Analysis]
|
| 91 |
Ohta H, Miyake T, Ueki T, Kojima M, Kawasaki M, Tatsuta T, Iuchi T, Kamitani S, Shimizu T, Mekata E, Tani M. Predictors and clinical impact of postoperative diarrhea after colorectal cancer surgery: a prospective, multicenter, observational study (SHISA-1602). Int J Colorectal Dis 2022;37:657-64. [PMID: 35080636 DOI: 10.1007/s00384-022-04097-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 92 |
Kim J, Kim J, Kim B, Pai H. Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole? Infect Chemother 2022;54:213. [DOI: 10.3947/ic.2022.0027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 93 |
Tang Q, Tang M. Gut Microbiota and Metabolic Diseases. JBM 2022;10:113-141. [DOI: 10.4236/jbm.2022.1011010] [Reference Citation Analysis]
|
| 94 |
Kumar T, Chauhan NS. Microbiome Therapeutics: A Path Toward Sustainable Healthcare. Comprehensive Gut Microbiota 2022. [DOI: 10.1016/b978-0-12-819265-8.00010-3] [Reference Citation Analysis]
|
| 95 |
Wang Y, Salmasian H, Schluger A, Gomez-simmonds A, Choy A, Li J, Axelrad JE, Freedberg DE. A Prediction Model Incorporating Peripheral Eosinopenia as a Novel Risk Factor for Death After Hospitalization for Clostridioides difficile Infection. Gastro Hep Advances 2022;1:38-44. [DOI: 10.1016/j.gastha.2021.10.002] [Reference Citation Analysis]
|
| 96 |
Rao A, Gokhale R. Ulcerative Colitis. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition 2022. [DOI: 10.1007/978-3-030-80068-0_30] [Reference Citation Analysis]
|
| 97 |
Revolinski S, Huang AM, Gibble A. Rapid Diagnostics in Infection Prevention. Infection Prevention 2022. [DOI: 10.1007/978-3-030-98427-4_31] [Reference Citation Analysis]
|
| 98 |
Seshadri A, Briggs A, Peitzman A. Surgical Rescue and Failure to Rescue. The Acute Management of Surgical Disease 2022. [DOI: 10.1007/978-3-031-07881-1_11] [Reference Citation Analysis]
|
| 99 |
Claeys KC, Blanco N, Leekha S. The Importance of C. difficile Colonization in Infection Prevention. Infection Prevention 2022. [DOI: 10.1007/978-3-030-98427-4_26] [Reference Citation Analysis]
|
| 100 |
Paquette IM, Stewart DB. Clostridium difficile Infection. The ASCRS Textbook of Colon and Rectal Surgery 2022. [DOI: 10.1007/978-3-030-66049-9_52] [Reference Citation Analysis]
|
| 101 |
Penney J, Wick J, Basein T, Doron S. C. difficile Microbiome Manipulation. Infection Prevention 2022. [DOI: 10.1007/978-3-030-98427-4_16] [Reference Citation Analysis]
|
| 102 |
El Ouali S, Achkar J. Management of Hospitalized Patients with Inflammatory Bowel Disease and CMV Infection or Clostridium Difficile Infection. Management of Inpatient Inflammatory Bowel Disease 2022. [DOI: 10.1007/978-1-0716-1987-2_8] [Reference Citation Analysis]
|
| 103 |
Chen Y, Li Y. Metabolic reprogramming and immunity in cancer. Cancer Immunology and Immunotherapy 2022. [DOI: 10.1016/b978-0-12-823397-9.00006-5] [Reference Citation Analysis]
|
| 104 |
Zou B, Liu SX, Li XS, He JY, Dong C, Ruan ML, Xu L, Bai T, Huang ZH, Shu SN. Long-term safety and efficacy of fecal microbiota transplantation in 74 children: A single-center retrospective study. Front Pediatr 2022;10:964154. [PMID: 36304525 DOI: 10.3389/fped.2022.964154] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 105 |
Liu Y, Zhang S, Wu X, Li Q, Wang Y, Huang Y, Zhang F, Cui B, Lu X. Instant messaging client gives the opportunity to recognize gut microbiota and dysbiosis-related disease: An investigation study on WeChat APP. Digit Health 2022;8:20552076221115018. [PMID: 35898289 DOI: 10.1177/20552076221115018] [Reference Citation Analysis]
|
| 106 |
Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 107 |
Chen S, Luo S, Yan C. Gut Microbiota Implications for Health and Welfare in Farm Animals: A Review. Animals (Basel) 2021;12:93. [PMID: 35011199 DOI: 10.3390/ani12010093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 108 |
Niu W, Yang F, Fu Z, Dong Y, Zhang Z, Ju J. The role of enteric dysbacteriosis and modulation of gut microbiota in the treatment of inflammatory bowel disease. Microb Pathog 2021;:105381. [PMID: 34974123 DOI: 10.1016/j.micpath.2021.105381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 109 |
Pan Q, Guo F, Huang Y, Li A, Chen S, Chen J, Liu HF, Pan Q. Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies. Front Immunol 2021;12:799788. [PMID: 34925385 DOI: 10.3389/fimmu.2021.799788] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 110 |
Douglas SJ, Remily EA, Sax OC, Pervaiz SS, Polsky EB, Delanois RE. THAs Performed Within 6 Months of Clostridioides difficile Infection Are Associated with Increased Risk of 90-Day Complications. Clin Orthop Relat Res 2021;479:2704-11. [PMID: 34033616 DOI: 10.1097/CORR.0000000000001837] [Reference Citation Analysis]
|
| 111 |
van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia JE, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild MJGT, Fitzpatrick F, Kuijper EJ; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021;27 Suppl 2:S1-S21. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 51.5] [Reference Citation Analysis]
|
| 112 |
Monika Laszkowska, Judith Kim, Adam S. Faye, Andrew M. Joelson, Myles Ingram, Han Truong, Elisabeth R. Silver, Benjamin May, William G. Greendyke, Jason Zucker, Benjamin Lebwohl, Chin Hur, Daniel E. Freedberg. Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19. Dig Dis Sci 2021;66. [PMID: 33479861 DOI: 10.1007/s10620-020-06760-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 113 |
Markovic S, Jankovic M, Kalaba A, Zogovic B, Sreckovic SS. Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series. Cureus 2021;13:e19019. [PMID: 34824934 DOI: 10.7759/cureus.19019] [Reference Citation Analysis]
|
| 114 |
Eindor-Abarbanel A, Healey GR, Jacobson K. Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood. Int J Mol Sci 2021;22:12506. [PMID: 34830388 DOI: 10.3390/ijms222212506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 115 |
Liu N, Zhang T, Sun J, Fu J, Li H. The clinical efficacy of faecal microbiota transplantation: An umbrella review of randomized controlled trials.. [DOI: 10.1101/2021.11.18.21266556] [Reference Citation Analysis]
|
| 116 |
Sehgal K, Zandvakili I, Tariq R, Pardi DS, Khanna S. Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34693838 DOI: 10.1080/14787210.2022.1997588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 117 |
Ianiro G, Porcari S, Bibbò S, Giambò F, Quaranta G, Masucci L, Sanguinetti M, Gasbarrini A, Cammarota G. Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. Dig Liver Dis 2021;53:1428-32. [PMID: 34030988 DOI: 10.1016/j.dld.2021.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 118 |
Pakhomovskaia NL, Tatyanina OF, Lazareva ТY. Approaches to prevention of antibiotic-associated diarrhea in children. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-17-1] [Reference Citation Analysis]
|
| 119 |
Gu X, Lu Q, Zhang C, Tang Z, Chu L. Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review. Semin Liver Dis 2021;41:495-506. [PMID: 34261137 DOI: 10.1055/s-0041-1732319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 120 |
Paparella AS, Aboulache BL, Harijan RK, Potts KS, Tyler PC, Schramm VL. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues. Nat Commun 2021;12:6285. [PMID: 34725358 DOI: 10.1038/s41467-021-26580-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 121 |
Hamo Z, Azrad M, Fichtman B, Peretz A. The Cytopathic Effect of Different Toxin Concentrations From Different Clostridioides difficile Sequence Types Strains in Vero Cells. Front Microbiol 2021;12:763129. [PMID: 34712220 DOI: 10.3389/fmicb.2021.763129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 122 |
Varesi A, Deumer US, Ananth S, Ricevuti G. The Emerging Role of Gut Microbiota in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Current Evidence and Potential Therapeutic Applications. J Clin Med 2021;10:5077. [PMID: 34768601 DOI: 10.3390/jcm10215077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 123 |
Lin D, Hu B, Li P, Zhao Y, Xu Y, Wu D. Roles of the intestinal microbiota and microbial metabolites in acute GVHD. Exp Hematol Oncol 2021;10:49. [PMID: 34706782 DOI: 10.1186/s40164-021-00240-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 124 |
Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, Zhang HC, Thomas AS, Okhuysen P, Wang Y. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients. J Cancer 2021;12:6498-506. [PMID: 34659541 DOI: 10.7150/jca.59251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 125 |
Burstiner LS, Silver J, Burstiner LJ, Teymoorian A, Pallav K, Jones D, Owings A, Glover S. Escherichia coli O157: H7 sepsis following fecal microbiota transplant in an IgA-deficient inflammatory bowel disease patient. Gastroenterology Report 2021. [DOI: 10.1093/gastro/goab041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 126 |
van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, Dekkers OM, Kuijper EJ, Keller JJ, van Prehn J. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00552-8. [PMID: 34655745 DOI: 10.1016/j.cmi.2021.09.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 127 |
Ma Y. Ethical Issues of Human Microbiome Research. eLS 2021. [DOI: 10.1002/9780470015902.a0029126] [Reference Citation Analysis]
|
| 128 |
Ressler A, Wang J, Rao K. Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211048127. [PMID: 34646358 DOI: 10.1177/17562848211048127] [Reference Citation Analysis]
|
| 129 |
Ashraf MF, Tageldin O, Nassar Y, Batool A. Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection: A Four-Year Single-Center Retrospective Review. Gastroenterology Res 2021;14:237-43. [PMID: 34527093 DOI: 10.14740/gr1436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 130 |
Aurelia H, Sorin R, Elena M, Eugen D, Magdalena DI. Performance and Consequences for Fecal Transplant in the Treatment of Pseudomembranous Colitis. ARS Medica Tomitana 2020;26:113-6. [DOI: 10.2478/arsm-2020-0023] [Reference Citation Analysis]
|
| 131 |
Baunwall SMD, Dahlerup JF, Engberg JH, Erikstrup C, Helms M, Juel MA, Kjeldsen J, Nielsen HL, Nilsson AC, Rode AA, Vinter-Jensen L, Hvas CL. Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scand J Gastroenterol 2021;56:1056-77. [PMID: 34261379 DOI: 10.1080/00365521.2021.1922749] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 132 |
Varma S, Faye AS, Kannan A, Lawlor G, Verma A, Axelrad J, Freedberg DE. Patients with More Severe IBD Get Clostridioides difficile Rather than Clostridioides difficile Increasing the Severity of IBD. Dig Dis Sci 2021;66:3113-23. [PMID: 32729015 DOI: 10.1007/s10620-020-06504-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 133 |
Shrestha MP, Taleban S. Colectomy Rates Are Increasing Among Inpatients With Concomitant Ulcerative Colitis and Clostridioides difficile. J Clin Gastroenterol 2021;55:709-15. [PMID: 32804686 DOI: 10.1097/MCG.0000000000001412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 134 |
Gupta S, Zhu J, McCarty TR, Pruce J, Kassam Z, Kelly C, Fischer M, Allegretti JR. Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection. J Gastroenterol Hepatol 2021;36:2432-40. [PMID: 33682170 DOI: 10.1111/jgh.15483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 135 |
Nho SW, Kim M, Kim SJ, Foley SL, Nayak R, Kweon O, Cerniglia CE. Pragmatic Strategy for Fecal Specimen Storage and the Corresponding Test Methods for Clostridioides difficile Diagnosis. Pathogens 2021;10:1049. [PMID: 34451512 DOI: 10.3390/pathogens10081049] [Reference Citation Analysis]
|
| 136 |
Shao HQ, Tan ZJ. Microbiota-targeted therapeutics in gastrointestinal diseases. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 841-848 [DOI: 10.11569/wcjd.v29.i15.841] [Reference Citation Analysis]
|
| 137 |
Gholam-Mostafaei FS, Yadegar A, Asadzadeh Aghdaei H, Shahrokh S, Ebrahimi Daryani N, Zali MR. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis. Acta Microbiol Immunol Hung 2021. [PMID: 34383708 DOI: 10.1556/030.2021.01498] [Reference Citation Analysis]
|
| 138 |
Elangovan A, Fischer M. When to use probiotics in luminal gastrointestinal disorders? Curr Opin Clin Nutr Metab Care 2020;23:336-43. [PMID: 32657791 DOI: 10.1097/MCO.0000000000000674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 139 |
Johnson TM, Molina KC, Howard AH, Schwarz K, Allen L, Huang M, Bajrovic V, Miller MA. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin Infect Dis 2021:ciab674. [PMID: 34665248 DOI: 10.1093/cid/ciab674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 140 |
Baek C, Li YG, Yoo HJ, Cui WY, Kang JT, Son J, Min J. Simple and portable on-site system for nucleic acid-based detection of Clostridium difficile in stool samples using two columns containing microbeads and loop-mediated isothermal amplification. Anal Bioanal Chem 2021. [PMID: 34341839 DOI: 10.1007/s00216-021-03557-4] [Reference Citation Analysis]
|
| 141 |
Cheng YW, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-Nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1627-34. [PMID: 32645451 DOI: 10.1016/j.cgh.2020.06.051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 142 |
Reggiani Bonetti L, Leoncini G, Daperno M, Principi MB, Baronchelli C, Manenti S, Caprioli F, Armuzzi A, Caputo A, Parente P, Cadei M, Villanacci V. Histopathology of non-IBD colitis practical recommendations from pathologists of IG-IBD Group. Dig Liver Dis 2021;53:950-7. [PMID: 33712395 DOI: 10.1016/j.dld.2021.01.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 143 |
Dhere T, Tager D, Kilakkathi SP, Woodworth MH, Kraft CS. Earlier use of fecal transplant administration during hospitalization for Clostridioides difficile infectionmay improve outcome. Eur J Gastroenterol Hepatol 2021;33:1132-3. [PMID: 34213510 DOI: 10.1097/MEG.0000000000002159] [Reference Citation Analysis]
|
| 144 |
Cançado GGL, Abreu ES, Nardelli MJ, Serwa P, Brachmann M. A cost of illness comparison for toxigenic Clostridioides difficile diagnosis algorithms in developing countries. Anaerobe 2021;70:102390. [PMID: 34058377 DOI: 10.1016/j.anaerobe.2021.102390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 145 |
Katzer KC, Hagel S, Reuken PA, Bruns T, Stallmach A. Development and validation of a simple and robust model to predict 30-day mortality in patients with Clostridioides difficile-associated enterocolitis. BMJ Open Gastroenterol 2020;7:e000468. [PMID: 32912845 DOI: 10.1136/bmjgast-2020-000468] [Reference Citation Analysis]
|
| 146 |
Song YN, Yang DY, Veldhuyzen van Zanten S, Wong K, Mcarthur E, Song CZ, Ianiro G, Cammarota G, Kelly C, Fischer M, Russell L, Kao D. Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile Infection: Systematic Review and Meta-analysis. Journal of the Canadian Association of Gastroenterology 2022;5:e1-e11. [DOI: 10.1093/jcag/gwab023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 147 |
Lazebnik LB, Sarsenbaeva AS, Avalueva EB, Oreshko LS, Sitkin SI, Golovanova EV, Turkina SV, Khlynova OV, Sagalova OI, Mironchev OV. Clinical guidelines “Chronic diarrhea in adults”. jour 2021. [DOI: 10.31146/1682-8658-ecg-188-4-7-67] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 148 |
Khanafer N, Vanhems P, Bennia S, Martin-Gaujard G, Juillard L, Rimmelé T, Argaud L, Martin O, Huriaux L, Marcotte G, Hernu R, Floccard B, Cassier P, Group S. Factors Associated with Clostridioides (Clostridium) Difficile Infection and Colonization: Ongoing Prospective Cohort Study in a French University Hospital. Int J Environ Res Public Health 2021;18:7528. [PMID: 34299978 DOI: 10.3390/ijerph18147528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 149 |
Araki K, Torigoe H, Hirano Y, Washio K. A case of <i>Clostridioides difficile</i> infection after lung cancer surgery. The Journal of the Japanese Association for Chest Surgery 2021;35:612-618. [DOI: 10.2995/jacsurg.35.612] [Reference Citation Analysis]
|
| 150 |
Suh Y, Ah YM, Chun HJ, Lee SM, Kim HS, Gu HJ, Kim AJ, Chung JE, Cho Y, Lee YH, Hwangbo SY, Kim J, Kim ES, Kim HB, Lee E, Lee JY. Potential Impact of the Involvement of Clinical Pharmacists in Antimicrobial Stewardship Programs on the Incidence of Antimicrobial-Related Adverse Events in Hospitalized Patients: A Multicenter Retrospective Study. Antibiotics (Basel) 2021;10:853. [PMID: 34356774 DOI: 10.3390/antibiotics10070853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 151 |
Gonzales-Luna AJ, Olaitan AO, Shen WJ, Deshpande A, Carlson TJ, Dotson KM, Lancaster C, Begum K, Alam MJ, Hurdle JG, Garey KW. Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection. Open Forum Infect Dis 2021;8:ofab365. [PMID: 34381844 DOI: 10.1093/ofid/ofab365] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 152 |
Asgary R, Snead JA, Wahid NA, Ro V, Halim M, Stribling JC. Risks and Preventive Strategies for Clostridioides difficile Transmission to Household or Community Contacts during Transition in Healthcare Settings. Emerg Infect Dis 2021;27:1776-82. [PMID: 34152967 DOI: 10.3201/eid2707.200209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 153 |
Tariq R, Saha S, Solanky D, Pardi DS, Khanna S. Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Journal of Clinical Gastroenterology 2021;55:542-547. [DOI: 10.1097/mcg.0000000000001398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 154 |
Wang B, Wang L, Wang H, Dai H, Lu X, Lee YK, Gu Z, Zhao J, Zhang H, Chen W, Wang G. Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders. J Nutr 2021;151:1703-16. [PMID: 33982127 DOI: 10.1093/jn/nxab103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 155 |
Feng J, Tang YN, Zhou LX, Pan JS. Standardized Nursing Procedures for Fecal Microbiota Transplantation via Upper Endoscopy. Gastroenterol Nurs 2021;44:227-32. [PMID: 34176888 DOI: 10.1097/SGA.0000000000000577] [Reference Citation Analysis]
|
| 156 |
van Rossen TM, Ooijevaar RE, Vandenbroucke-grauls CM, Dekkers OM, Kuijper EJ, Keller JJ, van Prehn J. GRADING prognostic factors for severe and recurrent Clostridioides difficile infection: expected and unexpected findings. A systematic review.. [DOI: 10.1101/2021.06.22.21259313] [Reference Citation Analysis]
|
| 157 |
Sanders DJ, Inniss S, Sebepos-Rogers G, Rahman FZ, Smith AM. The role of the microbiome in gastrointestinal inflammation. Biosci Rep 2021;41:BSR20203850. [PMID: 34076695 DOI: 10.1042/BSR20203850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 158 |
Adelman MW, Woodworth MH, Shaffer VO, Martin GS, Kraft CS. Critical Care Management of the Patient with Clostridioides difficile. Crit Care Med 2021;49:127-39. [PMID: 33156122 DOI: 10.1097/CCM.0000000000004739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 159 |
Mantri N, Patel H, Badipatla KR, Sun H, Shaikh D, Gongati S, Nayudu SK. Clostridioides difficile Infection and Liver Cirrhosis - A Retrospective, Cohort Study. Clin Exp Gastroenterol 2021;14:229-35. [PMID: 34113145 DOI: 10.2147/CEG.S308862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 160 |
Abad CLR, Safdar N. A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea. Gastroenterol Clin North Am 2021;50:323-40. [PMID: 34024444 DOI: 10.1016/j.gtc.2021.02.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 161 |
Agarwal A, Maheshwari A, Verma S, Arrup D, Phillips L, Vinayek R, Nair P, Hagan M, Dutta S. Superiority of Higher-Volume Fresh Feces Compared to Lower-Volume Frozen Feces in Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Colitis. Dig Dis Sci 2021;66:2000-4. [PMID: 32656604 DOI: 10.1007/s10620-020-06459-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 162 |
Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 107] [Cited by in F6Publishing: 82] [Article Influence: 53.5] [Reference Citation Analysis]
|
| 163 |
Grinevich VB, Kravchuk YA, Ped VI, Sas EI, Salikova SP, Gubonina IV, Tkachenko EI, Sitkin SI, Lazebnik LB, Golovanova EV, Belousova EA, Makarchuk PA, Eremina EY, Sarsenbaeva AS, Abdulganieva DI, Tarasova LV, Gromova OA, Ratnikov VA, Kozlov KV, Ratnikova AK. Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition). jour 2021. [DOI: 10.31146/1682-8658-ecg-187-3-5-82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 164 |
Song Y, Shao HY, Cheng X, Guo Y. First case of periprosthetic joint infection due to Clostridioides difficile in China. BMC Infect Dis 2021;21:462. [PMID: 34020604 DOI: 10.1186/s12879-021-06171-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 165 |
Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis 2021;21:456. [PMID: 34016040 DOI: 10.1186/s12879-021-06147-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 166 |
Sun J, Chen YL, Ding YC, Zhong H, Wu M, Liu ZH, Ge LP. Deposition of resistant bacteria and resistome through FMT in germ-free piglets. Lett Appl Microbiol 2021;73:187-96. [PMID: 33894059 DOI: 10.1111/lam.13490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 167 |
Chaar A, Feuerstadt P. Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:17562848211011953. [PMID: 33995583 DOI: 10.1177/17562848211011953] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 168 |
Cook L, Rees WD, Wong MQ, Peters H, Levings MK, Steiner TS. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection Enhances Adaptive Immunity to C difficile Toxin B. Gastroenterology 2021;160:2155-2158.e4. [PMID: 33444574 DOI: 10.1053/j.gastro.2021.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 169 |
Dolle RE, Mcgrane LK, Janetka JW, Hammill JT, Guy RK, Debnath A, Cheuka PM, Manach CL, Chibale K, Elhammer A, Handfield M, Dawson MJ, Donadio S, Park JH, Joslyn A. Anti‐Infective Case Histories. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc288] [Reference Citation Analysis]
|
| 170 |
Zhang L, Ma X, Liu P, Ge W, Hu L, Zuo Z, Xiao H, Liao W. Treatment and mechanism of fecal microbiota transplantation in mice with experimentally induced ulcerative colitis. Exp Biol Med (Maywood) 2021;246:1563-75. [PMID: 33926254 DOI: 10.1177/15353702211006044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 171 |
Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol 2021;14:17562848211009694. [PMID: 33959193 DOI: 10.1177/17562848211009694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 172 |
Chen J, Zaman A, Ramakrishna B, Olesen SW. Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank. Front Cell Infect Microbiol 2021;11:622949. [PMID: 33937092 DOI: 10.3389/fcimb.2021.622949] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 173 |
Ghasemi A, Mohabati Mobarez A, Mostafavi E. Investigation of Clostridium difficile in elderly people: A preliminary study in Iran. Trop Doct 2021;51:319-22. [PMID: 33847546 DOI: 10.1177/0049475521999221] [Reference Citation Analysis]
|
| 174 |
Khasanova GR, Yakupova GR, Kondratieva KA, Lokotkova A, Bulycheva IA, Shaikhrazieva ND. Physiciansʼ awareness level assessment of the epidemiology and diagnosis features of nosocomial infection caused by Clostridium difficile in a multidisciplinary hospitals. Epidemiology and Infectious Diseases 2021;25:167-173. [DOI: 10.17816/eid52696] [Reference Citation Analysis]
|
| 175 |
Voicu MN, Ahmet AM, Turcu-Stiolica A, Ungureanu BS, Dragoescu AN, Popescu F. Clostridoides difficile Infection Severity Assessment by Fecal Calprotectin: A Pilot Study. Curr Health Sci J 2021;47:204-8. [PMID: 34765239 DOI: 10.12865/CHSJ.47.02.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 176 |
Diseases of the Small Intestine and Colorectum. Non-Neoplastic Disorders of the Gastrointestinal Tract 2021. [DOI: 10.55418/9781933477930-04] [Reference Citation Analysis]
|
| 177 |
Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol 2021;116:647-56. [PMID: 33982930 DOI: 10.14309/ajg.0000000000001075] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 178 |
Schmidt EKA, Raposo PJF, Madsen KL, Fenrich KK, Kabarchuk G, Fouad K. What Makes a Successful Donor? Fecal Transplant from Anxious-Like Rats Does Not Prevent Spinal Cord Injury-Induced Dysbiosis. Biology (Basel) 2021;10:254. [PMID: 33804928 DOI: 10.3390/biology10040254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Cortés P, Bi Y, Stancampiano F, Valery JR, Cooper JH, Harris DM. Clostridioides Difficile Infection: A comprehensive review for primary providers. Rom J Intern Med 2021. [PMID: 33713592 DOI: 10.2478/rjim-2021-0010] [Reference Citation Analysis]
|
| 180 |
Voth E, Solanky D, Loftus EV Jr, Pardi DS, Khanna S. Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection. Therap Adv Gastroenterol 2021;14:1756284821997792. [PMID: 33786065 DOI: 10.1177/1756284821997792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 181 |
Chauhan A, Kumar R, Sharma S, Mahanta M, Vayuuru SK, Nayak B, Kumar S, Shalimar. Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study. Dig Dis Sci 2021;66:873-80. [PMID: 32279172 DOI: 10.1007/s10620-020-06246-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 182 |
Krishna SG, Chu BK, Blaszczak AM, Balasubramanian G, Hussan H, Stanich PP, Mumtaz K, Hinton A, Conwell DL. Hospital outcomes and early readmission for the most common gastrointestinal and liver diseases in the United States: Implications for healthcare delivery. World J Gastrointest Surg 2021; 13(2): 141-152 [PMID: 33643534 DOI: 10.4240/wjgs.v13.i2.141] [Reference Citation Analysis]
|
| 183 |
Berland M, Cadiou J, Levenez F, Galleron N, Quinquis B, Thirion F, Gauthier F, Le Chatelier E, Plaza Oñate F, Schwintner C, Rabot S, Lepage P, Ehrlich D, Doré J, Juste C. High engraftment capacity of frozen ready-to-use human fecal microbiota transplants assessed in germ-free mice. Sci Rep 2021;11:4365. [PMID: 33623056 DOI: 10.1038/s41598-021-83638-7] [Reference Citation Analysis]
|
| 184 |
Henson MA. Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection. PLoS Comput Biol 2021;17:e1008782. [PMID: 33617526 DOI: 10.1371/journal.pcbi.1008782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 185 |
O'Donnell JN, Novak GM, Bratek BR, Singh G, Duru OO, Mitchell CL, Roddy KM, Bidell MR. Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection. Int J Antimicrob Agents 2021;57:106311. [PMID: 33621602 DOI: 10.1016/j.ijantimicag.2021.106311] [Reference Citation Analysis]
|
| 186 |
Conley TE, Fiske J, Subramanian S. How to manage: acute severe colitis. Frontline Gastroenterol 2022;13:64-72. [PMID: 34970430 DOI: 10.1136/flgastro-2020-101710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 187 |
Elbeddini A, Gerochi R. Treatment of Clostridium difficile infection in community teaching hospital: a retrospective study. J Pharm Policy Pract 2021;14:19. [PMID: 33568232 DOI: 10.1186/s40545-020-00289-1] [Reference Citation Analysis]
|
| 188 |
Asano S, Katsura M. Determining the optimal surgical timing of fulminant Clostridium difficile colitis by using four objective factors and computed tomography findings: A case report. Int J Surg Case Rep 2021;80:105633. [PMID: 33609944 DOI: 10.1016/j.ijscr.2021.02.019] [Reference Citation Analysis]
|
| 189 |
Wang J, Ortiz C, Fontenot L, Mukhopadhyay R, Xie Y, Chen X, Feng H, Pothoulakis C, Koon HW. Therapeutic Mechanism of Macrophage Inflammatory Protein 1 α Neutralizing Antibody (CCL3) in Clostridium difficile Infection in Mice. J Infect Dis 2020;221:1623-35. [PMID: 31793629 DOI: 10.1093/infdis/jiz640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 190 |
Littmann ER, Lee JJ, Denny JE, Alam Z, Maslanka JR, Zarin I, Matsuda R, Carter RA, Susac B, Saffern MS, Fett B, Mattei LM, Bittinger K, Abt MC. Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection. Nat Commun 2021;12:755. [PMID: 33531483 DOI: 10.1038/s41467-020-20793-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 191 |
Aràjol C, Aira Gómez A, González-suárez B, Casals-pascual C, Martí Martí S, Domínguez Luzón MÁ, Soriano A, Guardiola Capón J. Donor selection for faecal microbiota transplantation. Consensus document of the Catalan Society of Gastroenterology and the Catalan Society of Infectious Diseases and Clinical Microbiology. Gastroenterología y Hepatología (English Edition) 2021;44:175-180. [DOI: 10.1016/j.gastre.2020.07.005] [Reference Citation Analysis]
|
| 192 |
Ramai D, Zakhia K, Fields PJ, Ofosu A, Patel G, Shahnazarian V, Lai JK, Dhaliwal A, Reddy M, Chang S. Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Dig Dis Sci 2021;66:369-80. [PMID: 32166622 DOI: 10.1007/s10620-020-06185-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 193 |
Vincenzo Villanacci, Luca Reggiani-Bonetti, Giuseppe Leoncini, Paola Parente, Moris Cadei, Luca Albarello, Giulio Mandelli, Alessandro Caputo. Histopathology of Non-IBD Colitis. A practical approach from the Italian Group for the study of the gastrointestinal tract (GIPAD). Pathologica 2021;113. [PMID: 33686310 DOI: 10.32074/1591-951X-234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 194 |
Gupta A, Wash C, Wu Y, Sorrentino D, Nguyen VQ. Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease. Dig Dis Sci 2021;66:547-553. [DOI: 10.1007/s10620-020-06205-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 195 |
Tijerina-rodríguez L, Garza-gonzález E, Martínez-meléndez A, Morfín-otero R, Camacho-ortiz A, Gonzalez-diaz E, Perez-gomez HR, Villarreal-treviño L, Maldonado-garza H, Esparza- Ahumada S, Rodríguez-noriega E. Clinical characteristics associated with the severity of Clostridium [Clostridioides] difficile infection in a tertiary teaching hospital from Mexico. Biomedical Journal 2021. [DOI: 10.1016/j.bj.2021.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 196 |
Seong E, Lim S, Lee M, Kim H. A Study of Antimicrobial Activity of Herbal Extracts on Clostridium difficile. J Korean Med Rehabil 2021;31:47-57. [DOI: 10.18325/jkmr.2021.31.1.47] [Reference Citation Analysis]
|
| 197 |
Бекетова Г, Солдатова О. Modern Possibilities of Correction of Microbiome Disorders in Children. The Role of Bifidobacterium Animalis Subspecies Lactis BB-12® from the Standpoint of Evidence-Based Medicine. Педиатрия. Восточная Европа 2021. [DOI: 10.34883/pi.2020.8.4.006] [Reference Citation Analysis]
|
| 198 |
Shedoeva LR, Chashkova EY, Rubtsov AS. Successful Experience of Fecal Transplantation in a Patient with Severe Pseudomembranous Colitis. Acta biomedica scientifica 2021;5:248-253. [DOI: 10.29413/abs.2020-5.6.32] [Reference Citation Analysis]
|
| 199 |
Fang H, Fu L, Li X, Lu C, Su Y, Xiong K, Zhang L. Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study. Microb Cell Fact 2021;20:18. [PMID: 33468164 DOI: 10.1186/s12934-021-01513-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 200 |
Loloi J, Mrowczynski O, Claxton B, Abdulbasit M, Schade M. Clostridium difficile Infection of a Total Hip Arthroplasty: Case Report and Review of the Literature. JBJS Case Connect 2020;10:e0266. [PMID: 32224686 DOI: 10.2106/JBJS.CC.19.00226] [Reference Citation Analysis]
|
| 201 |
Zhong M, Buch H, Wen Q, Long C, Cui B, Zhang F. Colonic Transendoscopic Enteral Tubing: Route for a Novel, Safe, and Convenient Delivery of Washed Microbiota Transplantation in Children. Gastroenterol Res Pract 2021;2021:6676962. [PMID: 33510783 DOI: 10.1155/2021/6676962] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 202 |
Yoon H, Shim HI, Seol M, Shin CM, Park YS, Kim N, Lee DH. Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection. Gut Liver 2021;15:61-9. [PMID: 32839363 DOI: 10.5009/gnl20135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 203 |
Feuerstadt P, Boules M, Stong L, Dahdal DN, Sacks NC, Lang K, Nelson WW. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis. SAGE Open Med 2021;9:2050312120986733. [PMID: 33505698 DOI: 10.1177/2050312120986733] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 204 |
Guery B, Barbut F, Tschudin-Sutter S. Diagnostic and therapy of severe Clostridioides difficile infections in the ICU. Curr Opin Crit Care 2020;26:450-8. [PMID: 32739967 DOI: 10.1097/MCC.0000000000000753] [Reference Citation Analysis]
|
| 205 |
Chen T, Xia C, Hu H, Wang H, Tan B, Tian P, Zhao X, Wang L, Han Y, Deng KY, Wei H, Xin HB. Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination. Int J Antimicrob Agents 2021;57:106277. [PMID: 33434677 DOI: 10.1016/j.ijantimicag.2021.106277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 206 |
Kim D, Yoo ER, Li AA, Tighe SP, Cholankeril G, Ahmed A. Trends in Hospitalizations for Clostridioides difficile Infection in End-Stage Liver Disease, 2005-2014. Dig Dis Sci 2021;66:296-307. [PMID: 32124196 DOI: 10.1007/s10620-020-06162-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 207 |
Hays RA, Surawicz C. Clostridium (Now Clostridioides) difficile-Associated Disease. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_71] [Reference Citation Analysis]
|
| 208 |
Akshita Gupta, Ashwin N. Ananthakrishnan. Economic burden and cost-effectiveness of therapies for
Clostridiodes difficile infection: a narrative
review. Therap Adv Gastroenterol 2021;14:17562848211018654. [PMID: 34104214 DOI: 10.1177/17562848211018654] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 209 |
Puricelli C, Rolla R, Gigliotti L, Boggio E, Beltrami E, Dianzani U, Keller R. The Gut-Brain-Immune Axis in Autism Spectrum Disorders: A State-of-Art Report. Front Psychiatry 2021;12:755171. [PMID: 35185631 DOI: 10.3389/fpsyt.2021.755171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 210 |
J Sadowsky M, Erickson R, Wang P, J Hamilton M, Hoo M, Kaiser T, Fryxell K, Khoruts A. Inactivation of Clostridioides Difficile Spores in Carpeting and Upholstery to Reduce Disease Recurrence in Households and Nursing Care Facilities. J Pub Health Issue Pract 2021;5. [DOI: 10.33790/jphip1100189] [Reference Citation Analysis]
|
| 211 |
Theodoropoulos GE. Gut Microbiome and Cancer. Gut Microbiome-Related Diseases and Therapies 2021. [DOI: 10.1007/978-3-030-59642-2_4] [Reference Citation Analysis]
|
| 212 |
Miljković I, Topuz A. The knowledge of nurses about prevention of infections caused by the bacteria Clostridium difficile. Biomed istr 2021;12:61-68. [DOI: 10.5937/bii2101061m] [Reference Citation Analysis]
|
| 213 |
Woods J, Bhatt N, Coimbra R. Clostridium difficile Infection in Surgical Patients. Infections in Surgery 2021. [DOI: 10.1007/978-3-030-62116-2_10] [Reference Citation Analysis]
|
| 214 |
Zhang VRY, Woo ASJ, Scaduto C, Cruz MTK, Tan YY, Du H, Feng M, Siah KTH. Systematic review on the definition and predictors of severe Clostridiodes difficile infection. J Gastroenterol Hepatol 2021;36:89-104. [PMID: 32424877 DOI: 10.1111/jgh.15102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 215 |
Allegretti JR, Mehta SR, Kassam Z, Kelly CR, Kao D, Xu H, Fischer M. Risk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection. Dig Dis Sci 2021;66:213-7. [PMID: 32170474 DOI: 10.1007/s10620-020-06198-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 216 |
Lügering N, Stallmach A. Clostridioides-difficile-Infektion. Therapie-Handbuch - Gastroenterologie und Hepatologie 2021. [DOI: 10.1016/b978-3-437-23847-5.00027-2] [Reference Citation Analysis]
|
| 217 |
Sommermeyer H, Piątek J. Clinical Picture of CDI. Clostridioides difficile 2021. [DOI: 10.1007/978-3-030-81100-6_7] [Reference Citation Analysis]
|
| 218 |
Frech TM, Mayer J, Bellando-randone S. Management Challenges in the Early Systemic Sclerosis Population: Navigating Side Effects of Therapeutics and Approach to Diarrhea. In Clinical Practice 2021. [DOI: 10.1007/978-3-030-53736-4_31] [Reference Citation Analysis]
|
| 219 |
Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology 2021;160:183-192.e3. [PMID: 33011173 DOI: 10.1053/j.gastro.2020.09.038] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 220 |
Pisano JC, Mullane KM. Clostridioides Difficile: Where Should the Management Strategies in Transplant Vary? Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_23] [Reference Citation Analysis]
|
| 221 |
Sultan K, Becher N. Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-81780-0_3] [Reference Citation Analysis]
|
| 222 |
Shedoeva LR, Chashkova EY, Karnoukhova OG, Kogan GY. The hardware method of biomaterial preparation for fecal transplantation. Alʹm klin med 2020;48:403-411. [DOI: 10.18786/2072-0505-2020-48-060] [Reference Citation Analysis]
|
| 223 |
Sarsenbaeva AS, Lazebnik LB. Features of intestinal damage in COVID-19. jour 2020. [DOI: 10.31146/1682-8658-ecg-184-12-16-22] [Reference Citation Analysis]
|
| 224 |
Escudero-Sánchez R, Ruíz-Ruizgómez M, Fernández-Fradejas J, García Fernández S, Olmedo Samperio M, Cano Yuste A, Valencia Alijo A, Díaz-Pollán B, Rodríguez Hernández MJ, Merino De Lucas E, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez Gutiérrez B, Rodríguez-Pardo D, Ramos Martínez A, De La Torre Cisneros J, López-Medrano F, Cobo Reinoso J. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. J Clin Med 2020;10:E2. [PMID: 33374989 DOI: 10.3390/jcm10010002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 225 |
Chowdhry M, Haden D, Kemper S, Helmick K, Kawsara M, Huggett A, Stark A, Khan A, Shah M, Bhaty M, Farooq J, Singh S, McJunkin B. Usual opioid dosing does not adversely affect the course of healthcare-associated Clostridioides difficile infection. Pain Manag 2021;11:151-7. [PMID: 33350354 DOI: 10.2217/pmt-2020-0066] [Reference Citation Analysis]
|
| 226 |
Axenfeld E, Greendyke WG, Li J, Green DA, Whittier S, Freedberg DE. Burden and risk factors for inappropriate Clostridioides Difficile infection testing among hospitalized patients. Diagn Microbiol Infect Dis 2021;99:115283. [PMID: 33360514 DOI: 10.1016/j.diagmicrobio.2020.115283] [Reference Citation Analysis]
|
| 227 |
Cheng YW, Fischer M. Fecal Microbiota Transplantation for Ulcerative Colitis. Are We Ready for Primetime? Gastroenterol Clin North Am 2020;49:739-52. [PMID: 33121693 DOI: 10.1016/j.gtc.2020.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 228 |
Ding X, Yang X, Wang H. Methodology, efficacy and safety of fecal microbiota transplantation in treating inflammatory bowel disease. Medicine in Microecology 2020;6:100028. [DOI: 10.1016/j.medmic.2020.100028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 229 |
Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol 2020;10:572912. [PMID: 33330122 DOI: 10.3389/fcimb.2020.572912] [Cited by in Crossref: 92] [Cited by in F6Publishing: 105] [Article Influence: 30.7] [Reference Citation Analysis]
|
| 230 |
Teixeira A, Tripathi K, Greeff Y, Sorour O, Mccallion P, Davis G, Sorour K. Intracolonic Administration of Vancomycin in Intensive Care Unit Patients with Severe Clostridium Difficile Colitis. Cureus 2020;12:e11573. [PMID: 33364098 DOI: 10.7759/cureus.11573] [Reference Citation Analysis]
|
| 231 |
Vural M, Gilbert B, Üstün I, Caglar S, Finckh A. Mini-Review: Human Microbiome and Rheumatic Diseases. Front Cell Infect Microbiol 2020;10:491160. [PMID: 33304855 DOI: 10.3389/fcimb.2020.491160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 232 |
Mondal SI, Draper LA, Ross RP, Hill C. Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection. Gut Microbes 2020;12:1813533. [PMID: 32985336 DOI: 10.1080/19490976.2020.1813533] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 233 |
Khoruts A, Hoffmann DE, Palumbo FB. The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation. J Law Med Ethics 2019;47:482-504. [PMID: 31957587 DOI: 10.1177/1073110519897726] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 234 |
DeLong K, Zulfiqar F, Hoffmann DE, Tarzian AJ, Ensign LM. Vaginal Microbiota Transplantation: The Next Frontier. J Law Med Ethics 2019;47:555-67. [PMID: 31957577 DOI: 10.1177/1073110519897731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 235 |
Scheeler A. Where Stool is a Drug: International Approaches to Regulating the use of Fecal Microbiota for Transplantation. J Law Med Ethics 2019;47:524-40. [PMID: 31957572 DOI: 10.1177/1073110519897729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 236 |
Aira A, Arajol C, Casals-Pascual C, González-Suárez B, Martí S, Domínguez MÁ, Guardiola J, Soriano Á; en representación del grupo catalán para el estudio y desarrollo de la transferencia de microbiota fecal. Recommendations for stool donor selection for fecal microbiota transplant. Consensus document endorsed by the Catalan Society of Digestology, Catalan Society of Infectious diseases and Clinical microbiology and the GEMBIOTA group from Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin (Engl Ed) 2020:S0213-005X(20)30292-5. [PMID: 33160712 DOI: 10.1016/j.eimc.2020.09.002] [Reference Citation Analysis]
|
| 237 |
Kitchin N, Remich SA, Peterson J, Peng Y, Gruber WC, Jansen KU, Pride MW, Anderson AS, Knirsch C, Webber C. A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years. Clin Infect Dis 2020;70:1-10. [PMID: 31125055 DOI: 10.1093/cid/ciz153] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 238 |
Cooper CW, Aithinne KAN, Stevenson BS, Black JE, Johnson DL. Comparison and evaluation of a high volume air sampling system for the collection of Clostridioides difficile endospore aerosol in health care environments. Am J Infect Control 2020;48:1354-60. [PMID: 32334002 DOI: 10.1016/j.ajic.2020.04.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 239 |
Chen M, Liu XL, Zhang YJ, Nie YZ, Wu KC, Shi YQ. Efficacy and safety of fecal microbiota transplantation by washed preparation in patients with moderate to severely active ulcerative colitis. J Dig Dis 2020;21:621-8. [PMID: 32909356 DOI: 10.1111/1751-2980.12938] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 240 |
Gallo A, Cancelli C, Ceron E, Covino M, Capoluongo E, Pocino K, Ianiro G, Cammarota G, Gasbarrini A, Montalto M. Fecal calprotectin and need of multiple microbiota trasplantation infusions in Clostridium difficile infection. J Gastroenterol Hepatol 2020;35:1909-15. [PMID: 32291810 DOI: 10.1111/jgh.15072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 241 |
Prechter F, Stallmach A. Clostridium difficile auf der Intensivstation. Wien klin Mag 2020;23:210-217. [DOI: 10.1007/s00740-020-00354-0] [Reference Citation Analysis]
|
| 242 |
Dembrovszky F, Gede N, Szakács Z, Hegyi P, Kiss S, Farkas N, Molnár Z, Imrei M, Dohos D, Péterfi Z. Fecal Microbiota Transplantation May Be the Best Option in Treating Multiple Clostridioides difficile Infection: A Network Meta-Analysis. Infect Dis Ther 2021;10:201-11. [PMID: 33106983 DOI: 10.1007/s40121-020-00356-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 243 |
Aràjol C, Aira Gómez A, González-Suárez B, Casals-Pascual C, Martí Martí S, Domínguez Luzón MÁ, Soriano A, Guardiola Capón J; en representación del Grupo Catalán para el Estudio y Desarrollo de la Transferencia de Microbiota Fecal. Donor selection for faecal microbiota transplantation. Consensus document of the Catalan Society of Gastroenterology and the Catalan Society of Infectious Diseases and Clinical Microbiology. Gastroenterol Hepatol 2021;44:175-80. [PMID: 33309073 DOI: 10.1016/j.gastrohep.2020.07.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 244 |
Jørgensen SMD, Rubak TMM, Damsgaard EM, Dahlerup JF, Hvas CL. Faecal microbiota transplantation as a home therapy to frail older people. Age Ageing 2020;49:1093-6. [PMID: 32365381 DOI: 10.1093/ageing/afaa073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 245 |
Carlson TJ, Gonzales-Luna AJ, Nebo K, Chan HY, Tran NT, Antony S, Lancaster C, Alam MJ, Begum K, Garey KW. Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection. Open Forum Infect Dis 2020;7:ofaa476. [PMID: 33209956 DOI: 10.1093/ofid/ofaa476] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 246 |
Desai TK, Chey WD. Response to Skole et al. Am J Gastroenterol 2020;115:1726. [PMID: 32769425 DOI: 10.14309/ajg.0000000000000758] [Reference Citation Analysis]
|
| 247 |
Carius BM, Liang SY, Koyfman A, Long B. Clostridioides difficile infection evaluation and management in the emergency department. The American Journal of Emergency Medicine 2020;38:2203-2208. [DOI: 10.1016/j.ajem.2020.06.083] [Reference Citation Analysis]
|
| 248 |
Hostler CJ, Bertumen JB, Park LP, Wilkins SB, Woods CW. Differences in time-to-testing and time-to-isolation between community-onset and hospital-onset Clostridioides difficile cases at a tertiary care VA medical center. Am J Infect Control 2020;48:1148-51. [PMID: 31911067 DOI: 10.1016/j.ajic.2019.12.008] [Reference Citation Analysis]
|
| 249 |
Joo H, Kim S, Kwon P, Ryu J, Yook K, Yu Y, Kim Y. Evaluation of the Usefulness of GDH & Toxin Test for the Diagnosis of Clostridioides difficile in a Tertiary Hospital in Seoul. BSL 2020;26:210-216. [DOI: 10.15616/bsl.2020.26.3.210] [Reference Citation Analysis]
|
| 250 |
Yoo SJ, Whang DH. Diagnostic Algorithm for the Rapid and Cost- Effective Detection of Clostridioides difficile Infection: Comparison between C. DIFF QUIK CHEK COMPLETE and VIDAS GDH & Toxin Assay. Lab Med Qual Assur 2020;42:130-139. [DOI: 10.15263/jlmqa.2020.42.3.130] [Reference Citation Analysis]
|
| 251 |
Zellmer C, Sater MRA, Huntley MH, Osman M, Olesen SW, Ramakrishna B. Shiga Toxin–Producing Escherichia coli Transmission via Fecal Microbiota Transplant. Clinical Infectious Diseases 2021;72:e876-80. [DOI: 10.1093/cid/ciaa1486] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 252 |
Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections. Clin Infect Dis 2021;73:e1613-20. [PMID: 32966574 DOI: 10.1093/cid/ciaa1430] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 253 |
Orozco-Aguilar J, Alfaro-Alarcón A, Acuña-Amador L, Chaves-Olarte E, Rodríguez C, Quesada-Gómez C. In vivo animal models confirm an increased virulence potential and pathogenicity of the NAP1/RT027/ST01 genotype within the Clostridium difficile MLST Clade 2. Gut Pathog 2020;12:45. [PMID: 32983262 DOI: 10.1186/s13099-020-00383-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 254 |
Liu C, Tang C, Han Y, Xu Y, Ni F, Jin K, Liu G. A 2-step algorithm combining glutamate dehydrogenase and nucleic acid amplification tests for the detection of Clostridioides difficile in stool specimens. Eur J Clin Microbiol Infect Dis 2021;40:345-51. [PMID: 32944896 DOI: 10.1007/s10096-020-04027-y] [Reference Citation Analysis]
|
| 255 |
Tan P, Li X, Shen J, Feng Q. Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update. Front Pharmacol. 2020;11:574533. [PMID: 33041818 DOI: 10.3389/fphar.2020.574533] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 256 |
Mizusawa M, Small BA, Hsu YJ, Sharara SL, Advic E, Kauffman C, Milstone AM, Feldman L, Pahwa AK, Trivedi JB, Landrum MB, Maragakis LL, Carroll KC, Cosgrove SE, Rock C. Prescriber Behavior in Clostridioides difficile Testing: A 3-Hospital Diagnostic Stewardship Intervention. Clin Infect Dis 2019;69:2019-21. [PMID: 31125399 DOI: 10.1093/cid/ciz295] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 257 |
Appaneal HJ, Caffrey AR, LaPlante KL. What Is the Role for Metronidazole in the Treatment of Clostridium difficile Infection? Results From a National Cohort Study of Veterans With Initial Mild Disease. Clin Infect Dis 2019;69:1288-95. [PMID: 30561531 DOI: 10.1093/cid/ciy1077] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 258 |
Amabebe E, Anumba DOC. Female Gut and Genital Tract Microbiota-Induced Crosstalk and Differential Effects of Short-Chain Fatty Acids on Immune Sequelae. Front Immunol 2020;11:2184. [PMID: 33013918 DOI: 10.3389/fimmu.2020.02184] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 259 |
Tarr GAM, Chui L, Lee BE, Pang XL, Ali S, Nettel-Aguirre A, Vanderkooi OG, Berenger BM, Dickinson J, Tarr PI, Drews S, MacDonald J, Kim K, Freedman SB. Performance of Stool-testing Recommendations for Acute Gastroenteritis When Used to Identify Children With 9 Potential Bacterial Enteropathogens. Clin Infect Dis 2019;69:1173-82. [PMID: 30517612 DOI: 10.1093/cid/ciy1021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 260 |
Chen J, Zaman A, Ramakrishna B, Olesen SW, OpenBiome Team. Stool banking for fecal microbiota transplantation: methods and operations at a large stool bank.. [DOI: 10.1101/2020.09.03.20187583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 261 |
Essrani R, Saturno D, Mehershahi S, Essrani RK, Hossain MR, Ravi SJK, Berger A, Mehmood A. The Impact of Appendectomy in Clostridium difficile Infection and Length of Hospital Stay. Cureus. 2020;12:e10342. [PMID: 33062466 DOI: 10.7759/cureus.10342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 262 |
Ponce-Alonso M, Sáez de la Fuente J, Rincón-Carlavilla A, Moreno-Nunez P, Martínez-García L, Escudero-Sánchez R, Pintor R, García-Fernández S, Cobo J. Impact of the coronavirus disease 2019 (COVID-19) pandemic on nosocomial Clostridioides difficile infection. Infect Control Hosp Epidemiol 2021;42:406-10. [PMID: 32895065 DOI: 10.1017/ice.2020.454] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 263 |
Zhong M, Sun Y, Wang HG, Marcella C, Cui BT, Miao YL, Zhang FM. Awareness and attitude of fecal microbiota transplantation through transendoscopic enteral tubing among inflammatory bowel disease patients. World J Clin Cases 2020; 8(17): 3786-3796 [PMID: 32953854 DOI: 10.12998/wjcc.v8.i17.3786] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 264 |
Cheng YW, Phelps E, Nemes S, Rogers N, Sagi S, Bohm M, El-Halabi M, Allegretti JR, Kassam Z, Xu H, Fischer M. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection. Clin Gastroenterol Hepatol 2020;18:2234-2243.e1. [PMID: 31923639 DOI: 10.1016/j.cgh.2019.12.029] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 265 |
Perler BK, Chen B, Phelps E, Allegretti JR, Fischer M, Ganapini V, Krajiceck E, Kumar V, Marcus J, Nativ L, Kelly CR. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection. J Clin Gastroenterol 2020;54:701-6. [PMID: 32011405 DOI: 10.1097/MCG.0000000000001281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 266 |
You JHS, Jiang X, Lee WH, Chan PKS, Ng SC. Cost‐effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2020;35:1515-1523. [DOI: 10.1111/jgh.15002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 267 |
Jaffal H, Achram R, Araj G, Mahfouz R. Diagnosis of Clostridiodes difficile infection: Assessing the performance of Quik Chek complete kit assay versus the GeneXpert PCR assay at a major tertiary care center in Lebanon. Meta Gene 2020;25:100715. [DOI: 10.1016/j.mgene.2020.100715] [Reference Citation Analysis]
|
| 268 |
Ramos CP, Lopes EO, Diniz AN, Lobato FCF, Vilela EG, Silva ROS. Evaluation of glutamate dehydrogenase (GDH) and toxin A/B rapid tests for Clostridioides (prev. Clostridium) difficile diagnosis in a university hospital in Minas Gerais, Brazil. Braz J Microbiol 2020;51:1139-43. [PMID: 32367261 DOI: 10.1007/s42770-020-00288-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 269 |
Raghu Subramanian C, Talluri S, Khan SU, Katz JA, Georgetson M, Sinh P. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital. Gastroenterology Res 2020;13:138-45. [PMID: 32864024 DOI: 10.14740/gr1275] [Reference Citation Analysis]
|
| 270 |
Zhao C, Guo S, Jia X, Xu X. Distribution and risk factor analysis for Clostridium difficile-associated diarrhea among hospitalized children over one year of age. Pediatr Investig 2020;4:37-42. [PMID: 32851340 DOI: 10.1002/ped4.12155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 271 |
Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, MacNair CR, French S, Carfrae LA, Bloom-Ackermann Z, Tran VM, Chiappino-Pepe A, Badran AH, Andrews IW, Chory EJ, Church GM, Brown ED, Jaakkola TS, Barzilay R, Collins JJ. A Deep Learning Approach to Antibiotic Discovery. Cell 2020;180:688-702.e13. [PMID: 32084340 DOI: 10.1016/j.cell.2020.01.021] [Cited by in Crossref: 529] [Cited by in F6Publishing: 380] [Article Influence: 176.3] [Reference Citation Analysis]
|
| 272 |
Matchett WE, Anguiano-Zarate S, Malewana GBR, Mudrick H, Weldy M, Evert C, Khoruts A, Sadowsky M, Barry MA. A Replicating Single-Cycle Adenovirus Vaccine Effective against Clostridium difficile. Vaccines (Basel) 2020;8:E470. [PMID: 32842679 DOI: 10.3390/vaccines8030470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 273 |
Singla A, Pash D. Diarrhea or No Diarrhea, It Still Hurts: An Atypical Case of Clostridioides difficile. Cureus 2020. [DOI: 10.7759/cureus.9900] [Reference Citation Analysis]
|
| 274 |
Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 275 |
Bushman FD, Conrad M, Ren Y, Zhao C, Gu C, Petucci C, Kim MS, Abbas A, Downes KJ, Devas N, Mattei LM, Breton J, Kelsen J, Marakos S, Galgano A, Kachelries K, Erlichman J, Hart JL, Moraskie M, Kim D, Zhang H, Hofstaedter CE, Wu GD, Lewis JD, Zackular JP, Li H, Bittinger K, Baldassano R. Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease. Cell Host Microbe 2020;28:422-433.e7. [PMID: 32822584 DOI: 10.1016/j.chom.2020.07.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 276 |
Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res 2021;19:265-74. [PMID: 32806873 DOI: 10.5217/ir.2020.00045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 277 |
, Hidalgo N. A Policy Change to Reduce Hospital-Acquired Clostridium Difficile Infection Rates: A Quality Improvement Project.. [DOI: 10.46409/sr.czcd1350] [Reference Citation Analysis]
|
| 278 |
Stallmach A, Katzer K, Reuken P. [Non-severe Clostridioides difficile Infection: Are the data adequate to give up metronidazole?]. Z Gastroenterol 2020;58:778-84. [PMID: 32785914 DOI: 10.1055/a-1190-5735] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 279 |
Lin Z, Iqbal Z, Ortiz JF, Khan SA, Jahan N. Fecal Microbiota Transplantation in Recurrent Clostridium Difficile Infection: Is it Superior to Other Conventional Methods? Cureus 2020;12:e9653. [PMID: 32923252 DOI: 10.7759/cureus.9653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 280 |
Bader MS, Hawboldt J, Main C, Mertz D, Loeb M, Farrell A, Joyce J. Review of high dose vancomycin in the treatment of Clostridioides difficile infection. Infect Dis (Lond) 2020;52:847-57. [PMID: 32744879 DOI: 10.1080/23744235.2020.1800080] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 281 |
Jouhten H, Ronkainen A, Aakko J, Salminen S, Mattila E, Arkkila P, Satokari R. Cultivation and Genomics Prove Long-Term Colonization of Donor's Bifidobacteria in Recurrent Clostridioides difficile Patients Treated With Fecal Microbiota Transplantation. Front Microbiol 2020;11:1663. [PMID: 32760391 DOI: 10.3389/fmicb.2020.01663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 282 |
Oh D, Cheon KA. Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview. Soa Chongsonyon Chongsin Uihak 2020;31:131-45. [PMID: 32665757 DOI: 10.5765/jkacap.190039] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 283 |
Kim M, Chung SK, Yang JC, Park JI, Nam SH, Park TW. Development of the Korean Form of the Premonitory Urge for Tics Scale: A Reliability and Validity Study. Soa Chongsonyon Chongsin Uihak 2020;31:146-53. [PMID: 32665758 DOI: 10.5765/jkacap.200013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 284 |
Huang GQ, Bai Y, Sun ZQ, Liu J. Successful Treatment of Pseudomembranous Colitis with Fecal Microbiota Transplantation - A Case Study on A Patient Rescued by Extracorporeal Cardiopulmonary Resuscitation After Cardiac Arrest. Ann Transplant 2020;25:e923283. [PMID: 32657282 DOI: 10.12659/AOT.923283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 285 |
Cook L, Rees WD, Wong MQ, Wang X, Peters H, Oliveira L, Lau T, Mah R, Bressler B, Gomez R, Chow I, James EA, Kwok WW, Levings MK, Steiner TS. Impaired Th17 immunity in recurrent C. difficile infection is ameliorated by fecal microbial transplantation.. [DOI: 10.1101/2020.06.05.20114876] [Reference Citation Analysis]
|
| 286 |
Bibbò S, Settanni CR, Porcari S, Bocchino E, Ianiro G, Cammarota G, Gasbarrini A. Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. J Clin Med 2020;9:E1757. [PMID: 32517023 DOI: 10.3390/jcm9061757] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 287 |
Allegretti JR, Marcus J, Storm M, Sitko J, Kennedy K, Gerber GK, Bry L. Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study. Dig Dis Sci 2020;65:1761-6. [PMID: 31667694 DOI: 10.1007/s10620-019-05900-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 288 |
Okumura H, Ueyama M, Shoji S, English M. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan. Journal of Infection and Chemotherapy 2020;26:611-8. [DOI: 10.1016/j.jiac.2020.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 289 |
Jachowicz E, Pobiega M, Różańska A, Wójkowska-Mach J. Growing consumption of antibiotics and epidemiology of Clostridioides difficile infections in Poland: A need to develop new solutions. Acta Microbiol Immunol Hung 2020;67:79-86. [PMID: 31813263 DOI: 10.1556/030.66.2019.024] [Reference Citation Analysis]
|
| 290 |
Wu Q, Savidge TC. Systems approaches for the clinical diagnosis of Clostridioides difficile infection. Translational Research 2020;220:57-67. [DOI: 10.1016/j.trsl.2020.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 291 |
Zhou H, Xu Q, Liu Y, Guo LT. Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy. World J Clin Cases 2020; 8(10): 1908-1915 [PMID: 32518780 DOI: 10.12998/wjcc.v8.i10.1908] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 292 |
Mangieri CW, Ling JA, Modlin DM, Rose ED, Burgess PL. Utilization of combination bowel preparation (CBP) is protective against the development of post-operative Clostridium difficile infection (CDI), decreases septic complications, and provides a survival benefit. Surg Endosc 2021;35:928-33. [DOI: 10.1007/s00464-020-07563-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 293 |
Pacyga K, Razim A, Martirosian G, Aptekorz M, Szuba A, Gamian A, Myc A, Górska S. The Bioinformatic and In Vitro Studies of Clostridioides Difficile Aminopeptidase M24 Revealed the Immunoreactive KKGIK Peptide. Cells 2020;9. [PMID: 32392707 DOI: 10.3390/cells9051146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 294 |
Le Roy T, Aron-wisnewsky J, Clément K. Le transfert de microbiote fécal : quel potentiel thérapeutique dans le traitement des maladies métaboliques ? Nutrition Clinique et Métabolisme 2020;34:108-115. [DOI: 10.1016/j.nupar.2019.12.001] [Reference Citation Analysis]
|
| 295 |
Modi A, Gonzalez BE, Brizendine KD. Clostridioides difficile Infections in Adult and Pediatric Intestinal and Multivisceral Transplant Patients. Infect Dis Clin Pract 2020;28:154-157. [DOI: 10.1097/ipc.0000000000000840] [Reference Citation Analysis]
|
| 296 |
Kimura T, Stanhope S, Sugitani T. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density. J Infect Chemother 2020;26:438-43. [PMID: 32081648 DOI: 10.1016/j.jiac.2019.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 297 |
Ducours M, Cazanave C. Place de la transplantation de microbiote fécal dans l’infection à Clostridium difficile. Colon Rectum 2020;14:88-93. [DOI: 10.3166/cer-2020-0144] [Reference Citation Analysis]
|
| 298 |
Jiang SS, Liu W, Liu L, Bai Y. Severe complicated Clostridium difficile infection: A case report. Shijie Huaren Xiaohua Zazhi 2020; 28(8): 308-312 [DOI: 10.11569/wcjd.v28.i8.308] [Reference Citation Analysis]
|
| 299 |
Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 300 |
Vega AD, Heil EL, Blackman AL, Banoub M, Kristie Johnson J, Leekha S, Claeys KC. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection. Pharmacotherapy 2020;40:398-407. [PMID: 32246501 DOI: 10.1002/phar.2393] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 301 |
Bauer CM, Zhang X, Long MD, Sandler RS. Characteristics of Fecal Microbiota Transplantation Use in Inflammatory Bowel Disease Cohort. Crohns Colitis 360 2020;2:otaa024. [PMID: 32421761 DOI: 10.1093/crocol/otaa024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 302 |
Gnocchi M, Gagliardi M, Gismondi P, Gaiani F, De' Angelis GL, Esposito S. Updated Management Guidelines for Clostridioides difficile in Paediatrics. Pathogens 2020;9:E291. [PMID: 32316346 DOI: 10.3390/pathogens9040291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 303 |
Fadda HM. The Route to Palatable Fecal Microbiota Transplantation. AAPS PharmSciTech 2020;21:114. [PMID: 32296975 DOI: 10.1208/s12249-020-1637-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 304 |
Voth E, Khanna S. Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. Expert Rev Anti Infect Ther 2020;18:669-76. [PMID: 32266848 DOI: 10.1080/14787210.2020.1752192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 305 |
Henson MA. Computational Modeling of the Gut Microbiota Predicts Metabolic Mechanisms of Recurrent Clostridioides difficile Infection.. [DOI: 10.1101/2020.04.10.036111] [Reference Citation Analysis]
|
| 306 |
Aljafel NA, Al-Shaikhy HH, Alnahdi MA, Thabit AK. Incidence of Clostridioides difficile infection at a Saudi Tertiary Academic Medical Center and compliance with IDSA/SHEA, ACG, and ESCMID guidelines for treatment over a 10-year period. J Infect Public Health 2020;13:1156-60. [PMID: 32276872 DOI: 10.1016/j.jiph.2020.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 307 |
Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clin Proc 2020;95:758-69. [PMID: 32247350 DOI: 10.1016/j.mayocp.2019.08.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 308 |
Albarrak AA, Romana BS, Uraz S, Yousef MH, Juboori AA, Tahan V. Clostridium Difficile Infection in Inflammatory Bowel Disease Patients. Endocr Metab Immune Disord Drug Targets 2019;19:929-35. [PMID: 30827274 DOI: 10.2174/1871530319666190301120558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 309 |
Fang H, Fu L, Li X, Wang J, Xiong K, Su Y, Zhang L. Long-term efficacy and safety of single fecal microbiota transplantation for recurrent active ulcerative colitis.. [DOI: 10.1101/2020.03.16.20022293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 310 |
Yang Z. Is fecal microbiota transplantation a promising strategy for type 2 diabetes mellitus? EMIJ 2020;8. [DOI: 10.15406/emij.2020.08.00275] [Reference Citation Analysis]
|
| 311 |
Houghton D. CE: Infection in Acute Care: Evidence for Practice. Am J Nurs 2019;119:24-32. [PMID: 31567249 DOI: 10.1097/01.NAJ.0000586160.03391.82] [Reference Citation Analysis]
|
| 312 |
Kang CY, Huang IH, Chou CC, Wu TY, Chang JC, Hsiao YY, Cheng CH, Tsai WJ, Hsu KC, Wang S. Functional analysis of Clostridium difficile sortase B reveals key residues for catalytic activity and substrate specificity. J Biol Chem 2020;295:3734-45. [PMID: 32005667 DOI: 10.1074/jbc.RA119.011322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 313 |
Kanner EV, Gorelov AV, Maksimov ML, Ermolayeva AS, Bulgakova IS. What methods are currently available to prevent and treat antibiotic-associated diarrhoea in children? Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-1-177-184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 314 |
Yamaguchi T, Konishi H, Aoki K, Ishii Y, Chono K, Tateda K. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother 2020;26:483-91. [PMID: 32165071 DOI: 10.1016/j.jiac.2019.12.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 315 |
Bellali S, Bou Khalil J, Fontanini A, Raoult D, Lagier JC. A new protectant medium preserving bacterial viability after freeze drying. Microbiol Res 2020;236:126454. [PMID: 32200250 DOI: 10.1016/j.micres.2020.126454] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 316 |
AbdelKhalek A, Mohammad H, Mayhoub AS, Seleem MN. Screening for potent and selective anticlostridial leads among FDA-approved drugs. J Antibiot (Tokyo) 2020;73:392-409. [PMID: 32132676 DOI: 10.1038/s41429-020-0288-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 317 |
O’brien S. Gastrointestinal infections. Oxford Textbook of Medicine 2020. [DOI: 10.1093/med/9780198746690.003.0313] [Reference Citation Analysis]
|
| 318 |
Day AS. Chronic Diarrhoea in Infants and Children: Approaching and Managing the Problem. Curr Treat Options Peds 2020;6:1-11. [DOI: 10.1007/s40746-020-00187-3] [Reference Citation Analysis]
|
| 319 |
Yokoyama M, Nagai H, Matsumoto R, Saito T, Nozawa S, Gochi E. Fulminant <i>Clostridium difficile</i> Colitis Successfully Treated by Loop Ileostomy with Colonic Lavage Following Transverse Colectomy and Distal Gastrectomy. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2020;53:246-256. [DOI: 10.5833/jjgs.2018.0150] [Reference Citation Analysis]
|
| 320 |
Bar-Yoseph H, Daoud H, Ben Hur D, Chowers Y, Waterman M. Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with Clostridioides difficile infection? Int J Colorectal Dis 2020;35:513-9. [PMID: 31927638 DOI: 10.1007/s00384-019-03502-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 321 |
Dorsaz S, Charretier Y, Girard M, Gaïa N, Leo S, Schrenzel J, Harbarth S, Huttner B, Lazarevic V. Changes in Microbiota Profiles After Prolonged Frozen Storage of Stool Suspensions. Front Cell Infect Microbiol 2020;10:77. [PMID: 32185143 DOI: 10.3389/fcimb.2020.00077] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 322 |
Jin CY, Hu Y, Jin B. Faecal microbiota transplantation: Application in treatment of some digestive diseases and safety concerns. Shijie Huaren Xiaohua Zazhi 2020; 28(4): 135-143 [DOI: 10.11569/wcjd.v28.i4.135] [Reference Citation Analysis]
|
| 323 |
Tate DG, Wheeler T, Lane GI, Forchheimer M, Anderson KD, Biering-Sorensen F, Cameron AP, Santacruz BG, Jakeman LB, Kennelly MJ, Kirshblum S, Krassioukov A, Krogh K, Mulcahey MJ, Noonan VK, Rodriguez GM, Spungen AM, Tulsky D, Post MW. Recommendations for evaluation of neurogenic bladder and bowel dysfunction after spinal cord injury and/or disease. J Spinal Cord Med 2020;43:141-64. [PMID: 32105586 DOI: 10.1080/10790268.2019.1706033] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 324 |
Cheng YW, Fischer M. Fecal Microbiota Transplantation: Redefining Surgical Management of Refractory Clostridium difficile Infection. Clin Colon Rectal Surg 2020;33:92-7. [PMID: 32104162 DOI: 10.1055/s-0040-1701233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 325 |
Mi H, Bao R, Xiao Y, Cui Y, Sun W, Shen Y, Shi Q, Chen X, Lin J, Hu B, Gao X. Colonization of Toxigenic Clostridium difficile Among Intensive Care Unit Patients: A Multi-Centre Cross-Sectional Study. Front Cell Infect Microbiol 2020;10:12. [PMID: 32083021 DOI: 10.3389/fcimb.2020.00012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 326 |
Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes 2020;4:14. [PMID: 32076853 DOI: 10.1186/s41687-020-0179-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 327 |
Cheng Y, Fischer M. Clinical management of severe, fulminant, and refractory Clostridioides difficile infection. Expert Review of Anti-infective Therapy 2020;18:323-33. [DOI: 10.1080/14787210.2020.1730814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 328 |
Bishop PA, Isache C, McCarter YS, Smotherman C, Gautam S, Jankowski CA. Clinical impact of a pharmacist-led antimicrobial stewardship initiative evaluating patients with Clostridioides difficile colitis. J Investig Med 2020;68:888-92. [PMID: 32066570 DOI: 10.1136/jim-2019-001173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 329 |
Wu KS, Syue LS, Cheng A, Yen TY, Chen HM, Chiu YH, Hsu YL, Chiu CH, Su TY, Tsai WL, Chen WY, Huang CH, Hung HM, Huang LJ, Kuo HJ, Lin PC, Yang CH, Hong PL, Lee SS, Chen YS, Liu YC, Huang LM; Infectious Diseases Society of Taiwan., Medical Foundation in Memory of Dr. Deh-Lin Cheng., Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education., CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines., 5th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group. Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan. J Microbiol Immunol Infect 2020;53:191-208. [PMID: 32169531 DOI: 10.1016/j.jmii.2020.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 330 |
Bowman JA, Utter GH. Evolving Strategies to Manage Clostridium difficile Colitis. J Gastrointest Surg 2020;24:484-91. [PMID: 31768834 DOI: 10.1007/s11605-019-04478-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 331 |
Champredon D, Shoukat A, Moghadas SM. Effectiveness and cost-effectiveness of a Clostridium difficile vaccine candidate in a hospital setting. Vaccine 2020;38:2585-91. [PMID: 32014268 DOI: 10.1016/j.vaccine.2020.01.073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 332 |
Meighani A, Alimirah M, Ramesh M, Salgia R. Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease. Int J Hepatol 2020;2020:1874570. [PMID: 32047670 DOI: 10.1155/2020/1874570] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 333 |
Stalder T, Kapel N, Diaz S, Grenouillet F, Koch S, Limat S, Daval F, Vuitton L, Nerich V. A systematic review of economic evaluation in fecal microbiota transplantation. Infect Control Hosp Epidemiol 2020;41:458-66. [DOI: 10.1017/ice.2019.371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 334 |
Antonioli P, Bolognesi N, Valpiani G, Morotti C, Bernardini D, Bravi F, Di Ruscio E, Stefanati A, Gabutti G. A 2-year point-prevalence surveillance of healthcare-associated infections and antimicrobial use in Ferrara University Hospital, Italy. BMC Infect Dis 2020;20:75. [PMID: 31973704 DOI: 10.1186/s12879-020-4791-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 335 |
Pollock NR, Banz A, Chen X, Williams D, Xu H, Cuddemi CA, Cui AX, Perrotta M, Alhassan E, Riou B, Lantz A, Miller MA, Kelly CP. Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay. Clin Infect Dis 2019;68:78-86. [PMID: 29788296 DOI: 10.1093/cid/ciy415] [Cited by in Crossref: 21] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 336 |
Ouanounou A, Ng K, Chaban P. Adverse drug reactions in dentistry. Int Dent J 2020;70:79-84. [PMID: 31944297 DOI: 10.1111/idj.12540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 337 |
Jung N, Mayet W, Mertens P, Meyer (federführend) J, Müller O, Pfeifer M, Schellinger P, Weiss N, Wendtner C. ERKRANKUNGEN DER VERDAUUNGSORGANE. Rationelle Diagnostik und Therapie in der Inneren Medizin 2020. [DOI: 10.1016/b978-3-437-06282-7.50008-5] [Reference Citation Analysis]
|
| 338 |
Todorov SD, Kang HJ, Ivanova IV, Holzapfel WH. Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis. Front Bioeng Biotechnol 2020;8:581778. [PMID: 33042979 DOI: 10.3389/fbioe.2020.581778] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 339 |
Yang Z, Bu C, Yuan W, Shen Z, Quan Y, Wu S, Zhu C, Wang X. Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn's Disease. Dig Dis Sci 2020;65:150-7. [PMID: 31367877 DOI: 10.1007/s10620-019-05751-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 340 |
Pisano JC, Mullane KM. Clostridioides Difficile: Where Should the Management Strategies in Transplant Vary? Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_23-1] [Reference Citation Analysis]
|
| 341 |
Lübbert C, Schmiedel S. Gastroenteritiden und Peritonitis. Medizinische Mikrobiologie und Infektiologie 2020. [DOI: 10.1007/978-3-662-61385-6_124] [Reference Citation Analysis]
|
| 342 |
Zhao HJ, Luo X, Shi YC, Li JF, Pan F, Ren RR, Peng LH, Shi XY, Yang G, Wang J, Hu LY, Zou LP, Yang YS. The Efficacy of Fecal Microbiota Transplantation for Children With Tourette Syndrome: A Preliminary Study. Front Psychiatry 2020;11:554441. [PMID: 33424650 DOI: 10.3389/fpsyt.2020.554441] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 343 |
Saha S, Khanna S. C. difficile Infection and Antibiotic Associated Diarrhea. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.11069-4] [Reference Citation Analysis]
|
| 344 |
Hays RA, Surawicz C. Clostridium (Now Clostridioides) difficile-Associated Disease. Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_71-1] [Reference Citation Analysis]
|
| 345 |
Grinspan A, Boutros M. Organ-Preserving Strategies in the Management of Fulminant Clostridium difficile Colitis. The SAGES Manual of Colorectal Surgery 2020. [DOI: 10.1007/978-3-030-24812-3_35] [Reference Citation Analysis]
|
| 346 |
Himmel A, Watanabe J. Management of Clostridium difficile Infection. Chalk Talks in Internal Medicine 2020. [DOI: 10.1007/978-3-030-34814-4_17] [Reference Citation Analysis]
|
| 347 |
Renwick S, Allen-vercoe E. Manipulating the gut microbiota. The Developing Microbiome 2020. [DOI: 10.1016/b978-0-12-820602-7.00010-6] [Reference Citation Analysis]
|
| 348 |
Kosmidou M, Karavasili NT, Saridi M, Skamnelos A, Kavvadias A, Batistatou A, Gartzonika KG, Tsiara S, Katsanos KH, Christodoulou DK. Clostridium Difficile Infection in Patients Impact Suspected Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease. Mater Sociomed 2020;32:41-5. [PMID: 32410890 DOI: 10.5455/msm.2020.32.41-45] [Reference Citation Analysis]
|
| 349 |
Truitt MS, Pearcy C, Deramo P, Sela N, Alkhamesi NA. Colon Emergencies. The SAGES Manual of Acute Care Surgery 2020. [DOI: 10.1007/978-3-030-21959-8_6] [Reference Citation Analysis]
|
| 350 |
Kao D, Surawicz C. Fecal Microbiota Transplant. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65954-8] [Reference Citation Analysis]
|
| 351 |
Azimirad M, Yadegar A, Gholami F, Shahrokh S, Asadzadeh Aghdaei H, Ianiro G, Suzuki H, Cammarota G, Zali MR. Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease. J Inflamm Res 2020;13:563-70. [PMID: 32982371 DOI: 10.2147/JIR.S265520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 352 |
Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Uranishi H, Masuta M, Ikesue H, Hashida T, Iguchi K, Nakamura M. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. Int J Med Sci 2020;17:921-30. [PMID: 32308545 DOI: 10.7150/ijms.43789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 353 |
Nana T, Moore C, Boyles T, Brink AJ, Cleghorn J, Devenish LM, du Toit B, Fredericks ES, Lekalakala-Mokaba MR, Maluleka C, Rajabally MN, Reubenson G, Shuping L, Swart K, Swe Han KS, Wadula J, Wojno J, Lowman W. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis 2020;35:219. [PMID: 34485483 DOI: 10.4102/sajid.v35i1.219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 354 |
Pofahl WE, Manwaring ML. Benign Colorectal Disease in the Elderly. Principles and Practice of Geriatric Surgery 2020. [DOI: 10.1007/978-3-319-47771-8_73] [Reference Citation Analysis]
|
| 355 |
Kumar A, Dey D. Clostridium Difficile Infection—Diagnosis, Treatment and Prevention. Infectious Diseases in the Intensive Care Unit 2020. [DOI: 10.1007/978-981-15-4039-4_18] [Reference Citation Analysis]
|
| 356 |
Yao J, Han LL, Tian JH, Ma XJ, Wei HP, Meng WB, Yang LP. The Evaluation of Fecal Bacteria Products for the Treatment of <i>Clostridium difficile</i>-Associated Diarrhea: A Systematic Review and Network Meta-Analysis. SSRN Journal. [DOI: 10.2139/ssrn.3745780] [Reference Citation Analysis]
|
| 357 |
Rizzardi K, Åkerlund T, Norén T, Matussek A. Impact of ribotype on Clostridioides difficile diagnostics. Eur J Clin Microbiol Infect Dis 2020;39:847-53. [PMID: 31884555 DOI: 10.1007/s10096-019-03772-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 358 |
Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Clostridioides difficile recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. Am J Health Syst Pharm 2019;76:581-90. [PMID: 31361830 DOI: 10.1093/ajhp/zxz032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 359 |
Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 360 |
Patel H, Makker J, Vakde T, Shaikh D, Badipatla K, Dunne J, Mantri N, Nayudu SK, Glandt M, Balar B, Chilimuri S. Nonsteroidal Anti-Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with Clostridium difficile Infection. Clin Exp Gastroenterol 2019;12:449-56. [PMID: 31849510 DOI: 10.2147/CEG.S223886] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 361 |
Mikamo H, Kondo T, Okuyama K, Marcella SW, Ruzicka DJ. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study. Anaerobe 2020;61:102139. [PMID: 31830597 DOI: 10.1016/j.anaerobe.2019.102139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 362 |
Manthey CF, Dranova D, Christner M, Drolz A, Kluge S, Lohse AW, Fuhrmann V. Initial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI). Crit Care 2019;23:399. [PMID: 31815650 DOI: 10.1186/s13054-019-2648-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 363 |
Freeman J, Vernon J, Pilling S, Morris K, Nicolson S, Shearman S, Clark E, Palacios-Fabrega JA, Wilcox M; Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes’ Study Group. Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study. Eur J Clin Microbiol Infect Dis 2020;39:169-77. [PMID: 31811507 DOI: 10.1007/s10096-019-03708-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 364 |
Aggeletopoulou I, Konstantakis C, Assimakopoulos SF, Triantos C. The role of the gut microbiota in the treatment of inflammatory bowel diseases. Microb Pathog 2019;137:103774. [PMID: 31586663 DOI: 10.1016/j.micpath.2019.103774] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 365 |
Lei DK, Ollech JE, Andersen M, Weisshof R, Zmeter N, Sossenheimer P, Rubin DT. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol 2019;114:1904-8. [PMID: 31714359 DOI: 10.14309/ajg.0000000000000460] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 366 |
Banerjee P, Kishore S, Kaira SS. Clostridioides difficile: An Overview of Current Diagnostic and Infection Prevention Modalities. Journal of Medical Academics 2019;2:61-64. [DOI: 10.5005/jp-journals-10070-0043] [Reference Citation Analysis]
|
| 367 |
Elangovan A, Allegretti JR, Fischer M. Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. Expert Opinion on Biological Therapy 2019;19:1343-1355. [DOI: 10.1080/14712598.2019.1673725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 368 |
Byun J, Kim H, Kim JL, Kim D, Jeong SH, Shin JH, Kim YA, Shin JH, Shin KS, Uh Y. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea. Anaerobe 2019;60:102106. [DOI: 10.1016/j.anaerobe.2019.102106] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 369 |
Karpov OE, Zamyatin MN, Gusarov VG, Orlova OA, Fomina VS, Kamyshova DA, Kamenova EE, Dementienko MV, Petrova LV, Lashenkova NN, Kolozyan DA. The protocol of empirical antimicrobial therapy of the inpatient hospital of the National Medical and Surgical Center n. a. N. I. Pirogov (fourth edition, 2018). Medicinskij alfavit 2019;1:58-71. [DOI: 10.33667/2078-5631-2019-1-16(391)-58-71] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 370 |
Cheng YW, Fischer M. Treatment of Severe and Fulminnant Clostridioides difficile Infection. Curr Treat Options Gastroenterol 2019;17:524-33. [PMID: 31745820 DOI: 10.1007/s11938-019-00262-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 371 |
Infections of the Gastrointestinal Tract. Yamada's Handbook of Gastroenterology 2019. [DOI: 10.1002/9781119515777.ch41] [Reference Citation Analysis]
|
| 372 |
He Y, Li X, Yu H, Ge Y, Liu Y, Qin X, Jiang M, Wang X. The Functional Role of Fecal Microbiota Transplantation on Dextran Sulfate Sodium-Induced Colitis in Mice. Front Cell Infect Microbiol 2019;9:393. [PMID: 31803633 DOI: 10.3389/fcimb.2019.00393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 373 |
Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, Gonzalez MD, Jerris RC, Kehl SC, Patel R, Pritt BS, Richter SS, Robinson-Dunn B, Schwartzman JD, Snyder JW, Telford S 3rd, Theel ES, Thomson RB Jr, Weinstein MP, Yao JD. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018;67:e1-e94. [PMID: 29955859 DOI: 10.1093/cid/ciy381] [Cited by in Crossref: 200] [Cited by in F6Publishing: 219] [Article Influence: 50.0] [Reference Citation Analysis]
|
| 374 |
Champredon D, Zhang K, Smieja M, Moghadas SM. Clostridium difficile intervention timelines for diagnosis, isolation, and treatment. Am J Infect Control 2019;47:1370-4. [PMID: 31182236 DOI: 10.1016/j.ajic.2019.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 375 |
Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther 2019;50:1094-9. [PMID: 31612528 DOI: 10.1111/apt.15526] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 376 |
Hansen G, Young S, Wu AHB, Herding E, Nordberg V, Mills R, Griego-Fullbright C, Wagner A, Ong CM, Lewis S, Yoon J, Estis J, Sandlund J, Friedland E, Carroll KC. Ultrasensitive Detection of Clostridioides difficile Toxins in Stool by Use of Single-Molecule Counting Technology: Comparison with Detection of Free Toxin by Cell Culture Cytotoxicity Neutralization Assay. J Clin Microbiol 2019;57:e00719-19. [PMID: 31434724 DOI: 10.1128/JCM.00719-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 377 |
Shao X, AbdelKhalek A, Abutaleb NS, Velagapudi UK, Yoganathan S, Seleem MN, Talele TT. Chemical Space Exploration around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors. J Med Chem 2019;62:9772-91. [PMID: 31584822 DOI: 10.1021/acs.jmedchem.9b01198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 378 |
Cammarota G, Gallo A, Bibbò S. Fecal microbiota transplant for C. difficile infection: Just say yes. Anaerobe 2019;60:102109. [PMID: 31644957 DOI: 10.1016/j.anaerobe.2019.102109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 379 |
Mamo Y, Woodworth MH, Wang T, Dhere T, Kraft CS. Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis 2018;66:1705-11. [PMID: 29272401 DOI: 10.1093/cid/cix1097] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 380 |
Madar PC, Petre O, Baban A, Dumitrascu DL. Medical students' perception on fecal microbiota transplantation. BMC Med Educ 2019;19:368. [PMID: 31601212 DOI: 10.1186/s12909-019-1804-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 381 |
Mendo-Lopez R, Villafuerte-Gálvez J, White N, Mahoney MV, Kelly CP, Alonso CD. Recent developments in the management of recurrent Clostridioides difficile infection. Anaerobe 2020;62:102108. [PMID: 31606481 DOI: 10.1016/j.anaerobe.2019.102108] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 382 |
Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm EJ. Framework for rational donor selection in fecal microbiota transplant clinical trials. PLoS One 2019;14:e0222881. [PMID: 31600222 DOI: 10.1371/journal.pone.0222881] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 383 |
Andrade-Oliveira V, Foresto-Neto O, Watanabe IKM, Zatz R, Câmara NOS. Inflammation in Renal Diseases: New and Old Players. Front Pharmacol 2019;10:1192. [PMID: 31649546 DOI: 10.3389/fphar.2019.01192] [Cited by in Crossref: 123] [Cited by in F6Publishing: 130] [Article Influence: 30.8] [Reference Citation Analysis]
|
| 384 |
Bobenchik AM. Battleground Zero: A Review of Best Practice Recommendations for Clostridioides (Clostridium) difficile Testing. Clinical Microbiology Newsletter 2019;41:175-83. [DOI: 10.1016/j.clinmicnews.2019.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 385 |
Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, Tolomeo P, Wise J, Tamma PD; Antibacterial Resistance Leadership Group. Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. Clin Infect Dis 2018;66:172-7. [PMID: 29190320 DOI: 10.1093/cid/cix767] [Cited by in Crossref: 97] [Cited by in F6Publishing: 103] [Article Influence: 24.3] [Reference Citation Analysis]
|
| 386 |
Lin TC, Hung YP, Ko WC, Ruan JW. Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: Establishment and implementation. J Microbiol Immunol Infect 2019;52:841-50. [PMID: 31607571 DOI: 10.1016/j.jmii.2019.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 387 |
Pasqualotto AC, Almeida CS, Kliemann DA, Barcellos GB, Queiroz-Telles F, Abdala E, Resende M, Batista FP, Vidal JE, Rocha J, Raboni SM, Cimerman S, Gales AC. Top 10 evidence-based recommendations from the Brazilian Society of Infectious Diseases for the Choosing Wisely Project. Braz J Infect Dis 2019;23:331-5. [PMID: 31562852 DOI: 10.1016/j.bjid.2019.08.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 388 |
Johnson PT, Alvin MD, Ziegelstein RC. Transitioning to a High-Value Health Care Model: Academic Accountability. Acad Med 2018;93:850-5. [PMID: 29095705 DOI: 10.1097/ACM.0000000000002045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 389 |
Wu X, Dai M, Buch H, Bai J, Long W, Long C, Tang X, Tu H, Zhang R, Zhu C, Yang S, Cui B, Ji G, Zhang F. The recognition and attitudes of postgraduate medical students toward fecal microbiota transplantation: a questionnaire study. Therap Adv Gastroenterol 2019;12:1756284819869144. [PMID: 31516555 DOI: 10.1177/1756284819869144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 390 |
Mullane KM, Dubberke ER, on behalf of the AST ID Community of Practice. Management ofClostridioides(formerlyClostridium)difficileinfection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13564] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 391 |
Angarone M, Snydman DR; AST ID Community of Practice. Diagnosis and management of diarrhea in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:e13550. [PMID: 30913334 DOI: 10.1111/ctr.13550] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 392 |
Jump RLP, Crnich CJ, Mody L, Bradley SF, Nicolle LE, Yoshikawa TT. Infectious Diseases in Older Adults of Long-Term Care Facilities: Update on Approach to Diagnosis and Management. J Am Geriatr Soc 2018;66:789-803. [PMID: 29667186 DOI: 10.1111/jgs.15248] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 393 |
Krajicek E, Bohm M, Sagi S, Fischer M. Fulminant Clostridium difficile Infection Cured by Fecal Microbiota Transplantation in a Bone Marrow Transplant Recipient With Critical Neutropenia. ACG Case Rep J 2019;6:e00198. [PMID: 31737727 DOI: 10.14309/crj.0000000000000198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 394 |
Thabit AK, Alsolami MH, Baghlaf NA, Alsharekh RM, Almazmumi HA, Alselami AS, Alsubhi FA. Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines. Infection 2019;47:899-909. [PMID: 31428991 DOI: 10.1007/s15010-019-01348-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 395 |
Das DJ, Shankar A, Johnson JB, Thomas S. Critical insights into antibiotic resistance transferability in probiotic Lactobacillus. Nutrition 2020;69:110567. [PMID: 31733594 DOI: 10.1016/j.nut.2019.110567] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 396 |
Yano Y, Kuga T, Sakamoto R, Shigeta M. A Case of Severe Pseudomembranous Colitis with Septic Shock. Yamaguchi Medical Journal 2019;68:81-84. [DOI: 10.2342/ymj.68.81] [Reference Citation Analysis]
|
| 397 |
Boyanova L, Kalvatchev N, Yordanov D, Hadzhiyski P, Markovska R, Gergova G, Mitov I. Clostridioides ( Clostridium ) difficile carriage in asymptomatic children since 2010: a narrative review. Biotechnology & Biotechnological Equipment 2019;33:1228-36. [DOI: 10.1080/13102818.2019.1650666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 398 |
Wilcox MH, Rahav G, Dubberke ER, Gabryelski L, Davies K, Berry C, Eves K, Ellison MC, Guris D, Dorr MB. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. Open Forum Infect Dis 2019;6:ofz293. [PMID: 31375837 DOI: 10.1093/ofid/ofz293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 399 |
Allegretti JR, Mullish BH, Kelly C, Fischer M. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. Lancet 2019;394:420-31. [PMID: 31379333 DOI: 10.1016/S0140-6736(19)31266-8] [Cited by in Crossref: 182] [Cited by in F6Publishing: 176] [Article Influence: 45.5] [Reference Citation Analysis]
|
| 400 |
Kim KO, Schwartz MA, Lin OST, Chiorean MV, Gluck M. Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection. Adv Ther 2019;36:2052-61. [PMID: 31154629 DOI: 10.1007/s12325-019-00974-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 401 |
Tijerina-Rodríguez L, Villarreal-Treviño L, Baines SD, Morfín-Otero R, Camacho-Ortíz A, Flores-Treviño S, Maldonado-Garza H, Rodríguez-Noriega E, Garza-González E. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates. PLoS One 2019;14:e0220671. [PMID: 31365590 DOI: 10.1371/journal.pone.0220671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 402 |
Staley C, Kaiser T, Vaughn BP, Graiziger C, Hamilton MJ, Kabage AJ, Khoruts A, Sadowsky MJ. Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection. mBio 2019;10:e01586-19. [PMID: 31337728 DOI: 10.1128/mBio.01586-19] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 403 |
Shin JH, Chaplin AS, Hays RA, Kolling GL, Vance S, Guerrant RL, Archbald-Pannone L, Warren CA. Outcomes of a Multidisciplinary Clinic in Evaluating Recurrent Clostridioides difficile Infection Patients for Fecal Microbiota Transplant: A Retrospective Cohort Analysis. J Clin Med 2019;8:E1036. [PMID: 31315214 DOI: 10.3390/jcm8071036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 404 |
Guerri S, Danti G, Frezzetti G, Lucarelli E, Pradella S, Miele V. Clostridium difficile colitis: CT findings and differential diagnosis. Radiol Med 2019;124:1185-98. [PMID: 31302848 DOI: 10.1007/s11547-019-01066-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 405 |
Murphy CL, Zulquernain SA, Shanahan F. Faecal Microbiota Transplantation (FMT) - classical bedside-to-bench clinical research. QJM 2019:hcz181. [PMID: 31297516 DOI: 10.1093/qjmed/hcz181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 406 |
Duvallet C, Zellmer C, Panchal P, Budree S, Osman M, Alm E. Framework for rational donor selection in fecal microbiota transplant clinical trials.. [DOI: 10.1101/19000307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 407 |
Rosenblatt R, Mehta A, Cohen-Mekelburg S, Shen N, Snell D, Lucero C, Jesudian A, Fortune B, Crawford CV, Kumar S. The rise of Clostridioides difficile infections and fall of associated mortality in hospitalized advanced cirrhotics. Liver Int 2019;39:1263-70. [PMID: 30790420 DOI: 10.1111/liv.14077] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 408 |
Nowak A, Hedenstierna M, Ursing J, Lidman C, Nowak P. Efficacy of Routine Fecal Microbiota Transplantation for Treatment of Recurrent Clostridium difficile Infection: A Retrospective Cohort Study. Int J Microbiol 2019;2019:7395127. [PMID: 31354831 DOI: 10.1155/2019/7395127] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 409 |
Viazis N, Pontas C, Karmiris K, Dimas I, Fragaki M, Paspatis G, Drygiannakis I, Koutroubakis IE, Moschovis D, Tzouvala M, Theocharis G, Tsolias C, Thomopoulos K, Zampeli E, Axiaris G, Michopoulos S, Belesiotou E, Banasa M, Maraki S, Kouskoumpekou F, Apostolopoulos G, Stamouli V, Prifti H, Mantzaris GJ. Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. Eur J Gastroenterol Hepatol 2019;31:773-6. [PMID: 30973416 DOI: 10.1097/MEG.0000000000001414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 410 |
De Francesco MA, Lorenzin G, Piccinelli G, Corbellini S, Bonfanti C, Caruso A. Correlation between tcdB gene PCR cycle threshold and severe Clostridium difficile disease. Anaerobe 2019;59:141-4. [PMID: 31254653 DOI: 10.1016/j.anaerobe.2019.06.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 411 |
Dionne JC, Sullivan K, Mbuagbaw L, Takaoka A, Duan EH, Alhazzani W, Devlin JW, Duprey M, Moayyedi P, Armstrong D, Thabane L, Tsang JLY, Jaeschke R, Hamielec C, Karachi T, Cartin-Ceba R, Muscedere J, Alshahrani MSS, Cook DJ. Diarrhoea: interventions, consequences and epidemiology in the intensive care unit (DICE-ICU): a protocol for a prospective multicentre cohort study. BMJ Open 2019;9:e028237. [PMID: 31248929 DOI: 10.1136/bmjopen-2018-028237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 412 |
Aron-wisnewsky J, Clément K, Nieuwdorp M. Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? Curr Diab Rep 2019;19. [DOI: 10.1007/s11892-019-1180-z] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 413 |
Lee-Tsai YL, Luna-Santiago R, Demichelis-Gómez R, Ponce-de-León A, Ochoa-Hein E, Tamez-Torres KM, Bourlon MT, Bourlon C. Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases. Blood Res 2019;54:120-4. [PMID: 31309090 DOI: 10.5045/br.2019.54.2.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 414 |
Yue HU, Bin LYU. 粪菌移植的研究现状与展望. Zhejiang Da Xue Xue Bao Yi Xue Ban 2019;48. [PMID: 31496168 DOI: 10.3785/j.issn.1008-9292.2019.06.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 415 |
. Hygienemaßnahmen bei Clostridioides difficile-Infektion (CDI): Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsbl 2019;62:906-23. [DOI: 10.1007/s00103-019-02959-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 416 |
Gaviola ML, Scribe EC, Leverett HN, Howard ML. Statin Effects on Incidence, Treatment Success, and Mortality of Clostridium difficile Infections. J Pharm Pract 2020;33:497-505. [PMID: 31216928 DOI: 10.1177/0897190019854956] [Reference Citation Analysis]
|
| 417 |
Burz SD, Abraham AL, Fonseca F, David O, Chapron A, Béguet-Crespel F, Cénard S, Le Roux K, Patrascu O, Levenez F, Schwintner C, Blottière HM, Béra-Maillet C, Lepage P, Doré J, Juste C. A Guide for Ex Vivo Handling and Storage of Stool Samples Intended for Fecal Microbiota Transplantation. Sci Rep 2019;9:8897. [PMID: 31222022 DOI: 10.1038/s41598-019-45173-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 418 |
Ramai D, Noorani A, Ofosu A, Ofori E, Reddy M, Gasperino J. Practice measures for controlling and preventing hospital associated Clostridium difficile infections. Hosp Pract (1995) 2019;47:123-9. [PMID: 31177865 DOI: 10.1080/21548331.2019.1627851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 419 |
Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine 2019;44:716-29. [PMID: 31201141 DOI: 10.1016/j.ebiom.2019.05.066] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 420 |
Giau VV, Lee H, An SSA, Hulme J. Recent advances in the treatment of C. difficile using biotherapeutic agents. Infect Drug Resist 2019;12:1597-615. [PMID: 31354309 DOI: 10.2147/IDR.S207572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 421 |
Richmond J, Mangrum R, Wang G, Maurer M, Sofaer S, Yang M, Carman KL. An informed public's views on reducing antibiotic overuse. Health Serv Res 2019;54:1283-94. [PMID: 31172520 DOI: 10.1111/1475-6773.13175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 422 |
Srikumar S, Fanning S. The Therapeutic Potential of the “Yin-Yang” Garden in Our Gut. Role of Microbes in Human Health and Diseases 2019. [DOI: 10.5772/intechopen.80881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 423 |
Alukal J, Dutta SK, Surapaneni BK, Le M, Tabbaa O, Phillips L, Mattar MC. Safety and efficacy of fecal microbiota transplant in 9 critically ill patients with severe and complicated Clostridium difficile infection with impending colectomy. J Dig Dis 2019;20:301-7. [PMID: 30969003 DOI: 10.1111/1751-2980.12750] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 424 |
Vigvári S, Vincze Á, Solt J, Sipos D, Feiszt Z, Kovács B, Kappéter Á, Péterfi Z. Experiences with fecal microbiota transplantation in Clostridium difficile infections via upper gastrointestinal tract. Acta Microbiol Immunol Hung 2019;66:179-88. [PMID: 30585500 DOI: 10.1556/030.65.2018.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 425 |
Hall BR, Armijo PR, Leinicke JA, Langenfeld SJ, Oleynikov D. Prolonged non-operative management of clostridium difficile colitis is associated with increased mortality, complications, and cost. The American Journal of Surgery 2019;217:1042-6. [DOI: 10.1016/j.amjsurg.2019.01.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 426 |
McSweeney B, Allegretti JR, Fischer M, Xu H, Goodman KJ, Monaghan T, McLeod C, Mullish BH, Petrof EO, Phelps EL, Chis R, Edmison A, Juby A, Ennis-Davis R, Roach B, Wong K, Kao D. In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation. Gut Microbes 2020;11:51-62. [PMID: 31122134 DOI: 10.1080/19490976.2019.1611153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 427 |
Yousi F, Kainan C, Junnan Z, Chuanxing X, Lina F, Bangzhou Z, Jianlin R, Baishan F. Evaluation of the effects of four media on human intestinal microbiota culture in vitro. AMB Express 2019;9:69. [PMID: 31123874 DOI: 10.1186/s13568-019-0790-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 428 |
Viswesh V, Hincapie AL, Yu M, Khatchatourian L, Nowak MA. Development of a bedside scoring system for predicting a first recurrence of Clostridium difficile-associated diarrhea. Am J Health Syst Pharm 2017;74:474-82. [PMID: 28336757 DOI: 10.2146/ajhp160186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 429 |
Aouinti I, Kaabi W, Charfi O, Lakhoua G, Hamza I, Daghfous R, El Aidli S, Kastalli S, Zaiem A. Community-acquired pseudomembranous colitis precipitated by loperamide. Therapie 2019;74:499-502. [PMID: 31101326 DOI: 10.1016/j.therap.2019.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 430 |
Lee CC, Hsieh CC, Yang CY, Hong MY, Lee CH, Tang HJ, Ko WC. Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study. Int J Antimicrob Agents 2019;54:176-83. [PMID: 31108223 DOI: 10.1016/j.ijantimicag.2019.05.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 431 |
Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver 2019;13:16-24. [PMID: 30400734 DOI: 10.5009/gnl18071] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 432 |
Robert P Hirten, Ari Grinspan, Shih-Chen Fu, Yuying Luo, Mayte Suarez-Farinas, John Rowland, Eduardo J Contijoch, Ilaria Mogno, Nancy Yang, Tramy Luong, Philippe R Labrias, Inga Peter, Judy H Cho, Bruce E Sands, Jean Frederic Colombel, Jeremiah J Faith, Jose C Clemente. Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25. [PMID: 30852592 DOI: 10.1093/ibd/izy398] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 433 |
Sertkaya A, Wong HH, Ertis DH, Jessup A. Societal willingness to pay to avoid mortality and morbidity from Clostridioides difficile and carbapenem-resistant Enterobacteriaceae infections in the United States. Am J Infect Control 2019;47:521-6. [PMID: 30579590 DOI: 10.1016/j.ajic.2018.11.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 434 |
Inoue M, Yonemura T, de Solom R, Yamaji M, Aizawa M, Knirsch C, Pride MW, Jansen KU, Gruber W, Webber C. A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. Vaccine 2019;37:2600-7. [PMID: 30962095 DOI: 10.1016/j.vaccine.2019.03.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 435 |
Ma H, Zhang L, Zhang Y, Liu Y, He Y, Guo L. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. Infect Drug Resist. 2019;12:1047-1054. [PMID: 31118710 DOI: 10.2147/idr.s194715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 436 |
Shoaei P, Shojaei H, Jalali M, Khorvash F, Hosseini SM, Ataei B, Vakili B, Ebrahimi F, Tavakoli H, Esfandiari Z, Weese JS. Clostridium difficile isolated from faecal samples in patients with ulcerative colitis. BMC Infect Dis 2019;19:361. [DOI: 10.1186/s12879-019-3965-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 437 |
Chung HS, Park JS, Shin BM. Laboratory Diagnosis of Clostridium difficile Infection in Korea: The First National Survey. Ann Lab Med 2019;39:317-21. [PMID: 30623624 DOI: 10.3343/alm.2019.39.3.317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 438 |
Legenza LM, Barnett SG, Rose WE. Vaccines in development for the primary prevention of Clostridium difficile infection. J Am Pharm Assoc (2003) 2017;57:547-9. [PMID: 28712463 DOI: 10.1016/j.japh.2017.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 439 |
Jia J, Tian X, Jiang J, Ren Z, Lu H, He N, Xie H, Zhou L, Zheng S. Structural shifts in the intestinal microbiota of rats treated with cyclosporine A after orthotropic liver transplantation. Front Med 2019;13:451-60. [PMID: 31020543 DOI: 10.1007/s11684-018-0675-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 440 |
Jorgenson MR, Descourouez JL, Yang DY, Leverson GE, Saddler CM, Smith JA, Safdar N, Mandlebrot DA, Redfield RR. Epidemiology, Risk Factors, and Outcomes After Early Posttransplant Clostridiodes difficile Infection in Renal Transplant Recipients. Ann Pharmacother 2019;53:1020-5. [PMID: 31007034 DOI: 10.1177/1060028019845003] [Reference Citation Analysis]
|
| 441 |
Abreu Y Abreu AT, Velarde-Ruiz Velasco JA, Zavala-Solares MR, Remes-Troche JM, Carmona-Sánchez RI, Aldana-Ledesma JM, Camacho-Ortiz A, Contreras-Omaña R, Díaz-Seoane R, Elizondo-Vázquez CT, Garza-González E, Grajales-Figueroa G, Gómez-Escudero O, Jacobo-Karam JS, Morales-Arámbula M, Olivares-Guzmán LO, Sifuentes-Osornio J, Siu-Moguel AG, Soto-Solís R, Valdovinos-García LR, Valdovinos-Díaz MA, Vázquez-Elizondo G, Lazo-de la Vega Jasso SA. Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed) 2019;84:204-19. [PMID: 30987771 DOI: 10.1016/j.rgmx.2018.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 442 |
Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset. J Infect Chemother 2019;25:615-20. [PMID: 30987950 DOI: 10.1016/j.jiac.2019.03.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 443 |
Dayananda P, Wilcox MH. A Review of Mixed Strain Clostridium difficile Colonization and Infection. Front Microbiol 2019;10:692. [PMID: 31024483 DOI: 10.3389/fmicb.2019.00692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 444 |
Sandlund J, Mills R, Griego-Fullbright C, Wagner A, Estis J, Bartolome A, Almazan A, Tam S, Biscocho S, Abusali S, Nolan N, Bishop JJ, Todd J, Young S. Laboratory comparison between cell cytotoxicity neutralization assay and ultrasensitive single molecule counting technology for detection of Clostridioides difficile toxins A and B, PCR, enzyme immunoassays, and multistep algorithms. Diagn Microbiol Infect Dis 2019;95:20-4. [PMID: 31129008 DOI: 10.1016/j.diagmicrobio.2019.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 445 |
Abreu y Abreu A, Velarde-ruiz Velasco J, Zavala-solares M, Remes-troche J, Carmona-sánchez R, Aldana-ledesma J, Camacho-ortiz A, Contreras-omaña R, Díaz-seoane R, Elizondo-vázquez C, Garza-gonzález E, Grajales-figueroa G, Gómez-escudero O, Jacobo-karam J, Morales-arámbula M, Olivares-guzmán L, Sifuentes-osornio J, Siu-moguel A, Soto-solís R, Valdovinos-garcía L, Valdovinos-díaz M, Vázquez-elizondo G, Lazo-de la Vega Jasso S. Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection. Revista de Gastroenterología de México (English Edition) 2019;84:204-19. [DOI: 10.1016/j.rgmxen.2018.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 446 |
Pulse ME, Weiss WJ, Kers JA, DeFusco AW, Park JH, Handfield M. Pharmacological, Toxicological, and Dose Range Assessment of OG716, a Novel Lantibiotic for the Treatment of Clostridium difficile-Associated Infection. Antimicrob Agents Chemother 2019;63:e01904-18. [PMID: 30670434 DOI: 10.1128/AAC.01904-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 447 |
Jingjing S, Yanshu Z, Yu L, Qindong S, Xue W, Lei Z, Yingli H, Litao G. Factors related to antibiotic-associated diarrhea in patients in the intensive care unit receiving antifungals: a single-center retrospective study. J Int Med Res 2019;47:2067-76. [PMID: 30898003 DOI: 10.1177/0300060519836305] [Reference Citation Analysis]
|
| 448 |
Cammarota G, Gallo A, Ianiro G, Montalto M. Emerging drugs for the treatment of clostridium difficile. Expert Opin Emerg Drugs 2019;24:17-28. [PMID: 30841760 DOI: 10.1080/14728214.2019.1591371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 449 |
Bozkurt HS, Kara B. Combination of oral vancomycin and intra-colonic vancomycin: Successful treatment of complicated pseudomembranous colitis in a child patient. SAGE Open Med Case Rep 2019;7:2050313X19838442. [PMID: 30911393 DOI: 10.1177/2050313X19838442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 450 |
Ma Y, Chen H, Lan C, Ren J. Help, hope and hype: ethical considerations of human microbiome research and applications. Protein Cell 2018;9:404-15. [PMID: 29675808 DOI: 10.1007/s13238-018-0537-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 451 |
Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H, Feathers A, Rosen MH, Malter LB, Swaminath A, IBD-ReMEdY Study (Research, Mentoring, Education New York). Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection WithClostridium difficile. Inflammatory Bowel Diseases 2019;25:775-781. [DOI: 10.1093/ibd/izy308] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 452 |
Lebreton F, Cattoir V. Resistance to Glycopeptide Antibiotics. Bacterial Resistance to Antibiotics – From Molecules to Man 2019. [DOI: 10.1002/9781119593522.ch3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 453 |
Hong S, Lee E, Shin J. Proton‐pump inhibitors and the risk of Clostridium difficile –associated diarrhea in high‐risk antibiotics users: A population‐based case‐crossover study. Pharmacoepidemiol Drug Saf 2019;28:479-88. [DOI: 10.1002/pds.4745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 454 |
Kappel BA, Lehrke M. Mikrobiom, Diabetes und Herz: neue Zusammenhänge? Herz 2019;44:223-30. [DOI: 10.1007/s00059-019-4791-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 455 |
Chen C, Chen Y, Liou J, Wu M; for the Taiwan Gastrointestinal Disease and Helicobacter Consortium. From germ theory to germ therapy. Kaohsiung J Med Sci 2019;35:73-82. [DOI: 10.1002/kjm2.12011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 456 |
Zhou Y, Mao L, Yu J, Lin Q, Luo Y, Zhu X, Sun Z. Epidemiology of Clostridium difficile infection in hospitalized adults and the first isolation of C. difficile PCR ribotype 027 in central China. BMC Infect Dis 2019;19:232. [PMID: 30845918 DOI: 10.1186/s12879-019-3841-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 457 |
Cui QQ, Yang J, Niu YN, Qiang CX, Li ZR, Xu KY, Li RX, Shi DY, Wei HL, Zhao XZ, Wang XM, Sun SJ, Zhao JH. Epidemiological investigation of Clostridioides difficile colonization in Chinese community infants. Anaerobe 2019;56:116-23. [PMID: 30849459 DOI: 10.1016/j.anaerobe.2019.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 458 |
Solanky D, Pardi DS, Loftus EV, Khanna S. Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis 2019;25:610-9. [PMID: 30260451 DOI: 10.1093/ibd/izy291] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 459 |
Cho S, Spencer E, Hirten R, Grinspan A, Dubinsky MC. Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;68:343-7. [PMID: 30320666 DOI: 10.1097/MPG.0000000000002172] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 460 |
Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019;114:384-413. [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152] [Cited by in Crossref: 612] [Cited by in F6Publishing: 559] [Article Influence: 153.0] [Reference Citation Analysis]
|
| 461 |
Vigvári S, Sipos D, Solt J, Vincze Á, Kocsis B, Nemes Z, Kappéter Á, Feiszt Z, Kovács B, Péterfi Z. Faecal microbiota transplantation for Clostridium difficile infection using a lyophilized inoculum from non-related donors: A case series involving 19 patients. Acta Microbiol Immunol Hung 2019;66:69-78. [PMID: 29239198 DOI: 10.1556/030.64.2017.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 462 |
Campbell CT, Poisson MO, Hand EO. An Updated Review of Clostridium difficile Treatment in Pediatrics. J Pediatr Pharmacol Ther 2019;24:90-8. [PMID: 31019401 DOI: 10.5863/1551-6776-24.2.90] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 463 |
Wang J, Kuo C, Kuo F, Wang Y, Hsu W, Yu F, Hu H, Hsu P, Wang J, Wu D. Fecal microbiota transplantation: Review and update. Journal of the Formosan Medical Association 2019;118:S23-31. [DOI: 10.1016/j.jfma.2018.08.011] [Cited by in Crossref: 120] [Cited by in F6Publishing: 133] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 464 |
Lui SL, Yap D, Cheng V, Chan TM, Yuen KY. Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service. Nephrology 2019;24:98-129. [DOI: 10.1111/nep.13497] [Reference Citation Analysis]
|
| 465 |
Kyeong Ok Kim, Michael Gluck. Fecal Microbiota Transplantation: An Update on Clinical Practice. Clin Endosc 2019;52. [PMID: 30909689 DOI: 10.5946/ce.2019.009] [Cited by in Crossref: 99] [Cited by in F6Publishing: 89] [Article Influence: 24.8] [Reference Citation Analysis]
|
| 466 |
Mcfarland LV, Surawicz CM, Vindigni SM. Clostridium DifficileInfections: Epidemiology, Diagnosis, and Treatment. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 467 |
Reed HL, Van Schooneveld TC, Reha CG, Bergman SJ. Use of a best practice alert linking Clostridioides difficile infection test results to a severity-based treatment order set. Infect Control Hosp Epidemiol 2019;40:467-9. [PMID: 30799805 DOI: 10.1017/ice.2019.18] [Reference Citation Analysis]
|
| 468 |
Li Y, Zou Z, Bian X, Huang Y, Wang Y, Yang C, Zhao J, Xie L. Fecal microbiota transplantation research output from 2004 to 2017: a bibliometric analysis. PeerJ. 2019;7:e6411. [PMID: 30809438 DOI: 10.7717/peerj.6411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 469 |
Figueroa Castro CE, Munoz-price LS. Advances in Infection Control for Clostridioides (Formerly Clostridium) difficile Infection. Curr Treat Options Infect Dis 2019;11:12-22. [DOI: 10.1007/s40506-019-0179-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 470 |
Phalak P, Henson M. Metabolic Modeling of Clostridium difficile Associated Dysbiosis of the Gut Microbiota. Processes 2019;7:97. [DOI: 10.3390/pr7020097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 471 |
Sarna KV, Gross AE. Vancomycin Versus Metronidazole for Nonsevere Clostridioides difficile Infection: Are the Data Adequate to Change Practice? Ann Pharmacother 2019;53:845-52. [PMID: 30734567 DOI: 10.1177/1060028019829764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 472 |
Carter KA, Malani AN. Laxative use and testing for Clostridium difficile in hospitalized adults: An opportunity to improve diagnostic stewardship. Am J Infect Control 2019;47:170-4. [PMID: 30301657 DOI: 10.1016/j.ajic.2018.08.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 473 |
Tariq R, Law CCY, Khanna S, Murthy S, McCurdy JD. The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2019;53:127-33. [PMID: 29206751 DOI: 10.1097/MCG.0000000000000968] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 474 |
Hong SJ, Feuerstadt P, Brandt LJ. MELD is the only predictor of short-term mortality in cirrhotic patients with C. difficile infection. Dig Liver Dis 2019;51:275-80. [PMID: 30172651 DOI: 10.1016/j.dld.2018.07.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 475 |
Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant 2019;19:501-11. [PMID: 30085388 DOI: 10.1111/ajt.15058] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 17.8] [Reference Citation Analysis]
|
| 476 |
Rancich M, Roman C. Updated guidelines for diagnosing and managing Clostridium difficile. JAAPA 2019;32:48-50. [PMID: 30694953 DOI: 10.1097/01.JAA.0000552734.33929.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 477 |
Munson E. Biographical Feature: Peter H. Gilligan, Ph.D., D(ABMM), F(AAM). J Clin Microbiol 2019;57:e01872-18. [PMID: 30541940 DOI: 10.1128/JCM.01872-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 478 |
Carlucci C, Jones CS, Oliphant K, Yen S, Daigneault M, Carriero C, Robinson A, Petrof EO, Weese JS, Allen-Vercoe E. Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile. Sci Rep 2019;9:885. [PMID: 30696914 DOI: 10.1038/s41598-018-37547-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 479 |
Icho S, Melnyk RA. Dismantling a Toxin to Disarm a Superbug. Trends Pharmacol Sci 2019;40:155-6. [PMID: 30685063 DOI: 10.1016/j.tips.2019.01.007] [Reference Citation Analysis]
|
| 480 |
Chia BY, Teo JQ, Lee W, Liew YX, Ee RP, Chlebicki MP, Oon LL, Kwa AL. Do antimicrobial stewardship programme interventions reduce the rate of and protect against Clostridium difficile infection? J Glob Antimicrob Resist 2019;17:312-5. [PMID: 30682564 DOI: 10.1016/j.jgar.2019.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 481 |
de Belvis AG, Barbara A, Giubbini G, Traglia S, Angioletti C, Ianiro G, Masucci L, Sanguinetti M, Laurenti P, Cambieri A, Gasbarrini A, Ricciardi W, Cammarota G. Impact evaluation of a Critical Pathway for patients with Clostridium difficile infection: A pre-post analysis in a Third Level Referral Center. Int J Infect Dis 2019;80:105-10. [PMID: 30682499 DOI: 10.1016/j.ijid.2019.01.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 482 |
Marttila-Vaara M, Ylipalosaari P, Kauma H. Clostridium difficile infections in teaching hospital in northern Finland. BMC Infect Dis 2019;19:48. [PMID: 30634939 DOI: 10.1186/s12879-018-3663-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 483 |
Gleich S, Schaffer A, Mai CH, Schick S, Hirl B. [Clostridium difficile-associated deaths from 2013-2016 in Munich and Nuremberg : Reporting behavior and patient characteristics]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017;60:1067-74. [PMID: 28852777 DOI: 10.1007/s00103-017-2605-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 484 |
Deeks ED. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence. Drugs 2017;77:1657-63. [PMID: 28865041 DOI: 10.1007/s40265-017-0809-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 485 |
Mankal PK, Abed J, Latte-Naor S, Grinspan A, Kotler DP. Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis. Am J Ther 2019;26:e115-7. [PMID: 30601771 DOI: 10.1097/MJT.0000000000000573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 486 |
Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, Abu-Zidan FM, Ansaloni L, Augustin G, Bala M, Ben-Ishay O, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cortese F, Cui Y, Czepiel J, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckmann C, Eiland EH, Forrester JD, Fraga GP, Frossard JL, Fry DE, Galeiras R, Ghnnam W, Gomes CA, Griffiths EA, Guirao X, Ahmed MH, Herzog T, Kim JI, Iqbal T, Isik A, Itani KMF, Labricciosa FM, Lee YY, Juang P, Karamarkovic A, Kim PK, Kluger Y, Leppaniemi A, Lohsiriwat V, Machain GM, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Ordoñez CA, Pagani L, Petrosillo N, Portela F, Rasa K, Rems M, Sakakushev BE, Segovia-Lohse H, Sganga G, Shelat VG, Spigaglia P, Tattevin P, Tranà C, Urbánek L, Ulrych J, Viale P, Baiocchi GL, Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019;14:8. [PMID: 30858872 DOI: 10.1186/s13017-019-0228-3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 487 |
Kobus-cisowska J, Szymanowska D, Maciejewska P, Kmiecik D, Gramza-michałowska A, Kulczyński B, Cielecka-piontek J. In vitro screening for acetylcholinesterase and butyrylcholinesterase inhibition and antimicrobial activity of chia seeds (Salvia hispanica). Electronic Journal of Biotechnology 2019;37:1-10. [DOI: 10.1016/j.ejbt.2018.10.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 488 |
Zucko J, Starcevic A, Diminic J, Oros D. Microbiota: Novel Gateway Towards Personalised Medicine. Personalized Medicine in Healthcare Systems 2019. [DOI: 10.1007/978-3-030-16465-2_9] [Reference Citation Analysis]
|
| 489 |
Abu-Sbeih H, Choi K, Tran CN, Wang X, Lum P, Shuttlesworth G, Stroehlein JR, Okhuysen PC, Wang Y. Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients. Eur J Gastroenterol Hepatol 2019;31:128-34. [PMID: 30339561 DOI: 10.1097/MEG.0000000000001288] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 490 |
Brown I, Miller GC. Large Intestine: Inflammatory Patterns. Endoscopic Biopsy Interpretation 2019. [DOI: 10.1007/978-3-319-79117-3_10] [Reference Citation Analysis]
|
| 491 |
Zhang L, Wu T. Inflammatory Bowel Disease. Surgical Pathology of Non-neoplastic Gastrointestinal Diseases 2019. [DOI: 10.1007/978-3-030-15573-5_15] [Reference Citation Analysis]
|
| 492 |
Sappington PL. Principles of Antibiotic Prescription in Intensive Care Unit Patients and Patients With Acute Renal Failure. Critical Care Nephrology 2019. [DOI: 10.1016/b978-0-323-44942-7.00097-2] [Reference Citation Analysis]
|
| 493 |
Leedahl DD, Personett HA, Nagpal A, Barreto EF. Prevention of Clostridium difficile Infection in Critically Ill Adults. Pharmacotherapy 2019;39:399-407. [PMID: 30506900 DOI: 10.1002/phar.2200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 494 |
Vely AP, Ferrada P. Clostridium difficile Infection. Emergency General Surgery 2019. [DOI: 10.1007/978-3-319-96286-3_23] [Reference Citation Analysis]
|
| 495 |
Reygner J, Kapel N. Current Status of Fecal Microbiota Transplantation. Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications 2019. [DOI: 10.1016/b978-0-12-815249-2.00016-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 496 |
Vaughn BP, Rank KM, Khoruts A. Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease. Clin Gastroenterol Hepatol 2019;17:353-61. [PMID: 30055267 DOI: 10.1016/j.cgh.2018.07.026] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 497 |
Crowell KT, Messaris E. Clostridium difficile Colitis. Clinical Algorithms in General Surgery 2019. [DOI: 10.1007/978-3-319-98497-1_63] [Reference Citation Analysis]
|
| 498 |
Lügering N, Domschke W. Clostridium-difficile-Infektion. Therapie-Handbuch 2019. [DOI: 10.1016/b978-3-437-24951-8.00025-7] [Reference Citation Analysis]
|
| 499 |
Tache T, Chirică R, Radu M, Gegiu G, Rugină S. Prevalence of infections with Clostridium difficile on potential pathology groups. Ovidius University Annals of Chemistry 2019;30:21-24. [DOI: 10.2478/auoc-2019-0004] [Reference Citation Analysis]
|
| 500 |
Fawley J, Napolitano LM. Vancomycin Enema in the Treatment ofClostridium difficileInfection. Surgical Infections 2019;20:311-316. [DOI: 10.1089/sur.2018.238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 501 |
Davidovics ZH, Michail S, Nicholson MR, Kociolek LK, Pai N, Hansen R, Schwerd T, Maspons A, Shamir R, Szajewska H, Thapar N, de Meij T, Mosca A, Vandenplas Y, Kahn SA, Kellermayer R; FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2019;68:130-43. [PMID: 30540704 DOI: 10.1097/MPG.0000000000002205] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 502 |
Meda M, Virgincar N, Gentry V, Walker A, Macdonald N, Hooper M, Wells S, Anderson C, Garner D, Mumtaz S, Smith A. Clostridium difficile infection in pregnant and postpartum women in 2 hospitals and a review of literature. Am J Infect Control 2019;47:e7-e14. [PMID: 30612611 DOI: 10.1016/j.ajic.2018.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 503 |
Srishti Saha, Sahil Khanna. Management of Clostridioides difficile colitis: insights for the gastroenterologist. Therap Adv Gastroenterol 2019;12:1756284819847651. [PMID: 31105766 DOI: 10.1177/1756284819847651] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 504 |
Keddy KH, Smith AM. Bacterial Gastroenteritis. Gastrointestinal Diseases and their Associated Infections 2019. [DOI: 10.1016/b978-0-323-54843-4.00012-x] [Reference Citation Analysis]
|
| 505 |
Pouch SM, Friedman-Moraco RJ. Prevention and Treatment of Clostridium difficile-Associated Diarrhea in Solid Organ Transplant Recipients. Infect Dis Clin North Am 2018;32:733-48. [PMID: 30146033 DOI: 10.1016/j.idc.2018.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 506 |
Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2018;. [PMID: 30458058 DOI: 10.1002/ijc.32003] [Cited by in Crossref: 113] [Cited by in F6Publishing: 123] [Article Influence: 22.6] [Reference Citation Analysis]
|
| 507 |
Zhang XY, Wang YZ, Li XL, Hu H, Liu HF, Li D, Xiao YM, Zhang T. Safety of fecal microbiota transplantation in Chinese children: A single-center retrospective study. World J Clin Cases 2018; 6(16): 1121-1127 [PMID: 30613670 DOI: 10.12998/wjcc.v6.i16.1121] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 508 |
Zhang X, Wang Y, Li X, Hu H, Liu H, Li D, Xiao Y, Zhang T. Safety of fecal microbiota transplantation in chinese children: A single-center retrospective study. WJCC 2018;6:1121-7. [DOI: 10.12998/wjcc.v6.i161.1121] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 509 |
Greenberg SA, Youngster I, Cohen NA, Livovsky DM, Strahilevitz J, Israeli E, Melzer E, Paz K, Fliss-Isakov N, Maharshak N. Five years of fecal microbiota transplantation - an update of the Israeli experience. World J Gastroenterol 2018; 24(47): 5403-5414 [PMID: 30598584 DOI: 10.3748/wjg.v24.i47.5403] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 510 |
Schmautz C, Müller N, Auer M, Ballweg I, Pfaffl MW, Kliem H. Immune cell counts and signaling in body fluids of cows vaccinated against Clostridium difficile. J Biol Res (Thessalon) 2018;25:20. [PMID: 30555805 DOI: 10.1186/s40709-018-0092-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 511 |
Peprah D, Chiu AS, Jean RA, Pei KY. Comparison of Outcomes Between Total Abdominal and Partial Colectomy for the Management of Severe, Complicated Clostridium Difficile Infection. J Am Coll Surg 2019;228:925-30. [PMID: 30576799 DOI: 10.1016/j.jamcollsurg.2018.11.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 512 |
Limketkai BN, Hendler S, Ting P, Parian AM. Fecal Microbiota Transplantation for the Critically Ill Patient. Nutrition in Clinical Practice 2019;34:73-9. [DOI: 10.1002/ncp.10228] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 513 |
Rac H, Gould AP, Eiland LS, Griffin B, McLaughlin M, Stover KR, Bland CM, Bookstaver PB. Common Bacterial and Viral Infections: Review of Management in the Pregnant Patient. Ann Pharmacother 2019;53:639-51. [PMID: 30556401 DOI: 10.1177/1060028018817935] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 514 |
Tabbaa OM, Aboelsoud MM, Mattar MC. Long-Term Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infection in Patients With and Without Inflammatory Bowel Disease: A Tertiary Care Center's Experience. Gastroenterology Res 2018;11:397-403. [PMID: 30627262 DOI: 10.14740/gr1091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 515 |
Martin LT, Vincent S, Gillian S, Moore K, Ratermann D, Droege CA. Pharmacologic Approach to Management of Clostridium difficile Infection. Crit Care Nurs Q 2019;42:2-11. [PMID: 30507659 DOI: 10.1097/CNQ.0000000000000232] [Reference Citation Analysis]
|
| 516 |
Zhang Y, Sun J, Zhang J, Liu Y, Guo L. Enzyme Inhibitor Antibiotics and Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018;24:8781-8788. [PMID: 30512009 DOI: 10.12659/msm.913739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 517 |
Gupta SB, Dubberke ER. Reprint of: Overview and changing epidemiology of Clostridium difficile infection. Seminars in Colon and Rectal Surgery 2018;29:206-211. [DOI: 10.1053/j.scrs.2018.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 518 |
Lopes Cançado GG, Silveira Silva RO, Rupnik M, Nader AP, Starling de Carvalho J, Miana de Mattos Paixão G, Martins Resende BA, Faria Lobato FC, Vilela EG. Clinical epidemiology of Clostridium difficile infection among hospitalized patients with antibiotic-associated diarrhea in a university hospital of Brazil. Anaerobe 2018;54:65-71. [DOI: 10.1016/j.anaerobe.2018.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 519 |
Mathias F, Curti C, Montana M, Bornet C, Vanelle P. Management of adult Clostridium difficile digestive contaminations: a literature review. Eur J Clin Microbiol Infect Dis 2019;38:209-31. [PMID: 30498879 DOI: 10.1007/s10096-018-3419-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 520 |
Palmieri LJ, Rainteau D, Sokol H, Beaugerie L, Dior M, Coffin B, Humbert L, Eguether T, Bado A, Hoys S, Janoir C, Duboc H. Inhibitory Effect of Ursodeoxycholic Acid on Clostridium difficile Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. Front Microbiol 2018;9:2849. [PMID: 30524414 DOI: 10.3389/fmicb.2018.02849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 521 |
Stuart RL, Marshall C, Harrington G, Sasko L, McLaws ML, Ferguson J. ASID/ACIPC position statement - Infection control for patients with Clostridium difficile infection in healthcare facilities. Infect Dis Health 2019;24:32-43. [PMID: 30691583 DOI: 10.1016/j.idh.2018.10.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 522 |
Maaß S, Otto A, Albrecht D, Riedel K, Trautwein-Schult A, Becher D. Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin. Cells 2018;7:E213. [PMID: 30445773 DOI: 10.3390/cells7110213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 523 |
Ohge H, Kajihara T, Kitano H. V. <i>Clostridioides Difficile</i> Infection. J Jpn Soc Intern Med 2018;107:2261-2268. [DOI: 10.2169/naika.107.2261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 524 |
Sun X, Jia Z. Microbiome modulates intestinal homeostasis against inflammatory diseases. Vet Immunol Immunopathol 2018;205:97-105. [PMID: 30459007 DOI: 10.1016/j.vetimm.2018.10.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 525 |
Allegretti JR, Allegretti AS, Phelps E, Xu H, Fischer M, Kassam Z. Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. Clin Gastroenterol Hepatol 2018;16:1832-3. [PMID: 29104129 DOI: 10.1016/j.cgh.2017.10.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 526 |
Igarashi Y, Tashiro S, Enoki Y, Taguchi K, Matsumoto K, Ohge H, Suzuki H, Nakamura A, Mori N, Morinaga Y, Yamagishi Y, Yoshizawa S, Yanagihara K, Mikamo H, Kunishima H. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. Journal of Infection and Chemotherapy 2018;24:907-914. [DOI: 10.1016/j.jiac.2018.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 527 |
Sandlund J, Bartolome A, Almazan A, Tam S, Biscocho S, Abusali S, Bishop JJ, Nolan N, Estis J, Todd J, Young S, Senchyna F, Banaei N. Ultrasensitive Detection of Clostridioides difficile Toxins A and B by Use of Automated Single-Molecule Counting Technology. J Clin Microbiol 2018;56:e00908-18. [PMID: 30158195 DOI: 10.1128/JCM.00908-18] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 528 |
Tokimatsu I, Shigemura K, Osawa K, Kinugawa S, Kitagawa K, Nakanishi N, Yoshida H, Arakawa S, Fujisawa M; Research Group of Japan Infection Prevention and Control Conference for National and Public University Hospitals. Molecular epidemiologic study of Clostridium difficile infections in university hospitals: Results of a nationwide study in Japan. J Infect Chemother 2018;24:641-7. [PMID: 29685855 DOI: 10.1016/j.jiac.2018.03.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 529 |
Abughanimeh O, Qasrawi A, Kaddourah O, Al Momani L, Abu Ghanimeh M. Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment. Hosp Pract (1995) 2018;46:266-77. [PMID: 30296190 DOI: 10.1080/21548331.2018.1533673] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 530 |
Godinho L, Feldman C. Clostridium difficile infection in Johannesburg, South Africa. Hospital Practice 2018;46:287-94. [DOI: 10.1080/21548331.2018.1534431] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 531 |
Shivashankar R, Lichtenstein GR. Mimics of Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;24:2315-21. [PMID: 29947781 DOI: 10.1093/ibd/izy168] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 532 |
Niccum BA, Stein DJ, Behm BW, Hays RA. Zinc Deficiency and the Recurrence of Clostridium difficile Infection after Fecal Microbiota Transplant: A Retrospective Cohort Study. J Nutr Metab 2018;2018:9682975. [PMID: 30405910 DOI: 10.1155/2018/9682975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 533 |
Ruiter-Ligeti J, Vincent S, Czuzoj-Shulman N, Abenhaim HA. Risk Factors, Incidence, and Morbidity Associated With Obstetric Clostridium difficile Infection. Obstet Gynecol. 2018;131:387-391. [PMID: 29324599 DOI: 10.1097/aog.0000000000002422] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 534 |
Paknikar R, Pekow J. Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection. Surg Infect (Larchmt). 2018;19:785-791. [PMID: 30300561 DOI: 10.1089/sur.2018.221] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 535 |
Walton J, Burns D, Gaehle KE. Process and Outcome of Fecal Microbiota Transplants in Patients With Recurrent Clostridium difficile Infection: A Prospective Study. Gastroenterol Nurs 2017;40:411-9. [PMID: 28957971 DOI: 10.1097/SGA.0000000000000233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 536 |
Zheng W, Wang K, Sun Y, Kuo SM. Dietary or supplemental fermentable fiber intake reduces the presence of Clostridium XI in mouse intestinal microbiota: The importance of higher fecal bacterial load and density. PLoS One 2018;13:e0205055. [PMID: 30278071 DOI: 10.1371/journal.pone.0205055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 537 |
Breslin AW, Gurysh KM, Broder JS. Toxic megacolon due to severe Clostridium difficile colitis. Visual Journal of Emergency Medicine 2018;13:15-17. [DOI: 10.1016/j.visj.2018.07.016] [Reference Citation Analysis]
|
| 538 |
Gabriel V, Grigorian A, Phillips JL, Schubl SD, Barrios C, Pejcinovska M, Won E, Nahmias J. A Propensity Score Analysis of Clostridium difficile Infection among Adult Trauma Patients. Surgical Infections 2018;19:661-6. [DOI: 10.1089/sur.2018.110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 539 |
Shelygin YA, Aleshkin VA, Sukhina MA, Mironov AY, Briko NI, Kozlov RS, Zverev VV, Achkasov SI, Kovalishena OV, Selkova EP, Safin AL, Grenkova TA, Khalif IL, Frolov SA, Kashnikov VN, Sushkov OI. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ НАЦИОНАЛЬНОЙ АССОЦИАЦИИ СПЕЦИАЛИСТОВ ПО КОНТРОЛЮ ИНФЕКЦИЙ, СВЯЗАННЫХ С ОКАЗАНИЕМ МЕДИЦИНСКОЙ ПОМОЩИ, И ОБЩЕРОССИЙСКОЙ ОБЩЕСТВЕННОЙ НЕКОММЕРЧЕСКОЙ ОРГАНИЗАЦИИ «АССОЦИАЦИЯ КОЛОПРОКТОЛОГОВ РОССИИ» ПО ДИАГНОСТИКЕ, ЛЕЧЕНИЮ И ПРОФИЛАКТИКЕ CLOSTRIDIUM DIFFICILE-АССОЦИИРОВАННОЙ ДИАРЕИ (CDI). Koloproktologiâ 2018. [DOI: 10.33878/2073-7556-2018-0-3-7-23] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 540 |
Abdel-mongy M, El-feky S, Masoud H, El-hendi A. Rapid Assays for Detection of Clostridium difficile and Its Toxins in Hospitalized Patients. J Pure Appl Microbiol 2018;12:1247-1254. [DOI: 10.22207/jpam.12.3.26] [Reference Citation Analysis]
|
| 541 |
Howerton A, Seymour CO, Murugapiran SK, Liao Z, Phan JR, Estrada A, Wagner AJ, Mefferd CC, Hedlund BP, Abel-Santos E. Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection. Antimicrob Agents Chemother 2018;62:e02251-17. [PMID: 30012758 DOI: 10.1128/AAC.02251-17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 542 |
Staley C, Kaiser T, Vaughn BP, Graiziger CT, Hamilton MJ, Rehman TU, Song K, Khoruts A, Sadowsky MJ. Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. Microbiome 2018;6:166. [PMID: 30227892 DOI: 10.1186/s40168-018-0549-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 543 |
Fang H, Fu L, Wang J. Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018;2018:8941340. [PMID: 30302341 DOI: 10.1155/2018/8941340] [Cited by in Crossref: 43] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 544 |
Murphy MM, Patatanian E, Gales MA. Extended duration vancomycin in recurrent Clostridium difficile infection: a systematic review. Ther Adv Infect Dis 2018;5:111-9. [PMID: 30430009 DOI: 10.1177/2049936118798276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 545 |
Ssepuuya G, Wynants E, Verreth C, Crauwels S, Lievens B, Claes J, Nakimbugwe D, Van Campenhout L. Microbial characterisation of the edible grasshopper Ruspolia differens in raw condition after wild-harvesting in Uganda. Food Microbiol 2019;77:106-17. [PMID: 30297041 DOI: 10.1016/j.fm.2018.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 546 |
Kunishima H, Ito K, Laurent T, Abe M. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study. J Infect Chemother 2018;24:892-901. [PMID: 30190105 DOI: 10.1016/j.jiac.2018.07.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 547 |
Bilinskaya A, Goodlet KJ, Nailor MD. Evaluation of a best practice alert to reduce unnecessary Clostridium difficile testing following receipt of a laxative. Diagnostic Microbiology and Infectious Disease 2018;92:50-5. [DOI: 10.1016/j.diagmicrobio.2018.04.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 548 |
Garcia PG, Chebli LA, da Rocha Ribeiro TC, Gaburri PD, de Lima Pace FH, Barbosa KVBD, Costa LA, de Almeida Cruz W, de Assis IC, Moraes BRM, Zanini A, Chebli JMF. Impact of superimposed Clostridium difficile infection in Crohn's or ulcerative colitis flares in the outpatient setting. Int J Colorectal Dis 2018;33:1285-94. [PMID: 29926235 DOI: 10.1007/s00384-018-3105-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 549 |
Smith EZ, Northup PG, Argo CK. Predictors of Mortality in Cirrhosis Inpatients With Clostridium difficile Infection. J Clin Gastroenterol 2018;52:747-51. [PMID: 28644310 DOI: 10.1097/MCG.0000000000000868] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 550 |
Chandradas S, Khalili H, Ananthakrishnan A, Wayman C, Reidel W, Waalen J, Konijeti GG. Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis? Dig Dis Sci 2018;63:2445-50. [PMID: 29779082 DOI: 10.1007/s10620-018-5108-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 551 |
Rezapour M, Galoosian A, Liu B, Bhuket T, Wong RJ. Clostridium difficile co-infection in inflammatory bowel disease is associated with significantly increased in-hospital mortality. Eur J Gastroenterol Hepatol 2018;30:1041-6. [PMID: 29894325 DOI: 10.1097/MEG.0000000000001185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 552 |
Sandora TJ, Bryant KK, Cantey JB, Elward AM, Yokoe DS, Bartlett AH. SHEA neonatal intensive care unit (NICU) white paper series: Practical approaches to Clostridioides difficile prevention. Infect Control Hosp Epidemiol 2018;39:1149-53. [PMID: 30160646 DOI: 10.1017/ice.2018.209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 553 |
Mounajjed M, Pease R, Jung-hynes B, Safdar N, Chen D. Performing Reflexive Toxin A/B Enzyme Immunoassay in a Two-Step Algorithm for the Diagnosis of Clostridium difficile Infection Has Limited Clinical Utility.. [DOI: 10.1101/384214] [Reference Citation Analysis]
|
| 554 |
Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 116] [Cited by in F6Publishing: 87] [Article Influence: 23.2] [Reference Citation Analysis]
|
| 555 |
Ford DC, Schroeder MC, Ince D, Ernst EJ. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients. American Journal of Health-System Pharmacy 2018;75:1110-21. [DOI: 10.2146/ajhp170554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 556 |
Ofori E, Ramai D, Dhawan M, Mustafa F, Gasperino J, Reddy M. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. Journal of Hospital Infection 2018;99:436-42. [DOI: 10.1016/j.jhin.2018.01.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 557 |
Lin SC, Alonso CD, Moss AC. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature. Transpl Infect Dis 2018;20:e12967. [PMID: 30011107 DOI: 10.1111/tid.12967] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 558 |
Jiang M, Leung NH, Ip M, You JHS. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection. PLoS One. 2018;13:e0201539. [PMID: 30048534 DOI: 10.1371/journal.pone.0201539] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 559 |
Banz A, Lantz A, Riou B, Foussadier A, Miller M, Davies K, Wilcox M. Sensitivity of Single-Molecule Array Assays for Detection of Clostridium difficile Toxins in Comparison to Conventional Laboratory Testing Algorithms. J Clin Microbiol 2018;56:e00452-18. [PMID: 29898996 DOI: 10.1128/JCM.00452-18] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 560 |
Moreira BDO, Pais LS, Costa LDA. Diarreia causada por Clostridium difficile: recentes avanços. HU Rev 2018;43:155-161. [DOI: 10.34019/1982-8047.2017.v43.2653] [Reference Citation Analysis]
|
| 561 |
Granato PA, Hansen G, Herding E, Chaudhuri S, Tang S, Garg SK, Rowell CR, Sickler JJ. Performance comparison of the cobas Liat and Cepheid GeneXpert systems for Clostridium difficile detection. PLoS One 2018;13:e0200498. [PMID: 30040852 DOI: 10.1371/journal.pone.0200498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 562 |
Shah S, Ereshefsky B, Pontiggia L, Cawley M. Impact of Delayed Oral Vancomycin for Severe Clostridium difficile Infection. Hosp Pharm 2019;54:294-9. [PMID: 31555004 DOI: 10.1177/0018578718787439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 563 |
Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. Predictors of Mortality Among a National Cohort of Veterans With Recurrent Clostridium difficile Infection. Open Forum Infect Dis 2018;5:ofy175. [PMID: 30327788 DOI: 10.1093/ofid/ofy175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 564 |
Litao G, Jingjing S, Yu L, Lei Z, Xiaona H, Zhijing Z. Risk Factors for Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018;24:5000-5007. [PMID: 30020891 DOI: 10.12659/msm.911308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 565 |
Vernaya M, McAdam J, Hampton MD. Effectiveness of probiotics in reducing the incidence of Clostridium difficile-associated diarrhea in elderly patients: a systematic review. JBI Database System Rev Implement Rep 2017;15:140-64. [PMID: 28085732 DOI: 10.11124/JBISRIR-2016-003234] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 566 |
Prechter F, Stallmach A. [Clostridium difficile in the intensive care unit]. Med Klin Intensivmed Notfmed 2020;115:81-7. [PMID: 29995234 DOI: 10.1007/s00063-018-0459-1] [Reference Citation Analysis]
|
| 567 |
Vargason AM, Anselmo AC. Clinical translation of microbe-based therapies: Current clinical landscape and preclinical outlook. Bioeng Transl Med 2018;3:124-37. [PMID: 30065967 DOI: 10.1002/btm2.10093] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 568 |
Salamonowicz M, Ociepa T, Frączkiewicz J, Szmydki-Baran A, Matysiak M, Czyżewski K, Wysocki M, Gałązka P, Zalas-Więcek P, Irga-Jaworska N, Drożyńska E, Zając-Spychała O, Wachowiak J, Gryniewicz-Kwiatkowska O, Czajńska-Deptuła A, Dembowska-Bagińska B, Chełmecka-Wiktorczyk L, Balwierz W, Bartnik M, Zielezińska K, Urasiński T, Tomaszewska R, Szczepański T, Płonowski M, Krawczuk-Rybak M, Pierlejewski F, Młynarski W, Gamrot-Pyka Z, Woszczyk M, Małas Z, Badowska W, Urbanek-Dądela A, Karolczyk G, Stolpa W, Sobol-Milejska G, Zaucha-Prażmo A, Kowalczyk J, Goździk J, Gorczyńska E, Jermakow K, Król A, Chybicka A, Ussowicz M, Kałwak K, Styczyński J. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 2018;37:1805-12. [PMID: 29978303 DOI: 10.1007/s10096-018-3316-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 569 |
King A, Mullish BH, Williams HRT, Aylin P. Comparative epidemiology of Clostridium difficile infection: England and the USA. Int J Qual Health Care 2017;29:785-91. [PMID: 29025123 DOI: 10.1093/intqhc/mzx120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 570 |
Jarrad AM, Blaskovich MAT, Prasetyoputri A, Karoli T, Hansford KA, Cooper MA. Detection and Investigation of Eagle Effect Resistance to Vancomycin in Clostridium difficile With an ATP-Bioluminescence Assay. Front Microbiol 2018;9:1420. [PMID: 30013531 DOI: 10.3389/fmicb.2018.01420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 571 |
Ianiro G, Masucci L, Quaranta G, Simonelli C, Lopetuso LR, Sanguinetti M, Gasbarrini A, Cammarota G. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther 2018;48:152-9. [PMID: 29851107 DOI: 10.1111/apt.14816] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 572 |
Cusini A, Béguelin C, Stampf S, Boggian K, Garzoni C, Koller M, Manuel O, Meylan P, Mueller NJ, Hirsch HH, Weisser M, Berger C, van Delden C; Swiss Transplant Cohort Study. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. Am J Transplant 2018;18:1745-54. [PMID: 29349869 DOI: 10.1111/ajt.14640] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 573 |
Vindigni SM, Surawicz CM. Managing Clostridium difficile: an old bug with new tricks. Am J Gastroenterol 2018;113:932-5. [PMID: 29686272 DOI: 10.1038/s41395-018-0059-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 574 |
Xu X, Luo Y, Song X, Ying J, Ye J, Lu Y, Cai J, Ma J, Wang X, Yu W, Wang Y, Jin D. Evaluation of an UltraFast LabChip V280 assay for detection of toxigenic Clostridium difficile. Diagn Microbiol Infect Dis 2018;92:279-83. [PMID: 30029809 DOI: 10.1016/j.diagmicrobio.2018.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 575 |
Chai J, Lee CH. Management of Primary and Recurrent Clostridium difficile Infection: An Update. Antibiotics (Basel) 2018;7:E54. [PMID: 29966323 DOI: 10.3390/antibiotics7030054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 576 |
Korayem GB, Eljaaly K, Matthias KR, Zangeneh TT. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study. Transplant Proc 2018;50:137-41. [PMID: 29407296 DOI: 10.1016/j.transproceed.2017.11.016] [Reference Citation Analysis]
|
| 577 |
Falcone M, Tiseo G, Iraci F, Raponi G, Goldoni P, Delle Rose D, Santino I, Carfagna P, Murri R, Fantoni M, Fontana C, Sanguinetti M, Farcomeni A, Antonelli G, Aceti A, Mastroianni C, Andreoni M, Cauda R, Petrosillo N, Venditti M. Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. Clin Microbiol Infect 2019;25:474-80. [PMID: 29964230 DOI: 10.1016/j.cmi.2018.06.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 578 |
Jessurun J. The Differential Diagnosis of Acute Colitis: Clues to a Specific Diagnosis. Surg Pathol Clin. 2017;10:863-885. [PMID: 29103537 DOI: 10.1016/j.path.2017.07.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 579 |
Migriauli I, Meunargia V, Chkhaidze I, Sabakhtarishvili G, Gujabidze K, Butsashvili M, Kamkamidze G. Factors affecting development of Clostridium difficile infection in hospitalized pediatric patients in the country Georgia. BMC Res Notes 2018;11:409. [PMID: 29941046 DOI: 10.1186/s13104-018-3517-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 580 |
Kodadek LM, Lipsett PA. Prevention and Treatment of Clostridium difficile Enterocolitis. Adv Surg 2018;52:29-42. [PMID: 30098619 DOI: 10.1016/j.yasu.2018.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 581 |
Burton HE, Mitchell SA, Watt M. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. Pharmacoeconomics 2017;35:1123-40. [PMID: 28875314 DOI: 10.1007/s40273-017-0540-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 582 |
Bovonratwet P, Bohl DD, Russo GS, Ondeck NT, Singh K, Grauer JN. Incidence, Risk Factors, and Impact of Clostridium difficile Colitis After Spine Surgery: An Analysis of a National Database. Spine (Phila Pa 1976) 2018;43:861-8. [PMID: 28953711 DOI: 10.1097/BRS.0000000000002430] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 583 |
Kers JA, DeFusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M. OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections. PLoS One 2018;13:e0197467. [PMID: 29894469 DOI: 10.1371/journal.pone.0197467] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 584 |
Ianiro G, Maida M, Burisch J, Simonelli C, Hold G, Ventimiglia M, Gasbarrini A, Cammarota G. Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis. United European Gastroenterol J. 2018;6:1232-1244. [PMID: 30288286 DOI: 10.1177/2050640618780762] [Cited by in Crossref: 104] [Cited by in F6Publishing: 107] [Article Influence: 20.8] [Reference Citation Analysis]
|
| 585 |
Goyal H, Perisetti A, Rehman MR, Singla U. New and emerging therapies in treatment of Clostridium difficile infection. Eur J Gastroenterol Hepatol 2018;30:589-97. [PMID: 29521664 DOI: 10.1097/MEG.0000000000001103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 586 |
Tobar-marcillo M, Guerrero-duran M, Avecillas-segovia A, Pacchiano-aleman L, Basante-díaz R, Vela-vizcaino H, Espinosa-aznar E, Castorena García P, Santiago-ramírez R, Rivas-bucio I. Metronidazole in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection in high-risk hospitalised patients. Gastroenterología y Hepatología (English Edition) 2018;41:362-368. [DOI: 10.1016/j.gastre.2018.06.007] [Reference Citation Analysis]
|
| 587 |
Charilaou P, Devani K, John F, Kanna S, Ahlawat S, Young M, Khanna S, Reddy C. Acute kidney injury impact on inpatient mortality in Clostridium difficile infection: A national propensity-matched study. J Gastroenterol Hepatol 2018;33:1227-33. [PMID: 29205514 DOI: 10.1111/jgh.14064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 588 |
Tobar-marcillo M, Guerrero-duran M, Avecillas-segovia A, Pacchiano-aleman L, Basante-díaz R, Vela-vizcaino H, Espinosa-aznar E, Castorena García P, Santiago-ramírez R, Rivas-bucio I. Metronidazol en la prevención de diarrea asociada a antibióticos e infección por Clostridium difficile en pacientes hospitalizados de alto riesgo. Gastroenterología y Hepatología 2018;41:362-8. [DOI: 10.1016/j.gastrohep.2018.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 589 |
Fareed S, Sarode N, Stewart FJ, Malik A, Laghaie E, Khizer S, Yan F, Pratte Z, Lewis J, Immergluck LC. Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children. PeerJ 2018;6:e4663. [PMID: 29868248 DOI: 10.7717/peerj.4663] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 590 |
Fisher A, Khanal P, Gniado E, Khaddour L, Orosey M, Hader I, Yadav S, Halalau A. A Retrospective Study Analyzing the Appropriateness of Initial Treatment of Clostridium difficile in Patients with Active Malignancy. Gastroenterol Res Pract 2018;2018:7192728. [PMID: 29991944 DOI: 10.1155/2018/7192728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 591 |
Chen T, Zhou Q, Zhang D, Jiang F, Wu J, Zhou J, Zheng X, Chen Y. Effect of Faecal Microbiota Transplantation for Treatment of Clostridium difficile Infection in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Cohort Studies. Journal of Crohn's and Colitis 2018;12:710-717. [DOI: 10.1093/ecco-jcc/jjy031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 592 |
Leal SM Jr, Popowitch EB, Levinson KJ, John TM, Lehman B, Rios MB, Gilligan PH, Miller MB. Quantitative Thresholds Enable Accurate Identification of Clostridium difficile Infection by the Luminex xTAG Gastrointestinal Pathogen Panel. J Clin Microbiol 2018;56:e01885-17. [PMID: 29643194 DOI: 10.1128/JCM.01885-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 593 |
Messias BA, Franchi BF, Pontes PH, Barbosa DÁDAM, Viana CAS. Fecal microbiota transplantation in the treatment of Clostridium difficile infection: state of the art and literature review. Rev Col Bras Cir 2018;45. [DOI: 10.1590/0100-6991e-20181609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 594 |
Mihaela L, Pascu O, Leucuta D, Andreica V. Fecal microbiota transplantation in recurrent Clostridium difficile infection: the first prospective study of 30 patients in Romania. Revista Romana de Medicina de Laborator 2018;26:201-10. [DOI: 10.2478/rrlm-2018-0013] [Reference Citation Analysis]
|
| 595 |
Theiss AM, Balla A, Ross A, Francis D, Wojewoda C. Searching for a Potential Algorithm for Clostridium difficile Testing at a Tertiary Care Hospital: Does Toxin Enzyme Immunoassay Testing Help? J Clin Microbiol 2018;56:e00415-18. [PMID: 29743303 DOI: 10.1128/JCM.00415-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 596 |
von Braun A, Lübbert C. Therapie akuter und rekurrenter Clostridium-difficile-Infektionen. Internist 2018;59:505-513. [DOI: 10.1007/s00108-018-0401-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 597 |
Caulfield AJ, Bolster Lasalle CM, Chang YH, Grys TE. Evaluation of 4 molecular assays as part of a 2-step algorithm for the detection of Clostridium difficile in stool specimens. Diagnostic Microbiology and Infectious Disease 2018;91:1-5. [DOI: 10.1016/j.diagmicrobio.2017.12.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 598 |
Ooijevaar R, van Beurden Y, Terveer E, Goorhuis A, Bauer M, Keller J, Mulder C, Kuijper E. Update of treatment algorithms for Clostridium difficile infection. Clinical Microbiology and Infection 2018;24:452-62. [DOI: 10.1016/j.cmi.2017.12.022] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 15.2] [Reference Citation Analysis]
|
| 599 |
Wang J, Ghali S, Xu C, Mussatto CC, Ortiz C, Lee EC, Tran DH, Jacobs JP, Lagishetty V, Faull KF, Moller T, Rossetti M, Chen X, Koon HW. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Gastroenterology 2018;154:1737-50. [PMID: 29360463 DOI: 10.1053/j.gastro.2018.01.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 600 |
Guo YF, Shu L, Tan ZJ. Role of intestinal Clostridium in pathogenesis and treatment of diarrhea. Shijie Huaren Xiaohua Zazhi 2018; 26(12): 693-699 [DOI: 10.11569/wcjd.v26.i12.693] [Reference Citation Analysis]
|
| 601 |
Johnston BC, Lytvyn L, Lo CK, Allen SJ, Wang D, Szajewska H, Miller M, Ehrhardt S, Sampalis J, Duman DG, Pozzoni P, Colli A, Lönnermark E, Selinger CP, Wong S, Plummer S, Hickson M, Pancheva R, Hirsch S, Klarin B, Goldenberg JZ, Wang L, Mbuagbaw L, Foster G, Maw A, Sadeghirad B, Thabane L, Mertz D. Microbial Preparations (Probiotics) for the Prevention of Clostridium difficile Infection in Adults and Children: An Individual Patient Data Meta-analysis of 6,851 Participants. Infect Control Hosp Epidemiol 2018;39:771-81. [PMID: 29695312 DOI: 10.1017/ice.2018.84] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 602 |
Ziegler M, Landsburg D, Pegues D, Alby K, Gilmar C, Bink K, Gorman T, Moore A, Bonhomme B, Omorogbe J, Tango D, Tolomeo P, Han JH. Clinical Characteristics and Outcomes of Hematologic Malignancy Patients With Positive Clostridium difficile Toxin Immunoassay Versus Polymerase Chain Reaction Test Results. Infect Control Hosp Epidemiol 2018;39:863-6. [PMID: 29690940 DOI: 10.1017/ice.2018.83] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 603 |
Zhang F, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9:462-473. [PMID: 29691757 DOI: 10.1007/s13238-018-0541-8] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 25.4] [Reference Citation Analysis]
|
| 604 |
Salazar CL, Reyes C, Cienfuegos-Gallet AV, Best E, Atehortua S, Sierra P, Correa MM, Fawley WN, Paredes-Sabja D, Wilcox M, Gonzalez A. Subtyping of Clostridium difficile PCR ribotypes 591, 106 and 002, the dominant strain types circulating in Medellin, Colombia. PLoS One 2018;13:e0195694. [PMID: 29649308 DOI: 10.1371/journal.pone.0195694] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 605 |
Larrainzar-Coghen T, Rodríguez-Pardo D, Fernández-Hidalgo N, Puig-Asensio M, Pigrau C, Ferrer C, Rodríguez V, Bartolomé R, Campany D, Almirante B. Secular trends in the epidemiology of Clostridium difficile infection (CDI) at a tertiary care hospital in Barcelona, 2006-2015: A prospective observational study. Anaerobe 2018;51:54-60. [PMID: 29655966 DOI: 10.1016/j.anaerobe.2018.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 606 |
Abuhakmeh Y, Watt J, Mckinney C. Infectious Disease. Surgical Critical Care and Emergency Surgery 2018. [DOI: 10.1002/9781119317913.ch9] [Reference Citation Analysis]
|
| 607 |
Joshi T, Elderd BD, Abbott KC. No appendix necessary: Fecal transplants and antibiotics can resolve Clostridium difficile infection. Journal of Theoretical Biology 2018;442:139-148. [DOI: 10.1016/j.jtbi.2018.01.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 608 |
Bakker GJ, Nieuwdorp M. Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. Microbiol Spectr 2017;5. [PMID: 28840809 DOI: 10.1128/microbiolspec.BAD-0008-2017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 609 |
Zahid U, Sagar F, Al Mohajer M, Majeed A. Management of Recurrent Clostridium difficile Infection During Intensive Chemotherapy and Stem Cell Transplantation for Leukemia: Case with Literature Review. Cureus 2018;10:e2413. [PMID: 29872594 DOI: 10.7759/cureus.2413] [Reference Citation Analysis]
|
| 610 |
Steinebrunner N, Stremmel W, Weiss KH. Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection. J Thorac Dis 2018;10:118-20. [PMID: 29600036 DOI: 10.21037/jtd.2017.12.117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 611 |
Quan KA, Yim J, Merrill D, Khusbu U, Madey K, Dickey L, Dangodara AA, Rudkin SE, O'Brien M, Thompson D, Parekh N, Albers CG, Wilson WC, Thrupp L, Bittencourt CE, Huang SS, Gohil SK. Reductions in Clostridium difficile Infection (CDI) Rates Using Real-Time Automated Clinical Criteria Verification to Enforce Appropriate Testing. Infect Control Hosp Epidemiol 2018;39:625-7. [PMID: 29552992 DOI: 10.1017/ice.2018.32] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 612 |
Kers JA, Sharp RE, Defusco AW, Park JH, Xu J, Pulse ME, Weiss WJ, Handfield M. Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection. Front Microbiol 2018;9:415. [PMID: 29615987 DOI: 10.3389/fmicb.2018.00415] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 613 |
Posteraro B, Pea F, Masucci L, Posteraro P, Sanguinetti M. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? Expert Opin Biol Ther 2018;18:469-76. [PMID: 29534621 DOI: 10.1080/14712598.2018.1452908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 614 |
Long C, Yu Y, Cui B, Jagessar SAR, Zhang J, Ji G, Huang G, Zhang F. A novel quick transendoscopic enteral tubing in mid-gut: technique and training with video. BMC Gastroenterol. 2018;18:37. [PMID: 29534703 DOI: 10.1186/s12876-018-0766-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 615 |
Casari E, De Luca C, Calabrò M, Scuderi C, Daleno C, Ferrario A. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control 2018;7:40. [PMID: 29564088 DOI: 10.1186/s13756-018-0332-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 616 |
Jin SJ, Seo KH, Wi YM. The effect of concomitant use of systemic antibiotics in patients with Clostridium difficile infection receiving metronidazole therapy. Epidemiol Infect 2018;146:558-64. [PMID: 29493484 DOI: 10.1017/S0950268818000390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 617 |
Floch MH. The Role of Prebiotics and Probiotics in Gastrointestinal Disease. Gastroenterol Clin North Am 2018;47:179-91. [PMID: 29413011 DOI: 10.1016/j.gtc.2017.09.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 618 |
Leopold SS. Editor's Spotlight/Take 5: How Common-and How Serious-Is Clostridium difficile Colitis After Geriatric Hip Fracture? Findings from the NSQIP Dataset. Clin Orthop Relat Res 2018;476:449-52. [PMID: 29443838 DOI: 10.1007/s11999.0000000000000206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 619 |
Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. International Journal of Antimicrobial Agents 2018;51:319-25. [DOI: 10.1016/j.ijantimicag.2017.08.033] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 620 |
Zhou F, Hamza T, Fleur AS, Zhang Y, Yu H, Chen K, Heath JE, Chen Y, Huang H, Feng H. Mice with Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes. Inflamm Bowel Dis 2018;24:573-82. [PMID: 29462386 DOI: 10.1093/ibd/izx059] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 621 |
Hrebinko K, Zuckerbraun BS. Clostridium difficile : What the surgeon needs to know. Seminars in Colon and Rectal Surgery 2018;29:28-36. [DOI: 10.1053/j.scrs.2017.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 622 |
Bovonratwet P, Bohl DD, Russo GS, Ondeck NT, Nam D, Della Valle CJ, Grauer JN. How Common-and How Serious- Is Clostridium difficile Colitis After Geriatric Hip Fracture? Findings from the NSQIP Dataset. Clin Orthop Relat Res 2018;476:453-62. [PMID: 29443839 DOI: 10.1007/s11999.0000000000000099] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 623 |
Whitaker A, Cosimi RA, Reveles KR, Evoy KE. Bezlotoxumab. Infect Dis Clin Pract 2018;26:60-65. [DOI: 10.1097/ipc.0000000000000571] [Reference Citation Analysis]
|
| 624 |
Tang C, Li Y, Liu C, Sun P, Huang X, Xia W, Qian H, Cui L, Liu G. Epidemiology and risk factors for Clostridium difficile-associated diarrhea in adult inpatients in a university hospital in China. Am J Infect Control 2018;46:285-90. [PMID: 29195778 DOI: 10.1016/j.ajic.2017.08.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 625 |
Jiang C, Li G, Huang P, Liu Z, Zhao B. The Gut Microbiota and Alzheimer's Disease. J Alzheimers Dis. 2017;58:1-15. [PMID: 28372330 DOI: 10.3233/jad-161141] [Cited by in Crossref: 416] [Cited by in F6Publishing: 433] [Article Influence: 83.2] [Reference Citation Analysis]
|
| 626 |
Banawas SS. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. Biomed Res Int 2018;2018:8414257. [PMID: 29682562 DOI: 10.1155/2018/8414257] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 627 |
Schneider KM, Wirtz TH, Kroy D, Albers S, Neumann UP, Strowig T, Sellge G, Trautwein C. Successful Fecal Microbiota Transplantation in a Patient with Severe Complicated Clostridium difficile Infection after Liver Transplantation. Case Rep Gastroenterol 2018;12:76-84. [PMID: 29606940 DOI: 10.1159/000481937] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 628 |
Gil F, Calderón IL, Fuentes JA, Paredes-Sabja D. Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies. Future Microbiol 2018;13:469-82. [PMID: 29464969 DOI: 10.2217/fmb-2017-0203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 629 |
Le P, Nghiem VT, Mullen PD, Deshpande A. Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review. Infect Control Hosp Epidemiol 2018;39:412-24. [PMID: 29463339 DOI: 10.1017/ice.2017.303] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 630 |
Barkin JA, Stollman N, Barkin JS. Increasing Incidence of Multiply Recurrent Clostridium difficile Infection. Ann Intern Med 2018;168:307-8. [PMID: 29459964 DOI: 10.7326/L17-0601] [Reference Citation Analysis]
|
| 631 |
Hirten RP, Grinspan A, Fu S, Luo Y, Suarez-farinas M, Rowland J, Contijoch EJ, Mogno I, Yang N, Luong T, Labrias PR, Peter I, Cho JH, Sands BE, Colombel JF, Faith JJ, Clemente JC. Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium difficile Patients With and Without IBD.. [DOI: 10.1101/267492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 632 |
Goldenberg SD, Batra R, Beales I, Digby-Bell JL, Irving PM, Kellingray L, Narbad A, Franslem-Elumogo N. Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review. Infect Dis Ther. 2018;7:71-86. [PMID: 29450831 DOI: 10.1007/s40121-018-0189-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 633 |
Adamski JK, Jäschke BB, Uusitalo-Seppälä RS, Moilanen KVJ, Pehkonen AV, Weigl W. Routine Treatment-Resistant Clostridium difficile Infection during Recovery from Myxedema. Case Rep Gastroenterol 2017;11:748-54. [PMID: 29430228 DOI: 10.1159/000484661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 634 |
Heath RD, Cockerell C, Mankoo R, Ibdah JA, Tahan V. Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders. North Clin Istanb. 2018;5:79-88. [PMID: 29607440 DOI: 10.14744/nci.2017.10692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 635 |
Itou Y, Shimizu T, Hasegawa M. Duration and Recurrence Rate of Vancomycin Powder, Metronidazole Tablets and Injections in the Treatment of <i>Clostridium Difficile</i> Associated Diarrhea. Jpn J Pharm Health Care Sci 2018;44:90-93. [DOI: 10.5649/jjphcs.44.90] [Reference Citation Analysis]
|
| 636 |
Chahine EB. The Rise and Fall of Metronidazole for Clostridium difficile Infection. Ann Pharmacother 2018;52:600-2. [PMID: 29424238 DOI: 10.1177/1060028018757446] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 637 |
Peng Z, Ling L, Stratton CW, Li C, Polage CR, Wu B, Tang YW. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7:15. [PMID: 29434201 DOI: 10.1038/s41426-017-0019-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 638 |
Gómez-Hurtado I, Gimenez P, García I, Zapater P, Francés R, González-Navajas JM, Manichanh C, Ramos JM, Bellot P, Guarner F, Such J. Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver Int 2018;38:295-302. [PMID: 28834270 DOI: 10.1111/liv.13551] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 639 |
Cejas D, Ríos Osorio NR, Quirós R, Sadorin R, Berger MA, Gutkind G, Fernández Canigia L, Radice M. Detection and molecular characterization of Clostridium difficile ST 1 in Buenos Aires, Argentina. Anaerobe 2018;49:14-7. [DOI: 10.1016/j.anaerobe.2017.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 640 |
Spiceland CM, Khanna S, Pardi DS. Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection. J Clin Gastroenterol 2018;52:151-4. [PMID: 28009682 DOI: 10.1097/MCG.0000000000000769] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 641 |
Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 642 |
Nanki K, Mizuno S, Matsuoka K, Ono K, Sugimoto S, Kiyohara H, Arai M, Nakashima M, Takeshita K, Saigusa K, Senoh M, Fukuda T, Naganuma M, Kato H, Suda W, Hattori M, Kanai T. Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis. Intest Res 2018;16:142-6. [PMID: 29422809 DOI: 10.5217/ir.2018.16.1.142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 643 |
Yang HT, Chen JW, Rathod J, Jiang YZ, Tsai PJ, Hung YP, Ko WC, Paredes-Sabja D, Huang IH. Lauric Acid Is an Inhibitor of Clostridium difficile Growth in Vitro and Reduces Inflammation in a Mouse Infection Model. Front Microbiol 2017;8:2635. [PMID: 29387044 DOI: 10.3389/fmicb.2017.02635] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 644 |
Fisher A, Dembry LM. Norovirus and Clostridium difficile outbreaks: squelching the wildfire. Curr Opin Infect Dis 2017;30:440-7. [PMID: 28538249 DOI: 10.1097/QCO.0000000000000382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 645 |
Bruno-murtha LA, Osgood RA, Alexandre CE. A Successful Strategy to Decrease Hospital-Onset Clostridium difficile. Infect Control Hosp Epidemiol 2018;39:234-6. [DOI: 10.1017/ice.2017.289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 646 |
Bang BW, Park JS, Kim HK, Shin YW, Kwon KS, Kwon HY, Baek JH, Lee JS. Fecal Microbiota Transplantation for Refractory and Recurrent Clostridium difficile Infection: A Case Series of Nine Patients. Korean J Gastroenterol 2017;69:226-31. [PMID: 28449424 DOI: 10.4166/kjg.2017.69.4.226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 647 |
Mawer DPC, Eyre DW, Griffiths D, Fawley WN, Martin JSH, Quan TP, Peto TEA, Crook DW, Walker AS, Wilcox MH. Contribution to Clostridium Difficile Transmission of Symptomatic Patients With Toxigenic Strains Who Are Fecal Toxin Negative. Clin Infect Dis 2017;64:1163-70. [PMID: 28158441 DOI: 10.1093/cid/cix079] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 648 |
Bakker GJ, Nieuwdorp M. Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile. Bugs as Drugs 2018. [DOI: 10.1128/9781555819705.ch12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 649 |
Schneider A, Maric L. Fecal Microbiota Transplantation as Therapy for Inflammatory Bowel Disease. Interventional Inflammatory Bowel Disease: Endoscopic Management and Treatment of Complications 2018. [DOI: 10.1016/b978-0-12-811388-2.00028-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 650 |
Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointestinal Endoscopy 2018;87:18-29. [DOI: 10.1016/j.gie.2017.05.036] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 651 |
Codipilly DC, Chedid V, Beyder A. 47-Year-Old Man With Abdominal Pain and Diarrhea. Mayo Clin Proc 2018;93:e1-6. [PMID: 29141774 DOI: 10.1016/j.mayocp.2017.02.023] [Reference Citation Analysis]
|
| 652 |
Lügering N, Domschke W. Clostridium-difficile-Infektion. Therapie-Handbuch 2018. [DOI: 10.1016/b978-3-437-24950-1.00051-2] [Reference Citation Analysis]
|
| 653 |
Marchioni Beery RM, Korzenik JR. Infectious Complications of Biologics. Treatment of Inflammatory Bowel Disease with Biologics 2018. [DOI: 10.1007/978-3-319-60276-9_12] [Reference Citation Analysis]
|
| 654 |
Friedman-Korn T, Livovsky DM, Maharshak N, Aviv Cohen N, Paz K, Bar-Gil Shitrit A, Goldin E, Koslowsky B. Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients. Dig Dis Sci 2018;63:198-203. [PMID: 29134299 DOI: 10.1007/s10620-017-4833-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 655 |
Bovonratwet P, Bohl DD, Malpani R, Nam D, Della Valle CJ, Grauer JN. Incidence, Risk Factors, and Impact of Clostridium difficile Colitis Following Primary Total Hip and Knee Arthroplasty. J Arthroplasty 2018;33:205-210.e1. [PMID: 28870746 DOI: 10.1016/j.arth.2017.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 656 |
Mullane K. The Revolving (Bathroom) Door. The Infectious Disease Diagnosis 2018. [DOI: 10.1007/978-3-319-64906-1_44] [Reference Citation Analysis]
|
| 657 |
Ison MG, Heldman M. Bacterial Infections. Hepatic Critical Care 2018. [DOI: 10.1007/978-3-319-66432-3_15] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 658 |
Sahara K, Ohta Y, Abe Y, Yabushita Y, Yabuno T, Tatsumi K, Mochizuki Y, Takahashi M, Sugita A. Progressive Severe <i>Clostridium difficile</i> Infection after Abdominoperineal Resection. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2018;51:162-169. [DOI: 10.5833/jjgs.2016.0211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 659 |
Blanco N, Leekha S. The Importance of C. difficile Colonization in Infection Prevention. Infection Prevention 2018. [DOI: 10.1007/978-3-319-60980-5_26] [Reference Citation Analysis]
|
| 660 |
Maida M, Mcilroy J, Ianiro G, Cammarota G. Faecal Microbiota Transplantation as Emerging Treatment in European Countries. Adv Exp Med Biol 2018;1050:177-95. [PMID: 29383670 DOI: 10.1007/978-3-319-72799-8_11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 661 |
Abou Khalil M, Boutros M. Fulminant Clostridium difficile Colitis: Colon-Preserving Therapies. Current Common Dilemmas in Colorectal Surgery 2018. [DOI: 10.1007/978-3-319-70117-2_10] [Reference Citation Analysis]
|
| 662 |
Duarte-Chavez R, Wojda TR, Zanders TB, Geme B, Fioravanti G, Stawicki SP. Early Results of Fecal Microbial Transplantation Protocol Implementation at a Community-based University Hospital. J Glob Infect Dis 2018;10:47-57. [PMID: 29910564 DOI: 10.4103/jgid.jgid_145_17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 663 |
Kim PK, Zhao P, Teperman S. Evolving Treatment Strategies for Severe Clostridium difficile Colitis: Defining the Therapeutic Window. Hot Topics in Acute Care Surgery and Trauma 2018. [DOI: 10.1007/978-3-319-59704-1_15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 664 |
Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection. Curr Opin Gastroenterol 2018;34:3-10. [PMID: 29189354 DOI: 10.1097/MOG.0000000000000410] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 17.4] [Reference Citation Analysis]
|
| 665 |
Chis R, Sheth PM, Petrof EO. Fecal Microbiota Transplants: Current Knowledge and Future Directions. Mechanisms Underlying Host-Microbiome Interactions in Pathophysiology of Human Diseases 2018. [DOI: 10.1007/978-1-4939-7534-1_11] [Reference Citation Analysis]
|
| 666 |
Shrestha MP, Bime C, Taleban S. Decreasing Clostridium difficile-Associated Fatality Rates Among Hospitalized Patients in the United States: 2004-2014. Am J Med 2018;131:90-6. [PMID: 28801226 DOI: 10.1016/j.amjmed.2017.07.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 667 |
Waltz P, Zuckerbraun BS. Minimally Invasive Approaches to Clostridium Difficile Colitis. Minimally Invasive Acute Care Surgery 2018. [DOI: 10.1007/978-3-319-64723-4_14] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 668 |
Tungland B. Intestinal-Based Diseases and Peripheral Infection Risk Associated with Gut Dysbiosis: Therapeutic use of Pre- and Probiotics and Fecal Microbiota Transplantation. Human Microbiota in Health and Disease 2018. [DOI: 10.1016/b978-0-12-814649-1.00006-5] [Reference Citation Analysis]
|
| 669 |
Wick J, Basein T, Doron S. C. difficile Microbiome Manipulation. Infection Prevention 2018. [DOI: 10.1007/978-3-319-60980-5_16] [Reference Citation Analysis]
|
| 670 |
Cambiaso-daniel J, Gallagher JJ, Norbury WB, Finnerty CC, Herndon DN, Culnan DM. Treatment of Infection in Burn Patients. Total Burn Care 2018. [DOI: 10.1016/b978-0-323-47661-4.00011-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 671 |
Revolinski S, Huang AM, Gibble A. Rapid Diagnostics in Infection Prevention. Infection Prevention 2018. [DOI: 10.1007/978-3-319-60980-5_32] [Reference Citation Analysis]
|
| 672 |
Álvarez-hernández D, González-chávez A, González-hermosillo-cornejo D, Franyuti-kelly G, Díaz-girón-gidi A, Vázquez-lópez R. Present and past perspectives on Clostridium difficile infection. Revista de Gastroenterología de México (English Edition) 2018;83:41-50. [DOI: 10.1016/j.rgmxen.2017.07.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 673 |
Rizzatti G, Ianiro G, Gasbarrini A. Antibiotic and Modulation of Microbiota. Journal of Clinical Gastroenterology 2018;52:S74-S77. [DOI: 10.1097/mcg.0000000000001069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 674 |
Matsuno T, Tanaka S, Miyanishi K, Kawano Y, Nakamura H, Sakamoto H, Hayasaka N, Ishikawa K, Murase K, Takada K, Takanashi K, Katsuki S, Kobune M, Kato J. A case of liver abscesses caused by <i>Clostridium difficile</i>. Acta hepatologica Japonica 2018;59:180-186. [DOI: 10.2957/kanzo.59.180] [Reference Citation Analysis]
|
| 675 |
Lopez ON, Bohanon FJ, Radhakrishnan RS, Chung DH. Surgical Management of Complications of Burn Injury. Total Burn Care 2018. [DOI: 10.1016/b978-0-323-47661-4.00036-8] [Reference Citation Analysis]
|
| 676 |
Andoh A, Bamba S. Current Status of <I>Clostridium Difficile</I> Infection. Journal of Japan Society of Coloproctology 2018;71:456-469. [DOI: 10.3862/jcoloproctology.71.456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 677 |
Alkhamesi NA. Fulminant Clostridium difficile Colitis: Indications and Extent of Surgery. Current Common Dilemmas in Colorectal Surgery 2018. [DOI: 10.1007/978-3-319-70117-2_9] [Reference Citation Analysis]
|
| 678 |
Hunter KF, Northwood M, Haggar V, Bates F. Management of Fecal Incontinence in Frail Older Adults Living in the Community. Management of Fecal Incontinence for the Advanced Practice Nurse 2018. [DOI: 10.1007/978-3-319-90704-8_7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 679 |
Crobach MJT, Baktash A, Duszenko N, Kuijper EJ. Diagnostic Guidance for C. difficile Infections. Adv Exp Med Biol 2018;1050:27-44. [PMID: 29383662 DOI: 10.1007/978-3-319-72799-8_3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 680 |
Achkasov SI, Sukhina MA, Sushkov OI, Safin AL, Frolov SA. INCIDENCE OF TOXIN - PRODUCING STRAINS OF CLOSTRIDIUM SPP. AMONG MEDICAL STAFF IN COLOPROCTOLOGY DEPARTMENT. Koloproktologiâ 2017. [DOI: 10.33878/2073-7556-2017-0-4-17-23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 681 |
Battson ML, Lee DM, Weir TL, Gentile CL. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem 2018;56:1-15. [PMID: 29427903 DOI: 10.1016/j.jnutbio.2017.12.010] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 682 |
Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, Cohen D, Guzner-Gur H, Santo E, Halpern Z, Carmeli Y, Maharshak N. Clostridium difficile fecal toxin level is associated with disease severity and prognosis. United European Gastroenterol J 2018;6:773-80. [PMID: 30083340 DOI: 10.1177/2050640617750809] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 683 |
Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095. [PMID: 29257353 DOI: 10.1002/14651858.cd006095.pub4] [Cited by in Crossref: 121] [Cited by in F6Publishing: 121] [Article Influence: 20.2] [Reference Citation Analysis]
|
| 684 |
Kidane B, Lung K, McCreery G, El-Khatib C, Ott MC, Hernandez-Alejandro R, Vinden C, Gray D, Parry NG, Leslie KA, Mele TS. Early Rescue from Acute Severe Clostridium Difficile: A Novel Treatment Strategy. Surg Infect (Larchmt) 2018;19:78-82. [PMID: 29227201 DOI: 10.1089/sur.2017.147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 685 |
Patel JM, Fox ER, Zocchi M, Lee Z, Mazer-amirshahi M. Trends in United States Drug Shortages for Medications Used in Gastroenterology. Medicine Access @ Point of Care 2017;1:maapoc.0000012. [DOI: 10.5301/maapoc.0000012] [Reference Citation Analysis]
|
| 686 |
Kim HN, Kim H, Moon HW, Hur M, Yun YM. Toxin positivity and tcdB gene load in broad-spectrum Clostridium difficile infection. Infection 2018;46:113-7. [PMID: 29218569 DOI: 10.1007/s15010-017-1108-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 687 |
Daquigan N, Seekatz AM, Greathouse KL, Young VB, White JR. High-resolution profiling of the gut microbiome reveals the extent of Clostridium difficile burden. NPJ Biofilms Microbiomes 2017;3:35. [PMID: 29214047 DOI: 10.1038/s41522-017-0043-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 688 |
Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E. Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile. Ann Clin Microbiol Antimicrob 2017;16:77. [PMID: 29202797 DOI: 10.1186/s12941-017-0252-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 689 |
Yan LH, Le Roux A, Boyapelly K, Lamontagne AM, Archambault MA, Picard-Jean F, Lalonde-Seguin D, St-Pierre E, Najmanovich RJ, Fortier LC, Lafontaine D, Marsault É. Purine analogs targeting the guanine riboswitch as potential antibiotics against Clostridioides difficile. Eur J Med Chem 2018;143:755-68. [PMID: 29220796 DOI: 10.1016/j.ejmech.2017.11.079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 690 |
Czepiel J, Biesiada G, Dróżdż M, Gdula-Argasińska J, Żurańska J, Marchewka J, Perucki W, Wołkow P, Garlicki A. The presence of IL-8 +781 T/C polymorphism is associated with the parameters of severe Clostridium difficile infection. Microb Pathog 2018;114:281-5. [PMID: 29203364 DOI: 10.1016/j.micpath.2017.11.066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 691 |
Joly F, Nuzzo A, Kapel N, Thomas M. Lien entre les probiotiques et le microbiote : vision du clinicien. Cahiers de Nutrition et de Diététique 2017;52:S5-S12. [DOI: 10.1016/s0007-9960(17)30193-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 692 |
Siow VS, Bhatt R, Mollen KP. Management of acute severe ulcerative colitis in children. Semin Pediatr Surg 2017;26:367-72. [PMID: 29126505 DOI: 10.1053/j.sempedsurg.2017.10.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 693 |
Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A. Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial. Inflamm Bowel Dis 2017;23:2209-14. [PMID: 29084080 DOI: 10.1097/MIB.0000000000001249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 694 |
Kulaylat AS, Kassam Z, Hollenbeak CS, Stewart DB Sr. A Surgical Clostridium-Associated Risk of Death Score Predicts Mortality After Colectomy for Clostridium difficile. Dis Colon Rectum 2017;60:1285-90. [PMID: 29112564 DOI: 10.1097/DCR.0000000000000920] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 695 |
Naymagon S, Naymagon L, Wong SY, Ko HM, Renteria A, Levine J, Colombel JF, Ferrara J. Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. Nat Rev Gastroenterol Hepatol 2017;14:711-26. [PMID: 28951581 DOI: 10.1038/nrgastro.2017.126] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 12.2] [Reference Citation Analysis]
|
| 696 |
Ulrich RJ, Santhosh K, Mogle JA, Young VB, Rao K. Is Clostridium difficile infection a risk factor for subsequent bloodstream infection? Anaerobe 2017;48:27-33. [PMID: 28669864 DOI: 10.1016/j.anaerobe.2017.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 697 |
Moore SC. Clostridium difficile: More Challenging than Ever. Crit Care Nurs Clin North Am 2018;30:41-53. [PMID: 29413214 DOI: 10.1016/j.cnc.2017.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 698 |
Tung VS, Lopez A, Orenstein SB, Novitsky YW. Necrotizing Clostridium difficile Enteritis Complicating Fulminant Colitis. Surgical Infections Case Reports 2017;2:9-13. [DOI: 10.1089/crsi.2016.0054] [Reference Citation Analysis]
|
| 699 |
Verbeke F, Janssens Y, Wynendaele E, De Spiegeleer B. Faecal microbiota transplantation: a regulatory hurdle? BMC Gastroenterol 2017;17:128. [PMID: 29179687 DOI: 10.1186/s12876-017-0687-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 700 |
Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, Chang HJ, Coward S, Goodman KJ, Xu H, Madsen K, Mason A, Wong GK, Jovel J, Patterson J, Louie T. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2017;318:1985-93. [PMID: 29183074 DOI: 10.1001/jama.2017.17077] [Cited by in Crossref: 354] [Cited by in F6Publishing: 343] [Article Influence: 59.0] [Reference Citation Analysis]
|
| 701 |
Fukuchi K, Akima E, Nakane K, Ugajin K, Tahara S, Niki Y. Occurrence of <i>Clostridium difficile</i> Infection in our Hospital and its Control Measures. Nihon Kankyou Kansen Gakkaishi 2017;32:364-368. [DOI: 10.4058/jsei.32.364] [Reference Citation Analysis]
|
| 702 |
Maxwell-Scott HG, Goldenberg SD. Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents. Med Mal Infect 2018;48:1-9. [PMID: 29169816 DOI: 10.1016/j.medmal.2017.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 703 |
Oh SH, Kang HY. Identification of target risk groups for population-based Clostridium difficile infection prevention strategies using a population attributable risk approach. Int J Infect Dis 2018;66:107-12. [PMID: 29162405 DOI: 10.1016/j.ijid.2017.11.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 704 |
Tieu JD, Schmidt SA, Miller JL, Kupiec KE, Skrepnek GH, Liu C, Smith WJ. Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy. J Oncol Pharm Pract 2019;25:520-8. [DOI: 10.1177/1078155217740945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 705 |
Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect 2018;24:780.e1-3. [PMID: 29104169 DOI: 10.1016/j.cmi.2017.10.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 706 |
Haran JP, Bradley E, Howe E, Wu X, Tjia J. Medication Exposure and Risk of Recurrent Clostridium difficile Infection in Community-Dwelling Older People and Nursing Home Residents. J Am Geriatr Soc 2018;66:333-8. [DOI: 10.1111/jgs.15176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 707 |
Bamba S, Nishida A, Imaeda H, Inatomi O, Sasaki M, Sugimoto M, Andoh A. Successful treatment by fecal microbiota transplantation for Japanese patients with refractory Clostridium difficile infection: A prospective case series. J Microbiol Immunol Infect 2019;52:663-6. [PMID: 29158082 DOI: 10.1016/j.jmii.2017.08.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 708 |
López-sanromán A, Rodríguez de Santiago E, Cobo Reinoso J, del Campo Moreno R, Foruny Olcina JR, García Fernández S, García García de Paredes A, Aguilera Castro L, Ferre Aracil C, Albillos Martínez A. Results of the implementation of a multidisciplinary programme of faecal microbiota transplantation by colonoscopy for the treatment of recurrent Clostridium difficile infection. Gastroenterología y Hepatología (English Edition) 2017;40:605-614. [DOI: 10.1016/j.gastre.2017.03.015] [Reference Citation Analysis]
|
| 709 |
Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo Clin Proc 2017;92:1617-24. [PMID: 29101931 DOI: 10.1016/j.mayocp.2017.08.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 710 |
Saffouri G, Gupta A, Loftus EV Jr, Baddour LM, Pardi DS, Khanna S. The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease. Scand J Gastroenterol 2017;52:1240-7. [PMID: 28782372 DOI: 10.1080/00365521.2017.1362466] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 711 |
Couture-cossette A, Carignan A, Ilangumaran S, Valiquette L. Bezlotoxumab for the prevention ofClostridium difficilerecurrence. Expert Opinion on Biological Therapy 2017. [DOI: 10.1080/14712598.2017.1363886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 712 |
López-sanromán A, Rodríguez de Santiago E, Cobo Reinoso J, del Campo Moreno R, Foruny Olcina JR, García Fernández S, García García de Paredes A, Aguilera Castro L, Ferre Aracil C, Albillos Martínez A. Resultados de la implementación de un programa multidisciplinar de trasplante de microbiota fecal por colonoscopia para el tratamiento de la infección recurrente por Clostridium difficile. Gastroenterología y Hepatología 2017;40:605-14. [DOI: 10.1016/j.gastrohep.2017.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 713 |
Staley C, Khoruts A, Sadowsky MJ. Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans. Archives of Medical Research 2017;48:766-773. [DOI: 10.1016/j.arcmed.2017.11.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 714 |
Shin HS, Chandraker A. Causes and management of postrenal transplant diarrhea: an underappreciated cause of transplant-associated morbidity. Current Opinion in Nephrology and Hypertension 2017;26:484-93. [DOI: 10.1097/mnh.0000000000000368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 715 |
Kachrimanidou M, Tsachouridou O, Ziogas IA, Christaki E, Protonotariou E, Metallidis S, Skoura L, Kuijper E. Clostridium difficile infections in a university hospital in Greece are mainly associated with PCR ribotypes 017 and 126. J Med Microbiol 2017;66:1774-81. [PMID: 29087273 DOI: 10.1099/jmm.0.000623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 716 |
Asempa TE, Nicolau DP. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging 2017;12:1799-809. [PMID: 29123385 DOI: 10.2147/CIA.S149089] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 717 |
Prechter F, Katzer K, Bauer M, Stallmach A. Sleeping with the enemy: Clostridium difficile infection in the intensive care unit. Crit Care 2017;21:260. [PMID: 29058580 DOI: 10.1186/s13054-017-1819-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 718 |
D'Ostroph AR, So TY. Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infect Drug Resist 2017;10:365-75. [PMID: 29089778 DOI: 10.2147/IDR.S119571] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 719 |
Ohnishi K, Ainoda Y, Imamura A, Iwabuchi S, Okuda M, Nakano T; Japanese Association for Infectious Disease/Japanese Society of Chemotherapy., JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee., Intestinal Infections Working Group (WG). JAID/JSC Guidelines for Infection Treatment 2015-Intestinal infections. J Infect Chemother 2018;24:1-17. [PMID: 28986191 DOI: 10.1016/j.jiac.2017.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 720 |
Tamez-Torres KM, Torres-González P, Leal-Vega F, García-Alderete A, López García NI, Mendoza-Aguilar R, Galindo-Fraga A, Bobadilla-Del Valle M, Ponce de León A, Sifuentes-Osornio J. Impact of Clostridium difficile infection caused by the NAP1/RT027 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center. Int J Infect Dis 2017;65:44-9. [PMID: 28986313 DOI: 10.1016/j.ijid.2017.09.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 721 |
Dembinski GM, Picard CJ. Effects of microbial DNA on human DNA profiles generated using the PowerPlex® 16 HS system. J Forensic Leg Med 2017;52:208-14. [PMID: 28963943 DOI: 10.1016/j.jflm.2017.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 722 |
Meighani A, Hart BR, Bourgi K, Miller N, John A, Ramesh M. Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2017;62:2870-5. [PMID: 28451916 DOI: 10.1007/s10620-017-4580-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 723 |
Kelly CR, Allegretti JR. FMT in IBD: What Have We Learned? Dig Dis Sci 2017;62:2618-20. [PMID: 28840580 DOI: 10.1007/s10620-017-4713-9] [Reference Citation Analysis]
|
| 724 |
Brandt LJ. Fecal Microbiota Therapy With a Focus on Clostridium difficile Infection. Psychosom Med 2017;79:868-73. [PMID: 28976455 DOI: 10.1097/PSY.0000000000000511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 725 |
Velarde Ruiz-velasco J, Aldana-ledesma J, Ibarra-estrada M, Aguirre Díaz S, Fernández-ramírez J, Cárdenas-lara F, Álvarez López F, Rodríguez-noriega L, Pérez-gómez H, Morfín-otero M. Clinical and endoscopic features in patients with hospital-acquired diarrhea associated with Clostridium difficile infection. Revista de Gastroenterología de México (English Edition) 2017;82:301-8. [DOI: 10.1016/j.rgmxen.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 726 |
Nascimento M. Oral Microbiota Transplant: A Potential New Therapy for Oral Diseases. Journal of the California Dental Association 2017;45:565-568. [DOI: 10.1080/19424396.2017.12222506] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 727 |
El Hage R, Hernandez-Sanabria E, Van de Wiele T. Emerging Trends in "Smart Probiotics": Functional Consideration for the Development of Novel Health and Industrial Applications. Front Microbiol 2017;8:1889. [PMID: 29033923 DOI: 10.3389/fmicb.2017.01889] [Cited by in Crossref: 101] [Cited by in F6Publishing: 101] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 728 |
Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 729 |
Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23(35): 6500-6515 [PMID: 29085200 DOI: 10.3748/wjg.v23.i35.6500] [Cited by in CrossRef: 141] [Cited by in F6Publishing: 144] [Article Influence: 23.5] [Reference Citation Analysis]
|
| 730 |
Kelly BJ, Tebas P. Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. Chest. 2018;153:266-277. [PMID: 28923757 DOI: 10.1016/j.chest.2017.09.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 731 |
Salazar CL, Reyes C, Atehortua S, Sierra P, Correa MM, Paredes-Sabja D, Best E, Fawley WN, Wilcox M, González Á. Molecular, microbiological and clinical characterization of Clostridium difficile isolates from tertiary care hospitals in Colombia. PLoS One 2017;12:e0184689. [PMID: 28902923 DOI: 10.1371/journal.pone.0184689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 732 |
Visconti V, Brunetti G, Cuomo MR, Giordano A, Raponi G. Nosocomial-acquired and community-onset Clostridium difficile infection at an academic hospital in Italy: Epidemiology, recurrences and toxin genes distribution. J Infect Chemother 2017;23:763-8. [PMID: 28899610 DOI: 10.1016/j.jiac.2017.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 733 |
Tkhawkho L, Jackson K, Nitzan O, Peretz A. Destruction of Clostridium difficile spores colitis using acidic electrolyzed water. Am J Infect Control 2017;45:1053. [PMID: 28863807 DOI: 10.1016/j.ajic.2017.06.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 734 |
Dávila LP, Garza-gonzález E, Rodríguez-zulueta P, Morfín-otero R, Rodríguez-noriega E, Vilar-compte D, Rodríguez-aldama JC, Camacho-ortiz A. Increasing rates of Clostridium difficile infection in Mexican hospitals. The Brazilian Journal of Infectious Diseases 2017;21:530-4. [DOI: 10.1016/j.bjid.2017.05.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 735 |
Qin J, Dai Y, Ma X, Wang Y, Gao Q, Lu H, Li T, Meng H, Liu Q, Li M. Nosocomial transmission of Clostridium difficile Genotype ST81 in a General Teaching Hospital in China traced by whole genome sequencing. Sci Rep 2017;7:9627. [PMID: 28851988 DOI: 10.1038/s41598-017-09878-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 736 |
Splinter LE, Kerstenetzky L, Jorgenson MR, Descourouez JL, Leverson GE, Saddler CM, Smith JA, Safdar N, Redfield RR. Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients. Ann Pharmacother 2017;52:113-9. [DOI: 10.1177/1060028017727756] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 737 |
Draper K, Ley C, Parsonnet J. Probiotic guidelines and physician practice: a cross-sectional survey and overview of the literature. Beneficial Microbes 2017;8:507-19. [DOI: 10.3920/bm2016.0146] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 738 |
Arbel LT, Hsu E, McNally K. Cost-Effectiveness of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium Difficile Infection: A Literature Review. Cureus 2017;9:e1599. [PMID: 29067223 DOI: 10.7759/cureus.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 739 |
Chopra T, Goldstein EJ, Gorbach SL. Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection. Pharmacotherapy 2016;36:1281-9. [PMID: 27862113 DOI: 10.1002/phar.1863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 740 |
Crobach MJT, Voor In 't Holt AF, Knetsch CW, van Dorp SM, Bras W, Harmanus C, Kuijper EJ, Vos MC. An outbreak of Clostridium difficile infections due to new PCR ribotype 826: epidemiologic and microbiologic analyses. Clin Microbiol Infect 2018;24:309.e1-4. [PMID: 28830806 DOI: 10.1016/j.cmi.2017.08.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 741 |
Robin C, Héquette-Ruz R, Guery B, Boyle E, Herbaux C, Galperine T. Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable? Med Mal Infect 2017;47:532-9. [PMID: 28823390 DOI: 10.1016/j.medmal.2017.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 742 |
. BEZLOTOXUMAB: A NEW DRUG FOR THE TOXIC EFFECTS OF CLOSTRIDIUM DIFFICILE. Gastroenterol Nurs 2017;40:325-6. [PMID: 28746119 DOI: 10.1097/SGA.0000000000000296] [Reference Citation Analysis]
|
| 743 |
Barbut F, Gouot C, Lapidus N, Suzon L, Syed-zaidi R, Lalande V, Eckert C. Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case–control study. Eur J Clin Microbiol Infect Dis 2017;36:2423-30. [DOI: 10.1007/s10096-017-3080-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 744 |
Manthey C, Eckmann L, Fuhrmann V. Therapy for Clostridium difficile infection – any news beyond Metronidazole and Vancomycin? Expert Review of Clinical Pharmacology 2017;10:1239-50. [DOI: 10.1080/17512433.2017.1362978] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 745 |
Blanco N, Foxman B, Malani AN, Zhang M, Walk S, Rickard AH, Eisenberg MC. An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection. PLoS One 2017;12:e0182815. [PMID: 28800598 DOI: 10.1371/journal.pone.0182815] [Reference Citation Analysis]
|
| 746 |
Napolitano LM, Edmiston CE. Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update. Surgery 2017;162:325-48. [DOI: 10.1016/j.surg.2017.01.018] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 747 |
Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis? Diagnostic Microbiology and Infectious Disease 2017;88:322-9. [DOI: 10.1016/j.diagmicrobio.2017.05.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 748 |
Fashandi AZ, Wang PT, Hedrick TL, Friel CM, Hays RA, Hallowell PT. Recurrent Clostridium difficile Infection after Diverting Loop Ileostomy and Colonic Lavage: An Unreported Complication of the Novel Surgical Therapy. The American Surgeon 2017;83:335-8. [DOI: 10.1177/000313481708300825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 749 |
Lan N, Ashburn J, Shen B. Fecal microbiota transplantation for Clostridium difficile infection in patients with ileal pouches. Gastroenterol Rep (Oxf) 2017;5:200-7. [PMID: 28852524 DOI: 10.1093/gastro/gox018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 750 |
Cheng YW, Fischer M. The Present Status of Fecal Microbiota Transplantation and Its Value in the Elderly. Curr Treat Options Gastroenterol 2017;15:349-62. [PMID: 28748314 DOI: 10.1007/s11938-017-0143-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 751 |
Kosai K, Iwanaga Y, Akamatsu N, Okada Y, Kaku N, Uno N, Morinaga Y, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K. Performance evaluation of the Verigene®Clostridium difficile nucleic acid test, an automated multiplex molecular testing system for detection of C. difficile toxin. J Infect Chemother 2017;23:674-7. [PMID: 28751156 DOI: 10.1016/j.jiac.2017.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 752 |
Shen NT, Leff JA, Schneider Y, Crawford CV, Maw A, Bosworth B, Simon MS. Cost-Effectiveness Analysis of Probiotic Use to Prevent Clostridium difficile Infection in Hospitalized Adults Receiving Antibiotics. Open Forum Infect Dis 2017;4:ofx148. [PMID: 29230429 DOI: 10.1093/ofid/ofx148] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 753 |
D’Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol 2017; 23(27): 4986-5003 [PMID: 28785153 DOI: 10.3748/wjg.v23.i27.4986] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 754 |
Hassouna H, Deshpande A. Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection. Evid Based Med 2017;22:150-1. [PMID: 28716810 DOI: 10.1136/ebmed-2017-110722] [Reference Citation Analysis]
|
| 755 |
Alonso CD, Braun DA, Patel I, Akbari M, Oh DJ, Jun T, McMasters M, Hammond SP, Glotzbecker B, Cutler C, Leffler DA, Ballen KK, Kelly CP. A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients. Transpl Infect Dis 2017;19. [PMID: 28544102 DOI: 10.1111/tid.12728] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 756 |
Álvarez-Hernández DA, González-Chávez AM, González-Hermosillo-Cornejo D, Franyuti-Kelly GA, Díaz-Girón-Gidi A, Vázquez-López R. Present and past perspectives on Clostridium difficile infection. Rev Gastroenterol Mex (Engl Ed) 2018;83:41-50. [PMID: 28684034 DOI: 10.1016/j.rgmx.2017.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 757 |
Wu MA, Leidi F; On behalf of Gruppo di Autoformazione Metodologica (GrAM). Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality. Intern Emerg Med 2017;12:871-2. [DOI: 10.1007/s11739-017-1710-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 758 |
Villafuerte Gálvez JA, Kelly CP. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence ofClostridium difficileinfection. Expert Review of Gastroenterology & Hepatology 2017;11:611-622. [DOI: 10.1080/17474124.2017.1344551] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 759 |
Abrahamian FM, Talan DA, Krishnadasan A, Citron DM, Paulick AL, Anderson LJ, Goldstein EJ, Moran GJ, Abrahamian F, Moore J, Femling J, Chiang W, Lovecchio F, Jui J, Garg M, Steele M, Sullivan D, Rothman R. Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting. Annals of Emergency Medicine 2017;70:19-27.e4. [DOI: 10.1016/j.annemergmed.2016.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 760 |
Safin AL, Achkasov SI, Sukhina MA, Sushkov OI. QOSTRIDIUM DIFFICILE INFECTION: QINIC, DIAGNOSTICS AND TREATMENT (review). Koloproktologiâ 2017. [DOI: 10.33878/2073-7556-2017-0-2-80-88] [Reference Citation Analysis]
|
| 761 |
Yun B, Song M, Park DJ, Oh S. Beneficial Effect of Bifidobacterium longum ATCC 15707 on Survival Rate of Clostridium difficile Infection in Mice. Korean J Food Sci Anim Resour 2017;37:368-75. [PMID: 28747822 DOI: 10.5851/kosfa.2017.37.3.368] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 762 |
Shin JH, Chaves-Olarte E, Warren CA. Clostridium difficile Infection. Microbiol Spectr 2016;4. [PMID: 27337475 DOI: 10.1128/microbiolspec.EI10-0007-2015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 763 |
Kwon SS, Gim JL, Kim MS, Kim H, Choi JY, Yong D, Lee K. Clinical and molecular characteristics of community-acquired Clostridium difficile infections in comparison with those of hospital-acquired C. difficile. Anaerobe 2017;48:42-6. [PMID: 28655581 DOI: 10.1016/j.anaerobe.2017.06.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 764 |
Manea E, Sojo-Dorado J, Jipa RE, Benea SN, Rodríguez-Baño J, Hristea A. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect 2018;24:180-4. [PMID: 28642147 DOI: 10.1016/j.cmi.2017.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 765 |
Solbach P, Dersch P, Bachmann O. [Individualized treatment strategies for Clostridium difficile infections]. Internist (Berl) 2017;58:675-81. [PMID: 28589214 DOI: 10.1007/s00108-017-0268-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 766 |
Berry AC, Learned M, Garland J, Berry L, Rodriguez S, Scott B, Berry BB. Intensive Care Unit Probiotic Utilization Rates: When Committee Recommendations and Physician Utilization Diverge. Infect Control Hosp Epidemiol 2017;38:1011-3. [PMID: 28592341 DOI: 10.1017/ice.2017.117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 767 |
Oami T, Hattori N, Matsumura Y, Watanabe E, Abe R, Oshima T, Takahashi W, Yamazaki S, Suzuki T, Oda S. The Effects of Fasting and Massive Diarrhea on Absorption of Enteral Vancomycin in Critically Ill Patients: A Retrospective Observational Study. Front Med (Lausanne) 2017;4:70. [PMID: 28642864 DOI: 10.3389/fmed.2017.00070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 768 |
Nathanson BH, Higgins TL, McGee WT. The dangers of extreme body mass index values in patients with Clostridium difficile. Infection 2017;45:787-93. [PMID: 28593617 DOI: 10.1007/s15010-017-1036-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 769 |
Crowell KT, Julian KG, Katzman M, Berg AS, Tinsley A, Williams ED, Koltun WA, Messaris E. Compliance with Clostridium difficile treatment guidelines: effect on patient outcomes. Epidemiol Infect 2017;145:2185-92. [PMID: 28578710 DOI: 10.1017/S0950268817000644] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 770 |
Simeunovic G, Sharma M, Riederer K, Khatib R. Relevance of indeterminate Clostridium difficile screening tests with detectable toxin genes: colonization or C. difficile disease? Infectious Diseases 2017;49:471-473. [DOI: 10.1080/23744235.2017.1279746] [Reference Citation Analysis]
|
| 771 |
Kobayashi K, Sekiya N, Ainoda Y, Kurai H, Imamura A. Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study. Eur J Clin Microbiol Infect Dis 2017;36:1947-53. [PMID: 28577158 DOI: 10.1007/s10096-017-3018-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 772 |
Maghdoori S, Moghadas SM. Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings. BMC Infect Dis 2017;17:384. [PMID: 28577357 DOI: 10.1186/s12879-017-2494-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 773 |
Staley C, Hamilton MJ, Vaughn BP, Graiziger CT, Newman KM, Kabage AJ, Sadowsky MJ, Khoruts A. Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. Am J Gastroenterol 2017;112:940-7. [PMID: 28195180 DOI: 10.1038/ajg.2017.6] [Cited by in Crossref: 118] [Cited by in F6Publishing: 124] [Article Influence: 19.7] [Reference Citation Analysis]
|
| 774 |
Mcfarland LV. Primary prevention of Clostridium difficile infections – how difficult can it be? Expert Review of Gastroenterology & Hepatology 2017;11:507-521. [DOI: 10.1080/17474124.2017.1312343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 775 |
Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, Simon MS, Evans AT. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology 2017;152:1889-1900.e9. [PMID: 28192108 DOI: 10.1053/j.gastro.2017.02.003] [Cited by in Crossref: 177] [Cited by in F6Publishing: 183] [Article Influence: 29.5] [Reference Citation Analysis]
|
| 776 |
Siehnel JT, Lavigne JE, Rightmier EA, Bossard WT, Li N, Slish JC. A Retrospective Study of Patient Factors That Indicate Provider Nonadherence to an Institutional Clostridium difficile Treatment Guideline. J Pharm Pract 2018;31:169-74. [PMID: 28569127 DOI: 10.1177/0897190017710349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 777 |
Khanal S, Veerman L, Nissen L, Hollingworth S. Use of Healthcare Services by Patients with Non-Communicable Diseases in Nepal: A Qualitative Study with Healthcare Providers. J Clin Diagn Res 2017;11:LC01-5. [PMID: 28764203 DOI: 10.7860/JCDR/2017/25021.9970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 778 |
Ma Y, Yang J, Cui B, Xu H, Xiao C, Zhang F. How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study. BMC Med Ethics. 2017;18:39. [PMID: 28569156 DOI: 10.1186/s12910-017-0200-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 779 |
Mentula S, Kotila SM, Lyytikäinen O, Ibrahem S, Ollgren J, Virolainen A. Clostridium difficile infections in Finland, 2008–2015: trends, diagnostics and ribotypes. Eur J Clin Microbiol Infect Dis 2017;36:1939-45. [DOI: 10.1007/s10096-017-3017-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 780 |
Yoshioka K, Kakihana K, Doki N, Ohashi K. Gut microbiota and acute graft-versus-host disease. Pharmacol Res 2017;122:90-5. [PMID: 28576475 DOI: 10.1016/j.phrs.2017.05.028] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 781 |
Yu K, Bi N, Xiong C, Cai S, Long Z, Guo Z, Gu G. Synthesis of Defined and Functionalized Glycans of Lipoteichoic Acid: A Cell Surface Polysaccharide from Clostridium difficile. Org Lett 2017;19:3123-6. [PMID: 28548838 DOI: 10.1021/acs.orglett.7b01242] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 782 |
Wolf-meyer MJ. Normal, Regular, and Standard: Scaling the Body through Fecal Microbial Transplants: Normal, Regular, and Standard. Medical Anthropology Quarterly 2017;31:297-314. [DOI: 10.1111/maq.12328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] |
